Bone marrow derived cells as endothelial precursors and the role of multi-potent progenitor cells in repairing ischaemic tissues. by Wragg, Andrew
Bone marrow derived cells as endothelial precursors and the role of multi-
potent progenitor cells in repairing ischaemic tissues.
Wragg, Andrew
 
 
 
 
 
The copyright of this thesis rests with the author and no quotation from it or information
derived from it may be published without the prior written consent of the author
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/jspui/handle/123456789/1640
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
Bone marrow derived cells as endothelial precursors 
and 
the role of multi-potent progenitor cells in repairing 
ischaernic tissues 
Dr Andrew Wragg 
Department of Clinical Pharmacology 
Barts and The London Medical School 
Queen Mary University of London 
UK 
AND 
Cardiovascular Branch 
Heart, Lung and Blood Institute 
National Institutes of Health 
USA 
SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
TO 
LONDON UNIVERSITY 
2007 
Abstract 
Introduction: Atherosclerosis and its complications are a major cause of death and 
disability and it remains a major challenge to develop new therapies for patients with 
irreversible end organ damage and ongoing ischaemia. The discovery of adult stem 
and progenitor cells with the ability to regenerate adult tissues holds great promise. 
Bone marrow is the source of both endothelial progenitor cells (EPCs) and multi-potent 
adult progenitor cells (MAPCs). MAPCs are rare pluripotent bone marrow derived cells 
with the theoretical potential to differentiate into tissues of all three germ cell layers, 
including endothelium. These cells may have the potential to facilitate cardiac repair. 
The aim of this thesis was to further characterise bone marrow derived endothelial 
progenitor cells including multi potent adult progenitor cells and assess their angiogenic 
potential and mechanisms of action in animal models of cardiovascular disease. 
Findings: EPCs were isolated from humans and mice and their phenotype, markers 
and function determined, including gene tracking experiments in mice utilising the 
Cre/Lox system. It was not possible to isolate cells with the same phenotype as 
MAPCs from rodent bone marrow. However, cells with pluri-potent properties, named 
rat multi-potent progenitor cells (rMPCs), were isolated from rat bone marrow. These 
cells had the ability to up regulate tissue specific antigens from all 3 germ cell lineages 
and in addition secreted multiple cytokines related to angiogenesis and inflammation. 
To investigate the in vivo properties of rMPCs a rat hind limb model of ischaemia was 
established and syngeneic rMPCs were transplanted into the ischaemic hind limbs. 
rMPCs engrafted selectively into the adventitia of arterioles of ischaemic muscles. 
However, engrafted cells did not differentiate into an endothelial or smooth muscle 
phenotype. Cytokine analysis of muscles 5 days after rMPC injection revealed raised 
levels of cytokines, including chemokines MCP1 and SDR. Limb perfusion, measured 
by microspheres, increased after rMPC injection. In addition a novel MRI based 
assessment of ischaemic muscles revealed a significant normalisation of MRI signal 
after rMPC transplantation. However, there was no improvement in limb function 
assessed by treadmill running distance 4 weeks after cell injection. These findings 
suggest that transplantation of rMPCs into ischaemic muscles may modulate local 
inflammatory and angiogenic responses through paracrine mechanisms. 
Conclusion: Despite the potential for stem and progenitor cells to be used for the 
treatment of chronic cardiac ischaemia the biology of stem cells is still relatively poorly 
understood, as is the mechanism of action of cells after transplantation. As set out in 
the aims, the work in this thesis adds further to our understanding of both EPCs and 
BM derived pluri-potent stem cells. In addition it provides insight into the hind limb 
ischaemia model and the mechanism of action of cell therapy after transplantation into 
ischaemic muscle. 
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OPN Osteopontin 
PCI Percutaneous coronary intervention 
PCR Polymerase chain reaction 
PDGF Platelet derived growth factor 
PLGF Placental growth factor 
RAOEC Rat aortic endothelial cells 
RBC Red blood cells 
RECA1 Rat endothelial cell antigen 1 
ROI Region of interest 
RT Reverse transcriptase 
SAGE Serial analysis of gene expression 
SCIF Stem cell factor 
SCIC Surface coil intensity correction 
SDF Stromal derived factor 
SHH Sonic hedgehog 
SITE Selenite, insulin, transferrin and ethanolamine 
SKY Spectral karyotyping 
SMact Smooth muscle actin 
SSEA1 Stage specific embryonic antigen 1 
TEM Tumour endothelial marker 
TGF Transforming growth factor 
TPO Thrombopoietin 
VEGF Vascular endothelial growth factor 
VEGFR1 Vascular endothelial growth factor receptor 1 
VEGFR2 Vascular endothelial growth factor receptor 2 (includes KDR/ FLK1) 
Vwf Von Willebrand factor 
WT Wild type 
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Chapter 1 Introduction 
The impact of cardiovascular disease: the clinical problem 
Despite the major advances in the treatment of atherosclerosis and its complications of 
myocardial infarction, stroke and peripheral arterial disease, complications of 
atherosclerosis still remain the major cause of death in developed countries and it is 
becoming increasingly prevalent in developing countries [1]. Although therapeutic 
interventions can significantly improve the outcome of patients with vascular diseases 
there are many patients who, as a consequence, have irreversible end organ damage 
and chronic ischaemia. These patients are, in part, a result of the success of initial 
cardiac interventions allowing improved survival. The present challenge is to develop 
new therapies for patients with irreversible end organ damage and chronic ischaemia. 
The discovery of stem and progenitor cells with the ability to regenerate adult tissues 
such as heart muscle and blood vessels has initiated a novel and exciting era in 
vascular biology and clinical medicine. Stem and progenitor cells hold great promise, 
not only as potential therapies for treating patients, but also for allowing for an 
increased understanding of disease processes and their repair. This thesis will focus 
on studying the biology of bone marrow derived cells as potential endothelial progenitor 
cells (EPCs) including multi-potent adult progenitor cells (MAPCs) and their potential 
role in cardiovascular disease and repair. 
Stem and progenitor Cells 
The rise in interest in stem and progenitor cells has been dramatic over recent years. 
Stem cells can be defined as undifferentiated primitive cells with the ability both to 
multiply and to differentiate into cells that make up specific tissues. In contrast, 
progenitor cells have a more limited capacity to proliferate and differentiate. The 
increased interest in stem cell biology has not only been as a result of the development 
of embryonic cells (ESs) from mice and humans, but also from the study and 
characterisation of adult stem cells. Adult tissue specific stem cells identified include 
haernatopoietic stem cells (HSCs) [2], neural [3], gastrointestinal [4], epidermal [5], 
hepatic [6] and mesenchymal stem cells (MSCs) [7] In addition, other tissue specific 
cells with more limited differentiation and proliferation potential, have been identified, 
including endothelial progenitor cells [8]. The study of the biology of stem and 
progenitor cells is a rapidly evolving field, which has the potential to impact significantly 
on the treatment of disease. Cardiology is already at the forefront of clinical research 
into novel cell therapies, and numerous clinical studies are already under way. The 
specific goals of cell therapy in cardiology are to regenerate cardiac muscle and to 
improve organ perfusion by a combination of angiogenesis and possibly 
vasculogenesis. Due to the plethora of different cell types presently under study it is not 
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clear which cell type, if any, will be optimal for cardiovascular applications. Numerous 
hurdles need to be overcome to establish that there is indeed a clinical benefit and at 
an acceptable risk (Table 1). As it is still not clear how cell therapy may improve 
perfusion or function of ischaemic organs there is still much basic research to be 
completed. This basic research needs to be independently confirmed and, only then, 
prudently translated into clinical practice. 
Table I Questions for cell therapy in cardiology 
Cell type e. g. bone marrow cells, HSCs, EPCs, MSCs, MAPCs, ES cells 
Cell donor: Autologous or tissue matched transplant 
Degree of cell differentiation: Undifferentiated stem cell or ex vivo manipulated/ 
differentiated cells 
Mechanism of delivery 
Timing of delivery 
Dose and dose frequency 
Immune rejection 
Risk of infection 
Risk of tumours 
Risk of arrhythmias 
HSC- haematopoietic stem cel/, MS(; - mesencl7ymal stromal cell, L: 6 emDryonic srem cell 
Focus of thesis 
The focus of this thesis will be on the study of bone marrow derived cells that may have 
the potential to differentiate into endothelium and, under appropriate conditions, 
improve perfusion and function of ischaemic tissues. Although there is clearly an 
overlap between cells involved in cardiomyocyte regeneration and endothelial 
progenitors (e. g. HSCs have been reported to differentiate into both cardiomyocytes 
and endothelium). This thesis will focus primarily on the potential of bone marrow 
derived endothelial progenitors and vascular regeneration. The term 'bone marrow 
derived endothelial progenitors' has been used in a broad sense which include 
circulating 'EPCs' and also cells isolated from the ex-vivo culture of bone marrow, 
including MAPCs. 
Plasticity of tissue specific stem cells 
It was previously thought that tissue specific stem cells could only differentiate 
into cells 
of their tissue of origin. However, recent studies suggest that tissue-specific stem cells 
can differentiate into lineages other than the tissue of origin. This has been most widely 
studied for haernatopoietic cells. After transplantation of bone marrow or enriched 
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HSCs, skeletal myoblasts [9], cardiac myoblasts [10], endothelium [8,11 ], hepatic and 
bilary duct epithelium [11 ] lung, gut and skin epithelia [12], and neuroectodermal cells 
of donor origin have been detected [13]. In addition some studies demonstrated that 
neural stem cells [14] as well as muscle cells [15] may actually be able to differentiate 
into haematopoietic cells. This ability for a stem cell from one tissue to differentiate into 
another is often referred to as plasticity. Whether these cells are able to 'change' into 
cells of a different lineage or actually are a more 'pluripotent' cell than previously 
considered is an area of ongoing research. However many reports have now indicated 
that there are numerous types of adult cells, including some non-stem cells, which 
have the ability to differentiate into endothelium. These observations have initiated a 
whole new area in cardiovascular research. Despite this enthusiasm the field of cell 
plasticity remains controversial. Cell fusion has been implicated as the explanation of 
some reports of plasticity [16]. Cell fusion can be defined as the fusing of 2 different 
cells to form a hybrid cell composed of the nuclear and cellular material of both cells. 
For example HSCs were originally observed to apparently differentiate into hepatocytes 
[11 ] however more recent studies suggest that fusion of myeloid intermediates is the 
most likely explanation [17]. Numerous studies have also questioned whether 
haernatopoietic cells can actually differentiate into endothelial cells [18-20] questioning 
whether the concept of a circulating EPC is correct [21 ]. 
Figure 1 Diagram of haernatopoietic stem cells differentiation 
The pluripotent haematopoietic stem cell is capable of not only proliferating indefinitely 
but also differentiation into all haematopoietic cell types to maintain these cell pools 
throughout the life of an organism. Putative sources of EPCs include the 
haematopoietic stem cell and monocytel macrophages. 
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Endothelial progenitor cells: EPCs 
Embryologically, the development of endothelial and haematopoietic stem cells (HSCs) 
are closely linked and both arise from the same precursor cells termed 
haemangioblasts [22]. This common lineage of blood and endothelium has been 
confirmed by the identification of common genes that are required for both endothelial 
and haernatopoietic lineage development. These genes include the vascular 
enclothelial receptor 2 [23] the stem cell leukaemia gene (SCL or Tal-1) [24] and Runx- 
1 [25], genes which are essential for both haematopoiesis and vascular development. 
In addition HSCs and endothelial cells have a number of phenotypic markers in 
common, such as the vascular endothelial receptor 2, VEGFR2, the angiopoietin 
receptor Tie-2 and CD34 [26] the human haematopoietic progenitor cell marker. It is 
speculated that a haemangioblast cell may exist in adults which would maintain the 
HSC and endothelial (or EPC) cell pool. However, at present there is limited evidence 
for the existence of such a cell as part of normal physiological homeostasis. 
Haernatopoiesis and haernatopoietic progenitors are maintained in adults through the 
self renewing Long Term HSC (LTHSC). Whether there is a common stem cell 
(haemangioblast) that maintains the HSC and EPC pool is not clear yet. Alternatively 
an enclothelial stem cell might exist, residing either in bone marrow or in the 
vasculature that can give rise to progenitors of enclothelial cells. This cell may well 
have similar markers to HSCs- 
Is there an endothelial stem cell and what is its 'niche'? 
Historically the generation of new blood vessels post-natally was believed to occur 
exclusively by angiogenesis. Angiogenesis is the generation of new blood vessels by 
the proliferation and sprouting of endothelial cells from differentiated cells of existing 
blood vessels, and not through the embryonic process of vasculogenesis [27] whereby 
blood vessels primarily are formed de novo by the initial differentiation of angioblast 
endothelial precursor cells [271. The discovery that there are endothelial progenitor cell 
populations in adults, arising from blood, has indicated that there may be an 
'endothelial stem cell' and that vasculogenesis may occur post natally. The concept 
that tissue specific stem cells exist within many organs is now accepted. For cells 
which continue to proliferate continuously throughout life, such as the gut and the skin, 
there are rare stem cells that can continue to divide and provide daughter cells 
throughout the life of the organism. Even in tissues with very low cell turn over, such as 
the heart and brain, stem cells have been isolated which can re-enter the cell cycle and 
produce differentiated daughter cells after appropriate stimuli [28]. Stem cells in animal 
tissues are often located and controlled by special tissue microenvironments known as 
niches. Studies of stem cell niches have revealed adhesive interactions, cell cycle 
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modifications and intercellular signals that operate to control stem cell behaviour in a 
tightly regulated manner. Candidate niches and regulatory molecules have been 
identified in many mammalian tissues, including bone marrow, skin, gut and brain [29]. 
Despite the discovery of EPCs, a definitive lendothelial stem cell' has not yet been 
clearly defined. An endothelial stem cell may well be located within the bone marrow or 
alternatively located locally within tissues. Although the HSC niche within bone marrow 
has been described [30] a specific niche for an endothelial stem cell locally within blood 
vessels has not yet been identified. 
The endothelial cell plays a key role in vessel development; during either 
vasculogenesis in the embryo or post natal angiogenesis in the adult it is the 
endothelial cell that initially forms a primitive capillary network which then results in the 
recruitment of mural cell progenitors which differentiate into supporting smooth muscle 
cells and pericytes [31]. Establishing the role of EPCs, tissue stem cells and local 
endothelial cells is fundamental to our understanding of vascular repair and neo- 
vascularisation. However, endothelial cells are a diverse heterogeneous population 
with distinct functional and phenotypic differences. It is likely that the mechanisms for 
the maintenance of vessel wall integrity by different fractions of stem cells and 
progenitors may be extremely complicated and will involve multiple cell types, including 
different fractions of cells with endothelial progenitor potential. 
What is an endothelial progenitor cell? 
The precise functional phenotype of EPCs is an area of ongoing research as there are 
different fractions within blood that may have endothelial progenitor potential. A 
working definition for EPCs are cells that circulate in blood and can differentiate into 
endothelial cells at sites of neo-vascularisation and vascular injury. At present these 
cells are considered to originate from bone marrow. EPCs are considered to be distinct 
from mature endothelial cells, both functionally and phenotypically although circulating 
mature endothelial cells (CECs) can also be found in peripheral blood [32] presumably 
sloughed from vessel walls. CECs are generally considered separate to EPCs primarily 
by their reduced ability to participate in vasculogenesis [33]. 
EPCs from haematopoietic progenitors 
EPCs were first described when a fraction of peripheral blood mononuclear cells 
enriched for CD34+ and VEGFR2+ haematopoietic progenitors cells [8] could be 
differentiated in vitro into endothelial-like cells and when these cells localised to areas 
of ischaemia in in vivo animal models. CD133, another haematopoietic progenitor cell 
surface marker of uncertain function, can also be used to identify EPCs [34]. As CID1 33 
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is not expressed on endothelial cells it allows them to be distinguished from CECs and 
differentiated endothelial cells. Numerous studies have demonstrated that populations 
of cells from blood, bone marrow, foetal liver and cord blood expressing the 
haematopoietic progenitor cell antigens CD34, sca-1 (mouse), c-kit, VEGFR2, CD133 
and side population cells are all enriched for endothelial progenitors [8,10,34-37]. The 
most commonly used surface phenotype in humans for EPCs is CD34, CD133 and 
VEGFR2, [38] markers that overlap with HSCs. However, it should be emphasised that 
when these markers are used simultaneously to identify EPCs, they identify only a very 
small fraction of circulating mononuclear cells [35]. 
Table 2 Putative surface markers of EPCs and MAPCs 
EPC MAPC 
CID1 33 + + 
VEGFR2 (Flkl) + + 
CD14 + 
SSEA1 + 
MHC Class I + 
EPCs from myelo-monocytic cells 
To confound the picture, CD14+ monocytes also have the ability to adopt an 
endothelial like phenotype and be incorporated into areas of neo-vascularisation and 
therefore have EPC potential [21,39-42]. Monocytes are known to be a relatively 
gplastic' cell type as they can differentiate into macrophages and dendritic cells. The 
phenotype and function of these macrophages is dependent on the tissue in which they 
reside. In the lung they become alveolar macrophages and in the liver they become 
Kupffer cells. In addition liver sinusoidal endothelial cells have features in common with 
monocytes as they express classical monocyte markers such as CD14, MHC Class 11 
and CD80 [39] and circulating monocytes also express a number of endothelial 
markers [39]. This indicates that CD14+ cells may represent a reserve of endothelial 
progenitors that can modulate their phenotype according to the local environment. 
Whether they act as temporary 'endothelial like macrophages' until they are replaced 
by other endothelial cells or act as true progenitor cells is still not clear yet. It has been 
suggested that CID1 4 derived 'EPCs' do not have the same angiogenic potential as true 
'EPCs' in ischaernic animal models [43]. Which fraction of blood or bone marrow 
harbouring the 'true' EPC is still not established and it is likely that both cell types are 
important. The differentiation of rare circulating HSCs into endothelium in significant 
numbers is likely to be an uncommon event whereas the differentiation to endothelium 
through a myeloid intermediate is likely to be a more frequent event [44]. Either way 
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more studies are required to establish the sequence of differentiation of EPCs into 
endothelium, in a way similar to the established differentiation pathways of HSCs into 
blood components through clearly defined progenitor intermediaries. Detailed gene 
tracking experiments using the cre-lox system should prove useful in answering these 
questions. The cre-lox system is based on the ability of the P1 bacteriophage 
cyclisation recombinase gene (cre) to effect recombination between pairs of specific 
loxP sites. Such recombination in a "Cre-lox" mouse can either activate or inactivate a 
gene of interest and can also be used to permanently track a specific cell type of 
interest by activation of a reporter gene at the genomic level. 
Other sources of endothelial progenitors 
In addition to haernatopoietic cells there is now evidence that there may be other 
sources of cells that have the ability to differentiate into endothelial cells. Mesenchymal 
stem cells fractions such as multi potent adult progenitor cells (MAPCs) can adopt an 
endothelial phenotype in vivo [45]. In addition tissue stem cells have been identified in 
skeletal muscle, cardiac muscle and within the adventitia of blood vessels that are able 
to adopt an endothelial like phenotype [28,46,47]. The relationship of these tissue 
stem cells and HSCs is not known, although it has been suggested that some tissue 
stem cells may actually be bone marrow derived [48]. It is conceivable that there may 
be subject between circulating cells and local stem and progenitor cells that is 
important for vascular repair and homeostasis. Whether HSC derived EPCs 
continuously replenish the endothelium or seed peripheral tissue stem cells is still not 
clear. 
Control, mobilisation and homing of bone marrow derived cells and EPCs 
Mobilisation of stem and progenitor cells, including EPCs, from their niche within the 
bone marrow is determined by the local environment, which is determined by 
fibroblasts, osteoblasts and endothelial cells as well as local and systemic cytokines. 
Mobilisation of EPCs is increased by a number of cytokines such as vascular 
endothelial growth factor (VEGF), erythropoietin (EPO), granulocyte colony stimulating 
factor (G-CSF), and stromal derived factor-1 (SDF-1), and also by the use of statins 
and by exercise, trauma and surgery (reviewed [38]). Physiologically, ischaernia is 
believed to be the predominant signal to induce EPC mobilisation from the bone 
marrow (Figure 2). Evidence suggests that VEGF may be a key mediator in this 
process [19,49]. VEGF initiates a cascade of events including the local release of 
SDF-1 - 
VEGF recruits bone marrow derived inflammatory cells probably via VEGFR1 
[19,50], and bone marrow derived EPCs via VEGFR2 [51]. Cells then home to the 
perivascular region of ischaemic vessels where they are retained by locally produced 
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SDF-1 binding to the chemokine receptor CXCR4 expressed by EPCs [38] and bone 
marrow derived inflammatory cells [19]. Recruited bone marrow derived cells 
subsequently secrete multiple factors that ultimately lead to the proliferation of local 
endothelial cells and angiogenesis. Which cell fractions acquire an endothelial cell 
phenotype is controversial, if it happens at all [19,49]. It is speculated that stem cells 
reside in a non-proliferative state. Under appropriate stimuli such as VEGF or placental 
growth factor (PIGF) EPCs are mobilised. VEGF induces the production of matrix 
metalloproteinase (MMP-9) within the BM which causes an increase in soluble Kit 
ligand (stem cell factor). Soluble Kit ligand results in increased cycling of quiescent 
stem and progenitor cells and enhanced translocation to a vascular niche that is 
conducive to stem-cell proliferation, differentiation and mobilisation to the peripheral 
circulation [52]. Angiogenic cytokine mediated MMP-9 activation is a crucial checkpoint 
in controlling the cell turnover and hence mobilisation of EPCs. Some evidence also 
points to an important role for the cell cycle inhibitors p2l [53] and p27 [54] in 
controlling the proliferation and mobilisation of EPCs and BM derived smooth muscle 
cells. Much remains poorly understood of the proliferation, migration, homing and 
differentiation of these cells. 
Figure 2 Homing, mobilisation and potential mechanism of action of EPCs 
Local ischaemia is believed to be the main drive for homing and recruitment of EPCs. 
Ischaemia results in the release of VEGF and SDF-1 which attract EPCs and trap them 
via the VEGF receptors and the SDF-1 receptor CXCR4. Other mechanisms for EPC 
mobilisation include statins via the NO (nitric oxide) pathway, VEGF and PIGF via 
MMP9. This results in soluble Kit ligand release, resulting in stem cell proliferation and 
mobilsation into the circulation. EPCs either act by differentiation into endothelail cells 
or alternatively by the secretion of paracrine cytokines which result in local endothelial 
cell proliferation. 
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p27 Kipl ,a member of the Cip/Kip family of cyclin-dependent kinase inhibitors, binds and 
alters the activities of cyclin D-, cyclin E-, and cyclin A-dependent kinases in quiescent 
non-cycling cells, leading to failure of Gj/S transition and cell cycle arrest [55]. An 
increase in the levels of p27 Kipl causes proliferating cells to exit the cell cycle, and a 
decrease in p27 Kipl is necessary for quiescent cells to resume division. p27-'ý- double 
knock-out mice develop hyperplasia in multiple organs, including endocrine tissues, 
thymus, and spleen [56]; however, the vascular phenotype of these mice is not known. 
The role of p27 Kipl in vascular disease is critical not only to understanding disease 
pathogenesis, but importantly, for the rational development of vascular therapies. For 
example, p27 Kipl mediates the anti-proliferative and anti-migratory activity of sirolimus 
coated stents [57]. If EPCs are integral to the normal homeostatic mechanism for 
repairing the vasculature, understanding their control mechanisms could prove a 
potentially valuable therapeutic target. The cell cycle inhibitor p2l"P' has already been 
shown to regulate EPCs and endothelial cells [53] and p27 Kipl may have a similar role. 
Evidence for the existence of EPCs in humans 
Many groups have demonstrated the ex vivo differentiation of human bone marrow or 
blood cells into cells with an endothelial like phenotype (reviewed [58]). In addition 
there are numerous animal studies indicating that EPCs incorporate into areas of neo- 
vascularisation and improve perfusion of ischaemic tissues [33,40,59,60]. However, 
data suggesting that EPCs exist under normal physiological conditions in humans is 
more limited. In patients who had left ventricular assist devices inserted, a proportion of 
the cells lining the assist devices were found to be CD133/ VEGFR2 + [61]. Although 
this suggests that circulating progenitors have the capacity to colonise neo-intimal 
surfaces, the colonisation of prosthetic devices may not be the same as neo- 
vascularisation. In a study of patients with Chronic Myeloid Leukaemia, it was possible 
to track bone marrow derived cells by using the BCR/ ABL fusion gene mutation, which 
is present in virtually all bone marrow derived cells. It was demonstrated that 
endothelial cells derived from the culture of blood had arisen from the same malignant 
cell clone, since they also contained the BCR-ABL-fusion gene. In addition in one 
patient, post mortern analysis of the vascular endothelium indicated a BM origin of 
some of these cells [62]. In a single case report of a man who had a sex mismatched 
peripheral blood stem cell transplant following an acute radiation accident, post mortem 
fluorescent in-situ hybridisation (FISH) analysis of vascular endothelium revealed that 
almost 25% of the endothelial cells of the aorta were of a female (XX) donor origin 
indicating the in vivo incorporation of donor derived EPCs [63]. Using a similar 
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approach, endothelial cells within tumours of patients who had received sex mis- 
matched bone marrow transplants were analysed by FISH of sex chromosomes [64]. 
Within these human tumour samples a small percentage of the endothelial cells within 
the tumours were found to be bone marrow derived, indicating that EPCs have a role in 
neo-vascularisation, although in much lower numbers than in animal models [50]. 
Similar studies in patients with sex-mismatched heart transplants indicated 24% of 
cardiac endothelial cells originated from the recipient, indicating that host circulating 
bone marrow derived cells may have been the source of these cells [65]. 
Despite the numerous studies reporting the differentiation of bone marrow derived cells 
into endothelium not all studies have confirmed this [18-20]. Many of these studies do 
confirm that bone marrow derived cells do accumulate close to blood vessels of 
ischaernic tissues or tumours, however they were unable to document actual 
differentiation of cells into an endothelial phenotype. It is their hypothesis, that while 
EIPCs do migrate and home to ischaemic tissues, they may improve perfusion through 
alternate paracrine mechanisms rather than differentiation. If EIPCs do not actually 
differentiate into endothelial cells, then the term 'endothelial progenitor cell' becomes 
misleading as these cells may not actually be progenitor cells after all. 
Quantifying EPCs in humans 
Circulating EPCs in humans have now been described by numerous groups that have 
used methods based on flow cytometry or ex vivo culture assays of blood to define and 
quantify them [8,33,66-69]. At present there is no 'gold standard' assay that can be 
used to quantify circulating EPCs in humans. Using flow cytometric analysis it is most 
commonly assumed that EPCs are CD34/CD133+ and VEGFR2+ cells. However, this 
does not take into account circulating myelo-monocytic cells. The detection and 
quantification of CD133NEGFR2+ cells, by flow cytometry is technically challenging 
due to the extreme rarity of these cells and there is no specific marker of an EPC [70]. 
As an alternative to flow cytometry, other assays for EPCs are based on the culture of 
whole blood or bone marrow mononuclear cells [67,71]. These approaches use 
density gradient separation of mononuclear cells followed by culture under specific 
conditions thought to encourage endothelial-like differentiation. Although purified 
populations of CD34 or CD133+ cells have been 'differentiated' into endothelial like 
cells, most culture assays use un-fractionated mononuclear cells. These cultures will 
inevitably contain a very low number of CD133NEGFR2+ cells but a significantly 
higher number of other cells such as monocytes. EPCs are quantified by counting the 
number of attached cells that take up acetylated LDL and bind the endothelial specific 
lectin Ulex Europaeus 1 [66] (acetylated LDL is also taken up by monocytes and 
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macrophages). Alternative approaches involve enumerating colonies with an 
I endothelial like phenotype' [67]. Important details of the culture process can make it 
difficult to compare an EPC estimate by one method/ laboratory to another (e. g. coating 
of culture surfaces such as human fibronectin or collagen, culture media, the cytokine 
supplements and serum used). In addition, the inter-laboratory reproducibility of these 
approaches is likely to be suboptimal because of the multiple steps and subjective 
evaluation of stained cells. At present there is no 'normal range' of EPCs as measured 
by tissue culture that will allow comparisons between different laboratories. Despite 
these concerns, it is possible that these different assays all measure the same thing. 
However at present there has been no systematic comparison of different techniques 
or a consensus on defining an EPC in an in vitro assay. 
Turnour endothelial markers as potential markers of endothelial progenitor cells 
At present there are no unique surface markers for circulating EPCs although there 
may be unique markers on endothelium at sites of angiogenesis or vasculogenesis. As 
EPCs may participate in angiogenesis [8] developing endothelium at sites of neo- 
vascularisation may have the same markers as EPCs. EPCs have been implicated as 
forming the neo-vasculature of developing tumours not only in mouse models [50] but 
also in humans [64]. Recently a novel group of markers called tumour endothelial 
markers (TEMs) have been identified which are selectively expressed on tumour 
endotheliurn but not on the normal vasculature [72]. These TEMs may be markers for 
developing endothelium and they may also be expressed on EPCs. 
EPCs as risk markers for CV risk 
It appears that despite the different approaches used for quantifying EPCs in humans 
and the uncertainty of their precise function under normal physiological conditions, 
EPCs do appear to provide useful clinical information about vascular risk and function. 
EPCs from similar cohorts of patients, such as those with ischaemic heart disease, but 
analysed by different laboratories, have similar findings in relative terms despite the 
different approaches used to quantify them [71,73]. Whether EIPCs are enumerated by 
the frequency of CD133/VEGFR2+ or by counting cultured cells or colonies, studies 
have shown that patients with established vascular disease have reduced number and 
function of EPCs. In addition, levels of EIPCs as measured by a culture assay appear to 
be inversely correlated with traditional risk factors for vascular disease [67]. This study 
suggested that levels of cultured EIPCs were a better predictor of vascular reactivity, 
measured by forearm plethysmography, than traditional cardiovascular risk factors. 
EPC level in patients with established coronary artery disease also provides prognostic 
information concerning the risk of future events [74]. It has been suggested that EPCs 
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may have a role in the maintenance of vascular health and that the reduction of EPCs 
seen in patients with cardiovascular disease may be a result of their depletion due to 
being consumed in repairing damaged endothelium resulting from chronic exposure to 
oxidative stress. This would also fit with the observation of reduced EPCs in elderly 
patients, indicating that their may be a finite supply of progenitors, presumably due to 
depletion of a bone marrow stem cell pool. However, theories such as this are 
speculative and at present the animal evidence for bone marrow-derived cells 
participating in post natal vasculogenesis under normal physiological conditions is 
limited. It appears that to significantly mobilise and engraft EPCs, some insult or 
stimulus is required. However, even under ischaemic conditions, not all studies can find 
evidence for incorporation of bone marrow derived cells into the endothelium of blood 
vessels [18]. 
Pre-clinical rational for clinical studies: evidence of benefit of EPCs and 
mechanism of action 
Numerous animal studies have demonstrated that infusion of bone marrow / blood 
derived EPCs can home to areas of ischaemia and become incorporated into vascular 
structures and in some studies improve perfusion and function [8,40,44,60,75-79]. 
Because the degree of engraftment of these cells between different studies is variable, 
it appears that not all of the improvements in function can be explained simply by de- 
novo formation of new blood vessels. In fact, endothelial differentiation is unlikely to 
explain the often remarkable benefits attributed to EPCs described in some animal 
models of ischaernia. In other studies, cell fusion may account for what was thought to 
be cell differentiation [16,80]. Whether true endothelial cell differentiation takes place 
to a degree that will ever be clinically useful is at present uncertain. It is likely that 
additional mechanisms may explain the favourable outcomes on function seen that 
may still result in a clinically beneficial response. These include paracrine effects, such 
as the release of angiogenic cytokines or the modulation of apoptosis and remodelling 
[21,60,81,82]. Cell therapy may thus prove therapeutically useful despite the lack of 
cell differentiation. 
Review of clinical trials using endothelial progenitor cells 
On the basis of encouraging animal experiments of cell therapy in myocardial and hind 
limb ischaernia models, numerous human studies are underway or have been 
completed. The concept of cardiomyocyte regeneration from HSC transplantation is at 
present controversial, due to conflicting results from studies in small mammals [10,83- 
85]. However, despite some studies being unable to demonstrate cardiomyocyte 
differentiation there still appears to be a benefit on LV function [86] and the premise of 
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improving tissue perfusion, by whatever mechanism, as the rationale for clinical trials, 
is still valid. Early clinical studies of cell therapy in cardiac disease were small, 
uncontrolled and non-randomised and delivered either freshly isolated BM MNCs [87- 
90], HSCs [91,92] or ex vivo cultured EPCs [93] to patients with chronic myocardial 
ischaemia or after acute myocardial infarction. All of these fractions may harbour 
endothelial progenitors although it is not possible to establish whether these cells 
actually differentiated into endothelium in these human studies. Cells have been 
delivered either by intra-coronary or direct myocardial injection, either at the time of 
cardiac surgery or after a percutaneous procedure. These small studies indicated that, 
in the short and medium term, the procedures appear well tolerated although there may 
be an increased risk of stent thrombosis and re-stenosis [92]. Although hard 
conclusions can not be made, the small studies suggested that their may be an 
improvement in LV function. 
Since these early studies there now have been a number of randomised controlled 
studies. The BOOST trial investigated the effects of intra-coronary autologous bone 
marrow cell infusion on left ventricular (LV) function measured by magnetic resonance 
imaging (MRI) after acute myocardial infarction and percutaneous coronary intervention 
(PCI) in 60 patients [83]. This study revealed an encouraging small improvement in LV 
function (increase of EF of 6.7 % in active treatment arm) although this was not 
associated with an improvement in LV dimensions or infarct size. In addition, the small 
effect on LV function was not maintained after 12 months follow up indicating the effect 
may have been due to more rapid recovery rather than an absolute benefit on LV 
function. This suggests that any beneficial effects were not as a result of an 
improvement in left ventricular remodelling. However, most patients in this study had 
reasonably well preserved LV function. This may have limited the ability to detect any 
benefit from cell therapy as the number of patients needed treat to detect small 
changes in LV function could potentially have exceeded the power of these studies. 
More recently there have been four more randomised controlled studies published [94- 
97] investigating the effects of transplantation of BM cell transplantation for cardiac 
ischaemia in the setting of acute myocardial infarction (AMI). The largest of these 
studies [94] (REPAIR-AMI study) was a multi-centre trial of intra-coronary infusion of 
BM cells after PCI for AMI. At 4 months there was an improvement in LV systolic 
function of 2.9 % measured by angiography in the BM treated group which was most 
pronounced in patients with the poorest LV function. However, the effect was modest 
and it remains to be seen whether the effects will be sustained or fade with time as in 
the BOOST study. 
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In contrast, the smaller ASTAMI study [96] did not find any improvement in LV function 
at 6 months follow up in the BM treated group, although this study may not have been 
powered to detect small changes in LV function. In another small randomised study by 
Janssens et al [97] there was no improvement in global LV function although infarct 
size and regional wall motion were improved in the BM treated group. 
Whether a more significant benefit would be seen in patients with more severe LV 
impairment needs to be addressed in future clinical trials. In addition, subtle differences 
in cell handling and delivery may affect outcome. The numerous studies published to 
date appear to indicate that, at present, cell therapy with bone marrow derived cells 
appears safe and technically feasible. To answer questions of clinical efficacy, future 
studies should be designed with sufficient power to detect clinically important outcome 
measures. 
Many important questions still remain regarding cell therapy for cardiac ischaemia. The 
optimal cell type and dose for clinical studies is not presently known. Although all of the 
cell types studied to date potentially contain EPCs, only one group has attempted to 
study ex vivo cultured EPCs [87]. It is hypothesised that culture modified EPCs 
encouraged to differentiate into a more endothelial like lineage may result in improved 
clinical efficacy. However, culturing cells considerably complicates the cell processing 
and potentially increases the risk of the procedure. Cultured cells can develop 
cytogenetic abnormalities and the consequences of introducing cytogenetically 
abnormal cells back into an individual are unknown. 
The clinical indication for cell therapy is also not established. Whether patients would 
benefit most from treatment after an acute MI or with chronic ischaemia is unclear. 
Another recent study (TOPCARE-CHD) [95] treated patients with chronic ischaemic 
heart disease with either BM or cultured blood progenitor cells in a crossover trial. BM 
cell transplantation resulted in significantly greater improvement in LV function than 
following cultured cell transplantation. This would suggest that there may be a benefit 
from cell therapy in chronic ischaemia as well as potentially facilitating recovery after 
AML 
Other clinical questions remain. Are patients who have been adequately revascularised 
by surgery or PCI likely to benefit, or should treatment be reserved for patients with 
evidence of persisting ischaemia? Also what is likely to be the optimal method of 
delivery, intra-coronary or by direct intra-myocardial injection? As EPC numbers and 
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their angiogenic potential are decreased in patients with coronary heart disease [71] 
this may limit the clinical usefulness of autologous cell therapy in these patients. The 
fate of cells after injection into humans also requires further studies. Although it is 
currently not possible to track cells at the single cell level in humans, more human 
studies are required to establish the duration of cell survival and their ultimate fate. MRI 
has been used to track MSCs labelled with iron particles in a porcine [98] and rat model 
{Stuckey, 2006 #20081 and could prove useful to study cell localisation in human 
studies. 
EPC mobilisation for the treatment of chronic ischaemia 
Another EPC-based strategy to improve perfusion in chronic ischaemia is to encourage 
mobilisation of endogenous EPCs. The circulating frequency of CD133NEGFR2+ 
EPCs is normally very low, but rises significantly after appropriate stimuli. Trauma [99] 
and ischaemia [59] have been shown to induce mobilisation of EPCs as have statins 
[66] and exercise [100]. Cytokines that mobilise EPCs include VEGF [76], EPO [101] 
G-CSF and SDF-1 [102]. It has been speculated that mobilising EPCs in patients with 
low levels, such as in patients with coronary artery disease, may result in beneficial 
effects on perfusion. This has been attempted in both acute myocardial infarction (AMI) 
[103-107] and chronic ischaemia [104,108] settings by using G-CSF Although no 
study has been sufficiently powered to fully assess clinical efficacy, circulating numbers 
of CD133NEGFR2+ cells can be increased significantly, even in coronary artery 
disease patients who typically have very low concentrations of these cells. The only 
randomised blinded studies of G-CSF treatment following AMI in patients treated with 
PCI failed to demonstrate any benefit on LV function although there were no excess of 
major adverse events in these studies. However, G-CSF may also have pro- 
inflammatory effects as it is associated with a pronounced rise in leucocytes and CRP. 
It is not yet known whether this is likely to be clinically significant, but accelerated stent 
re-stenosis [103,105] or atherosclerotic plaque instability may result from this pro- 
inflammatory state. A more low level, but sustained, increase in EPCs may be a more 
beneficial approach. Exercise [109] and statins [66] appear to increase EPC levels in 
blood and it has been speculated that this accounts for some of the beneficial effects of 
these interventions. 
Potential risks of cell therapy with endothelial progenitor cells 
Ensuring safety has been a priority of the early clinical trials of this new therapy. 
Although the studies described above using cell therapy have indicated the approach is 
safe there are theoretical risks. These include accelerated re-stenosis or stent 
thrombosis and formation of arrhythmogenic foci. As BM-derived cells may also 
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participate in turnour angiogenesis, potential malignant complications of angiogenic cell 
therapy will require long term follow up and surveillance. Circulating progenitor cells 
have also been implicated in the neo-vascularisation of atherosclerotic lesions [110] 
and may have deleterious effects on atherosclerotic plaque stability. A single animal 
study also revealed abnormal myocardial calcification after injection of unselected bone 
marrow cells into rat hearts after AMI indicating that unexpected differentiation events 
should also be monitored [111 ]. 
Multi-potent adult progenitor cells (MAPCs) 
A subset of BIVI derived stem cells, named multi-potent adult progenitor cells (MAPCs), 
have recently been isolated from mesenchymal stromal cell cultures. In addition to 
being able to proliferate extensively in vitro, IVIAPCs can differentiate into cells of all 3 
germ layers [45]. They also express the stem cell pluripotency gene, Oct 4, and have 
distinct surface marker differences to IVISCs (e. g. they are negative for the 
haematopoietic surface marker CD44 and express low levels of CID 133 and VEGFR2 
[45]). It has been suggested that IVIAPCs may therefore also be a precursor cell of 
EPCs [112]. Although there have been no reports of other laboratories isolating cells 
with precisely the same phenotype as IVIAPCs, other groups have subsequently 
demonstrated that fractions of bone marrow derived cells have similar tri-lineage 
pluripotent potential [113-115] and these cells may potentially regenerate the 
myocardium and vasculature after myocardial infarction. There is an inherent appeal of 
transplanting cell types capable of multi-lineage differentiation to regenerate diseased 
organs, as they may be able to restore the multiple cell types required to improve 
function of a diseased organ. However, any mechanism of action is likely to be 
complex. 
Phenotype of IVIAPCs 
MAPCs have been isolated from the bone marrow of humans, mice, pigs and monkeys 
[45]. MAPCs are isolated from the MSC fraction of cultured bone marrow in specific 
media optimised for their selection, which is characterised by low serum (2%), and the 
presence of platelet derived growth factor (PDGF-B), leukaemia inhibitory factor (LIF) 
and epidermal growth factor (EGF). In contrast to MSCs, MAPCs are able to be 
maintained for prolonged periods of time in culture without senescence and maintaining 
a high telomerase activity. MAPCs also express the transcription factors Oct 4 and 
Rex-1, normally associated with maintenance of the undifferentiated state of ES cells 
[116]. MAPCs express SSEA1 normally found on ES cells [117]. Mouse and rat 
MAPCs are dependent on the presence of leukaemia inhibitory factor (LIF) for ex vivo 
maintenance, again similar to ES cells. MAPCs are CD45 negative and negative for 
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other haematopoietic markers such as CD3, MAC-1, Gr-1, c-Kit, and CD34, indicating 
they do not fall within known haematopoietic cell fractions. MAPCs are also CD44 
negative, a marker normally present on MSCs [7]. MAPCs do not express MHC Class I 
or MHC Class 11 antigens. MHC Class I is normally expressed on all nucleated cells 
and erythrocytes and is the basis of recognition of self and cell mediated immunity 
through interaction with CD8+ T-cells. Lack of expression on an adult cell is unusual 
although again ES cells also have low MHC Class I expression. Low expression of 
MHC Class I also raises the possibility of allogenic cell transplantation. 
In addition to the above similarities to ES cells, MAPCs have also been differentiated 
into cells of all three germ layers in vitro (hepatocytes-endoderm, neurons-ectoderm 
and endothelium-mesoderm) and they incorporate into most somatic tissues when 
infused into minimally injured adult animals in vivo [45]. Most remarkably, mouse 
IVIAPCs injected into blastocysts formed chimeras of nearly all tissues studied, 
indicating properties similar to an ES cell. Cell fusion could, as mentioned previously, 
potentially account for this observation. 
MAPCs can differentiate into endothelium and may be the origin of endothelial 
progenitors 
MAPCs can be differentiated into endothelial like cells both in vitro and in vivo. In 
addition MAPCs contribute to neo-angiogenesis in a tumour and wound healing model 
[45]. As MAPCs also express CD1 33 and Flk1, it has been suggested that they may be 
the precursor cell to endothelial progenitors although evidence for the existence of 
MAPCs in vivo is lacking [45,118]. 
Potential negative aspects of using MAPCs 
As MAPC do not have specific markers it is not clear whether they exist in vivo or are a 
culture artefact as a result of reprogramming by the prolonged culture and isolation 
process. MAPCs are essentially defined by their ability to differentiate into cells of all 3 
germ cell lineages ex-vivo, hence requiring prolonged culture. MAPCs may also be the 
result of subtle cytogenetic abnormalities resulting in immortality and pluripotency, 
perhaps not detected by a non-detailed cytogenetic analysis. As MAPCs have so many 
similarities to ES cells, the formation of teratomas might be expected although this 
has 
not yet been reported [45]. Human and mouse ES cells can develop cytogenetic 
abnormalities after prolonged periods of culture and, despite the initial claims 
that 
MAPCs are cytogenetically stable, recent publications have acknowledged this risk 
[119]. As MAPCs are reported to be MHC Class I negative this may make them 
resistant to rejection form cell mediated immunity in non-autologous transplantation 
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experiments, but it may make them more susceptible to natural killer cells [120]. 
Finally, since the first report of MAPCs in 2002, no other laboratory has been able to 
independently isolate cells with the same phenotype. However, other groups have also 
isolated cells from cultured bone marrow with multi-potent properties [113-115] 
although each of these cell lines have different properties and markers. These and 
other studies do indicate that the concept of plasticity, or widespread pluripotency, of 
bone marrow derived cells may be a real phenomenon worthy of further study. 
MAPCs, appear to be a unique cell type that if their isolation can be reproduced will 
prove a great resource for research and potential clinical applications. The implications 
of isolating a pluripotent stem cell from adult bone marrow that can be expanded 
indefinitely in vitro, and be differentiated into any adult tissue, are profound. MAPCs 
have not been studied in ischaernic tissues; this will be a major focus the work of this 
PhD. 
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Hypotheses of thesis 
There is evidence that bone marrow derived cells have the potential to differentiate into 
non-haematopoietic tissues. Specifically, many studies have indicated that bone 
marrow may be a source of endothelial progenitor cells. These cells reportedly have 
the ability to differentiate into endothelium and be incorporated into areas of ischaernia. 
However, the origin and properties of EPCs has not yet been fully elucidated and 
remains controversial. 
Multi-potent adult progenitor cells (MAPCs) have a remarkable degree of pluripotency, 
including the ability to differentiate into endothelium [45]. MAPCs have been suggested 
to be the precursor to the putative 'EPC' [112]. Due to the apparent remarkable 
potential of MAPCs to differentiate into multiple tissues, MAPCs hold great promise 
both as a research tool and potential therapeutic cell source. 
The major hypotheses in this work are: 
1. EPCs can be isolated from haematopoietic cells of both humans and mice. 
2. EPCs originate from monocytes and, under certain conditions, can adopt an 
endothelial phenotype. 
3. The cell cycle inhibitor p27 kip is important for the control of EPC proliferation 
4. EPCs share surface markers in common with the neo-endothelium of tumours, and 
the neo-endothelium of tumours may originate from circulating EPCs. 
5. EPCs have exclusive novel markers allowing them to be distinguished from 
haematopoietic and endothelial cells 
6. MAPCs can be isolated from bone marrow and have tri-lineage, pluri-potent 
properties. 
7. MAPCs are a precursor cell of EPCs 
8. MAPCs can be differentiated into endothelium and will incorporate into sites of 
ischaemia and improve perfusion and function of ischaemic organs by undergoing 
differentiation into endothelial cells. 
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Aims of thesis 
Endothelial progenitor cells 
1) Isolate and phenotype EPCs from humans and mice in order to perform a serial 
analysis of gene expression (SAGE analysis) to identify novel gene markers of 
EPCs. 
2) Investigate the expression of tumour endothelial markers on EPCs 
3) Investigate the role of the cell cycle inhibitor p27 kip on EPCs 
4) Develop lineage tracing experiments using the Cre-Lox system to track the fate 
of haematopoietic cells and their role as potential endothelial progenitor cells 
Multi-potent adult progenitor cells 
1) Isolate MAPCs from mouse and rat bone marrow. 
2) Confirm the pluripotent capabilities of MAPCs by differentiating them into 
hepatocytes, neurones and endothelium. 
3) Develop an ischaernia hind limb model to investigate the effects of local delivery 
of cells into an ischaemic environment. 
4) Assess the angiogenic potential and mechanism of action of rMAPCs in the 
hind limb ischaemia model. 
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Chapter 2 Enclothelial Progenitor Cells 
Introduction 
Although endothelial progenitor cells were first described in 1997 [8], many 
fundamental questions about their biology remain unanswered. Controversy 
concerning the phenotype and surface markers of EPCs and their actual role in vivo 
during normal development and in disease states remains. Although bone marrow 
derived cells can adopt an endothelial phenotype in vitro, recent studies indicate that 
this may occur rarely or not at all in vivo [18-20,49,64]. In addition, the relationship 
between ex-vivo cultured cells (generally described as EPCs) and circulating cells 
remains unclear. Although EPC numbers and function appear diminished in patients 
with vascular disease there is a lack of evidence explaining the mechanism of this 
association. Also the pathways that control the proliferation of EPCs are not fully 
elucidated. In this chapter, I present work that addresses some of these issues. 
Human and mouse endothelial progenitor cells: phenotype and characterization 
Analysis of gene expression of endothelial progenitor cells 
Although EPCs have been functionally defined, their cell surface markers are shared 
with other cell types, including other progenitor cells. A molecular definition of EPCs 
using a technique such as Serial Analysis of Gene Expression (SAGE) [121] may allow 
us to identify unique markers for EPCs and also investigate their biology. By creating 
SAGE libraries of EPCs from patients with coronary artery disease, molecular targets 
might be identified that may account for the apparent difference in function and 
numbers of EPCs in patients with vascular disease [67]. This approach has been used 
successfully to identify novel surface markers for tumour endotheliurn . [72] 
Prior to constructing SAGE libraries of EPCs, defined as CD133NEGFR2+ cells, the 
phenotype and quantification of EPCs will be established by: 
1. Quantify CD133/VEGFR2 + cells in human peripheral blood. 
2. Attempt to culture EPC colonies from CID1 33 + cells. 
3. Confirm the 'endothelial like' phenotype of EPCs. 
4. Confirm that our methods of quantification of EPCs are reproducible. 
After these steps were completed (see results) it was decided that construction of a 
SAGE library using the present definition of an EPC (CD133/VEGFR2+) was not 
warranted due to the uncertainty of the relationship of CD133NEGFR2+ cells 
to 
cultured 'EPCs' and the unclear phenotype of EPCs. Work in this thesis 
demonstrates 
that EPCs may be related to monocytes and macrophages. In addition, isolating 
CD133NEGFR2+ cells in sufficient numbers for SAGE analysis would have been 
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technically challenging because of their low frequency in the peripheral blood of 
patients with vascular disease. 
The role of the cell cycle inhibitor p27 KIPI in regulating bone marrow derived 
endothelial progenitor cells in a mouse model of vascular injury 
As bone marrow derived EPCs are increasingly recognised as being potentially 
involved in vascular regeneration, the role of the cell cycle inhibitor p27 Kipl on EPC 
numbers, both at rest and after vascular injury, will be investigated. This was part of a 
larger study investigating the regulation of bone marrow derived immune cells in 
vascular disease by a p27 KiP1 dependent mechanism [122]. p27 Kipl ,a member of the 
Cip/Kip family of cycli n -dependent kinase inhibitors, binds and alters the activities of 
cyclin D-, cyclin E-, and cyclin A-dependent kinases in quiescent cells, leading to 
failure of G1/S transition and cell cycle arrest [55]. An increase in the levels of p27 Kipl 
causes proliferating cells to exit the cell cycle, and a decrease in p27 Kipl is necessary 
for quiescent cells to resume division. p27-'ý- mice develop hyperplasia in multiple 
organs, including endocrine tissues, thymus, and spleen [56]; however, the vascular 
phenotype of these mice is not known. The role of p27 Kipl in vascular diseases is critical 
not only to understanding disease pathogenesis, but importantly, to the design of 
vascular therapeutics. For example, p27 Kipl mediates the anti-proliferative and anti- 
migratory activity of sirolimus coated stents [57]. If EPCs are confirmed to be part of the 
normal homeostatic mechanism for repairing the vasculature, understanding the control 
mechanisms of EPC could prove a potentially valuable therapeutic option for patients 
with chronic ischaemic diseases. The cell cycle inhibitor p2lcP, has already been 
shown to regulate EPCs and endothelial cells [53] and it could be speculated that 
p27 Kipl may have a similar role. These experiments assume that EPCs circulate in 
blood, home to sites of vascular damage where they proliferate and participate in 
vascular repair in conjunction with cellular components from the local artery. However, 
the molecular mechanisms that regulate the contributions of any BM derived cell, 
including EPCs, to vascular lesions are not well understood. The hypothesis that p27 
Kipl 
directly regulates the proliferation of EPCs both at rest and after vascular injury will be 
explored in this thesis. 
Tumour endothelial markers as potential markers of endothelial progenitor cells 
At present there are no unique surface markers for circulating EPCs, however there 
may be specific surface markers on endothelial cells at sites of angiogenesis or 
vasculogenesis. As EPCs may participate in angiogenesis as suggested 
[8] it is 
hypothesised that developing endothelium at sites of neo-vascularisation may have the 
same markers as EPCs. EPCs have been reported to participate in the neo- 
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vasculature of developing tumours in mice models [50] as well as humans [64]. 
Recently a novel group of markers called Tumour endothelial markers (TEMs) have 
been identified (TEM 1,5,7 and 8) which are selectively expressed on tumour 
endothelium but not on the normal vasculature [72]. TEMs have been identified in 
multiple tumour types and also at sites of angiogenesis during wound healing and 
corpus luteum formation. Mice homologues of TEMs have been identified indicating 
these proteins are conserved across species [123]. In mice TEMs are also expressed 
during embryogenesis in addition to tumour vasculature. As TEMs are markers for 
developing endothelium in embryos, wounds and tumours they may also be expressed 
on EPCs. Using current definitions of EPCs in humans and mice I attempted to identify 
TEM expression. As there are no currently available antibodies to TEMs, I used a PCR- 
based approach to detect RNA expression of TEM 1,5,7 and 8 in humans and mice. 
Genetic lineage tracking of bone marrow derived cells in normal vascular 
development and after vascular injury using the Cre-Lox system 
To further investigate the origin of EPCs, and to investigate their role in normal 
vascular development and vascular injury repair, I designed experiments utilising 
lineage ancestry labelling based on the Cre-Lox system [124]. The cell of origin of 
EPCs remains controversial and CD34/CD133+ [8,35] or CD14+ cells [125] have been 
proposed. In addition, recent studies have questioned whether EPCs actually 
incorporate into the endothelial layer at all [18-20]. Numerous animal experiments 
purporting to demonstrate the differentiation of bone marrow derived cells into 
endothelium have used either bone marrow transplant experiments, transgenic mice 
utilising 'endothelial specific' promoters driving a reporter gene and immuno-fluorescent 
microscopy. Bone marrow transplant experiments often use unfractionated bone 
marrow resulting in the transplantation of numerous cell types, including bone marrow 
endothelium. This could explain the apparent endothelial engraftment, especially as 
ablative radiation is often utilised prior to the bone marrow transplant, which results in a 
degree of endothelial damage. The most commonly used reporter promoter to identify 
endotheliurn is Tie2 [126] which, although strongly expressed in endothelium [127], is 
also expressed in haernatopoietic stem cells and fractions of macrophages [128]. 
Finally failure to resolve overlapping cells that are closely localised during immuno- 
fluorescent tissue analysis [18] or the misinterpretation of tissue auto-fluorescence as 
coming from a transplanted GFP + cell [36] all potentially confound the reports of bone 
marrow cells differentiating into endothelium. As the original cell-specific markers of 
bone marrow cells are likely to change after they adopt a different phenotype, 
confirming the origin of a differentiated cell can be difficult. 
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To investigate whether endothelial cells are derived from cells of haematopoietic 
lineage during normal development and after vascular injury, mouse models were 
designed based on Cre-Lox technology to allow ancestry tracing of cells. Genetic 
lineage tracking using the Cre-Lox system allows a cell's origin to be permanently 
marked, independent of protein markers [129]. Mice were created in which the CD45 
(leucocytes), LysIVI (myeloid cells) or F4/80 (macrophages) cells, and their progeny, are 
irreversibly labelled with B-galactosidase. By analysing endothelial cells from these 
mice, it is possible to determine if they had originated from one of these lineages. In 
addition, in a femoral artery wire injury model, which causes a selective denudation of 
the endothelial layer [1301, the role of circulating blood cells in vascular repair was 
investigated. In addition by looking for B-Gal expression in the smooth muscle cells of 
the media the role of bone marrow derived smooth muscle progenitor cells was also 
investigated [131]. 
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Aims 
9 Establish the phenotype of EPCs in humans and mice. 
0 Establish if tumour enclothelial markers (TEMs) are expressed in endothelial 
progenitor cells. 
0 Investigate the role of the cell cycle inhibitor p27 KIP1 in regulating bone marrow 
derived endothelial progenitor cells in a mouse model of vascular injury. 
0 Use genetic lineage tracking of bone marrow derived cells in normal vascular 
development and after vascular injury using the cre-lox system. 
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Methods 
Animals 
All experiments were conducted according to the guidelines of the Animal Care and 
Use Committee of the National Heart, Lung, and Blood Institute. Tissues were 
harvested from wild type C57BL/6 mice unless otherwise stated. All surgery and tissue 
harvesting was performed on 8-12 week old mice. EPC responses were investigated in 
8 week old P27 kipl-/- [56] knockout mice after femoral artery wire injury and potential 
novel markers of EPCs investigated in ApoE4- mice. For lineage tracking experiments 
the Cre recombinase strains, Tie2-cre [127], CID45-cre [161, LysM-cre [132] and F4-80- 
cre [133] were crossed with the reporter strains R26R-LacZ [134]. Mice constitutively 
expressing the B-galactosidase gene (LacZ ROSA 26 mice) [135] served as positive 
controls for X-Gal staining. Eight week old Balb C mice were implanted with mouse 
renal cell carcinoma sub-cutaneously and tumours harvested 4 weeks later. 
Mouse sources 
ApoE-'-, C57BL/6 wild type (WT), Tie2-cre, R26R-LacZ, and ROSA26 were obtained 
from Jackson Laboratories. The CID45-cre mouse was a gift from Sean Morrison, 
Howard Hughes Medical Institute, USA. LysM-cre and F4/80-cre mice were obtained 
from Claus Pfeffer, University of DOsseldorf and p27 kipl-/- mice from Betsy Nabel, 
NHLBI, NIH. Balb C mice implanted with mouse renal cell carcinoma were supplied by 
Dr R Childs, NHLBI, NIH. Foetal livers were obtained from D17.5 embryos of C57BL/6 
mice from Cecilia Lo, NHLBI, NIH. 
Mouse genotyping 
Genotyping was performed by PCR amplification of mouse tail DNA using allele- 
specific probes. DNA was extracted using the DNAeasy kit (Qiagen, USA) as per 
manufacturer's instructions. 1 ul of eluted DNA was amplified with 92.5 ul ddH20,15 ul, 
1OX PCR Buffer, 15 ul DIVISO, 15 ul 10 mM dNTP, 5 ul primer F1 (10 mM stock), 5 ul 
primer R1 (10 mM stock), 2.5 ul TAQ polymerase (Applied Biosytems, USA). 1OX 
PCR 
Buffer was made with: 166 mM ammonium sulfate, 670 mM Tris pH 8.8,67 mMMgC12, 
50 mM 2-Me, 67uM EDTA. To detect the Cre transgene, PCR was performed on 
the 
above mix in a thermocycler (MJ Research) with 
forward 5- 
GAGTGATGAGGTTCGCAAGA-3' and reverse 3'-CTACACCAGAGACGGAAATC-5' 
primers (from Sean Morrison, Howard Hughes Medical Institute, 
USA), which amplify a 
615 bp fragment. Thirty cycles were performed: denaturing 94'C, 30 s; annealing 65"C, 
30 s; extension 720C, 2 min. To identify transgenic mice with the 
R26R promoter the 
following primers were used Fl: 5'-AAAGTCGCTCTGAGTTGTTAT-3', 
Rl: 5'- 
GCGAAGAGTTTGTCCTCAACC-3' and R2: 5' GGAGCGGGAGAAATGGATATG-3' 
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(Philip Soriano, Fred Hutchinson Cancer Research Centre, USA). F1+R1 amplifies a 
250 bp mutant PCR product and F1+R2 amplifies a 500 bp wild-type PCR product. 
Thirty cycles were performed: denaturing 94'C, 30 s; annealing 58*C, 30 s; extension 
65*C, 1 min. PCR products were resolved on 1% agarose gel in TBE buffer. 
Isolation of human endothelial progenitor cells by colony-forming assay 
A 20-ml sample of venous blood from healthy normal volunteers was used for the 
isolation of endothelial progenitor cells using a method developed at NIH (67]. 
Peripheral-blood mononuclear cells were isolated by Ficoll (Sigma-Aldrich, USA) 
density-gradient centrifugation. Briefly whole blood was layered over the Ficoll and 
centrifuged at 300g for 20 minutes at room temperature. Recovered cells were washed 
twice with phosphate-buffered saline and once in growth medium consisting of Medium 
199 (GIBCO, USA) supplemented with 20 percent foetal-calf serum (S igma-Ald rich), 
penicillin (100 U per millilitre), and streptomycin (100 pg per millilitre) (Sigma-Aldrich). 
Isolated cells were re-suspended in growth medium and plated on dishes pre-coated 
with human fibronectin (Biocoat, Becton Dickinson Labware, USA). To prevent the 
assay being contaminated with mature circulating endothelial cells, an initial pre-plating 
step was performed in a human fibronectin-coated six-well plate using 5 million 
peripheral-blood mononuclear cells per well in 5 ml of media. After 48 hours, the non- 
adherent cells were collected and 1 million cells in 1 ml of media were then re-plated 
onto human fibronectin(FN)-coated 24-well plates for a final assessment of the number 
of colonies. For immunohistochernistry (IHC), cells were also cultured on FN coated 
plastic chamber slides (1 million cells/ CM2) (Biocoat, Becton Dickinson Labware, USA). 
Growth medium was changed every three days, and the numbers of colonies counted 
7 days after plating. In separate experiments, freshly isolated human CD133 + cells 
(>99% purity confirmed by flow cytometry by blood bank) were provided by the NIH 
blood bank. CD133 cells were harvested from healthy normal volunteers after 
mobilisation with G-CSF (see below). Cells were cultured as for blood mononuclear 
cells. A colony of endothelial progenitor cells consisted of multiple thin, flat cells 
emanating from a central cluster of rounded cells (Figure 5, page 55). A central cluster 
alone without associated emerging cells was not counted as a colony. Counting the 
number of dual positive (LDL uptake and lectin binding) cells per high powered field 
was also used to quantify EPCs numbers. To confirm that human CD133+ cells were 
capable of proliferating, 1 million CD133+ cells were cultured for 14 days in 
1 ml of 
Stem Span media containing thrombopoietin 50ng/ml (TPO), G-CSF 10ng/ml and stem 
cell factor (SCF) 50 ng/ml (all from Stem Cell technologies, Ca) in 
24 well plates 
(Becton Dickinson Labware, USA). Growth medium was changed every three days, 
and the numbers of colonies counted 14 days after plating. Cultures were continued 
to 
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be observed for 21 days to detect late outgrowth colonies, however no highly 
proliferative cells were observed. 
Isolation of Human CD133+ cells from healthy human donors 
Healthy normal volunteers aged between 21 and 68 were given daily sub cutaneous 
injections of G-CSF (Filgrastim, Amgen, USA) 10 pg/kg/day for 5 days following 
baseline testing. This protocol was approved by the Scientific Review Committee and 
the Institutional Review Board of the National Heart, Lung, and Blood Institute, and 
informed written consent was obtained from all participants. G-CSF mobilised blood 
MNCs were then collected by aphaeresis on day 5. Following aphaeresis CD133+ cells 
were then isolated using CD1 33+ microbeads (Miltenyi Biotech, USA) and a CliniMACS 
automated cell sorter (Miltenyi Biotech, USA) as per manufacturer's instructions. 
Isolated leukocyte fractions (CD133 + and -) were then analysed by flow cytometry 
(EPICS, Beckman Coulter, USA) on EDTA-anticoagulated samples to confirm cell 
purity. Each sample was diluted with HBSS (Cambrex, USA) and 0.1% human serum 
albumin to achieve a WBC of 107 per ml/ tube, then incubated with human IgG for 
blocking and stained with fluorochrome-conjugated monoclonal antibodies to AC133- 
PE (Miltenyi Biotec, USA). A total of 105 events were acquired on each of two tubes. 
CD133+ populations were expressed as % of total leukocytes. Aliquots of 107 per ml/ 
tube CD133 + cells were then frozen in HBSS containing 10% DMSO. All CD133 cell 
processing was undertaken by the NIH Department of Transfusion Medicine. Aliquots 
of frozen CD1 33 + cells were subsequently supplied for experiments. 
Quantifying human enclothelial progenitor cells by flow cytometry 
Flow cytometry analysis for CD133 and VEGF-R2 was performed to quantify EPCs in 
peripheral blood mononuclear cells. Peripheral blood MNCs were isolated by Ficoll 
density-gradient centrifugation as above. Recovered cells were washed twice with 
phosphate-buffered saline and incubated with 20% mouse serum (Vector labs, USA) to 
block non-specific binding of antibodies. Two million MNCs were incubated with biotin- 
conjugated VEGFR-2 (Sigma, USA) PE conjugated CD133 (Miltenyi Biotech, CA, USA) 
and APC conjugated CD3 (T-lymphocytes), CD19 (B-lymphocytes) and CD33 
(monocytes) for 20 minutes at 40C (all from BID Biosciences). IgG isotypes were used 
as negative controls and to set flow gates. After washing twice, samples were 
incubated with avidin-PerCP (1: 10) for 45 minutes at 40C. Samples were washed with 
PBS and re-suspended in 300 pL of PBS prior to analysis on a FACS 
Calibur flow 
cytometer (BID Biosciences) with CellQuest Software (San Jose, 
Calif). After gating on 
mono-nuclear cells and excluding non viable cells (7-AAD + 
(BID Biosciences)) and 
cells in dump channel, dual VEGF-R2/ CD133 + cells were quantified. 
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Isolation of murine endothelial progenitor cells by colony-forming assay 
For the isolation of mouse endothelial progenitor cells, blood was collected via cardiac 
puncture and splenocytes isolated by gentle crushing of whole spleens followed by 40 
pM filtration. MNCs were then isolated by Ficoll (Sigma-Aldrich, USA) density-gradient 
centrifugation followed by incubation in red blood cell lysis buffer (LSM, ICN/ Cappel 
Biomedicals, USA) for 15 minutes on ice. Recovered cells were then washed twice with 
phosphate-buffered saline and re-suspended in growth medium. Cells were cultured in 
either Medium 199 (GIBCO) with 20% foetal-calf serum (Sigma-Aldrich) or EGM-2 
(Cambrex, MID, USA). EGM-2 is a proprietary media optimised and widely used for the 
culture of endothelial cells and EPCs. EGM-2 contains VEGF, epidermal growth factor 
(EGF), fibroblast growth factor (FGF), insulin like growth factor 1 (IGF-1) and 
hydrocortisone in addition to low dose FCS (2%). Isolated cells were then plated on 
dishes pre-coated with human fibronectin (BID Labware, USA). Growth medium was 
changed every three days, and the numbers of colonies counted 14 days after plating. 
Immuno-histochemistry and immuno-fluorescence of cultured cells 
Cells were washed with PBS and then fixed with 2% para-formaldehyde for 10 minutes 
then permeabilised with 1% NP40 before blocking with 10% horse serum (Vector labs, 
USA). Primary antibodies from mouse (5 uglml) were incubated at 40C overnight 
followed by secondary antibody of horse anti-mouse alkaline phosphatase (AP) 
conjugated (Vector labs, CA, USA) for 1 hour. After washing, slides were then 
incubated with fresh AP substrate (Vector labs, CA, USA). Slides were then dehydrated 
with alcohol prior to mounting with cover slip. Antibodies used against human cells 
included CD105 (RDI-CD105-SN, RDI, USA), CD146 (P1H12, MA1316985, Chemicon, 
USA), CD14 (RM052, Immunotech, USA), CD68 (EBM11, DAKO, USA) at a titre of 
1: 50-1: 100 to give final concentration of 5 pg/ml. 
DiL-Ac LDL uptake and lectin immuno-fluorescent staining 
For LDL uptake and lectin dual staining, unfixed cultured cells were incubated with 
1 
ug/ml of Di labelled acetylated LDL (Molecular Probes, USA) in media 
for 4 hours in an 
incubator at 370C. Cells were then washed carefully with PBS and 
fixed with 2% para- 
formaldehyde and incubated for 1 hour with UAE lectin for human and 
BS1 lectin for 
mouse 1 pg/ ml (both Sigma Aldrich). Slides were the dehydrated and mounted prior 
to 
microscopy. 
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Harvesting of murine tissues for TEMs expression analysis 
Aortas were obtained from 6 month old ApoE -- or WT male mice fed a western diet 
after euthanasia withC02. Turnours were removed from Balb C mice implanted with 
mouse renal cell carcinoma sub-cutaneously 28 days previously. Foetal livers were 
obtained from D17.5 embryos (from Cecilia Lo, NHLBI, NIH). 
Isolation of RNA 
RNA was isolated from human CD133+ cells, human and mouse cultured EPCs, 
mouse aortas, tumours and foetal livers using the RNA isolation system from Promega 
as described in manufacturers instructions. Tissues and cells were homogenised in a 
polytron (Brinkman, Germany). After addition of sodium acetate, RNA was extracted 
using phenol chloroform: alcohol separation. After centrifugation the aqueous phase 
was washed with isopropanol and RNA precipitated with 2 ethanol washes. RNA was 
quantified with a spectrophotometer (Biomate3, Thermo Electron Corp. MA, USA) 
measuring OD at 260 and 280 nm to confirm purity. In some preparations RNA was 
visualized after running on a MOPS/ formaldehyde 1.5% agarose gel. 
Design of turnour endothelial marker primers 
Specific primers for hTEMs and mTEMs were designed using Vector NTI software. 
Primer pairs were designed to cross an intron where possible with an optimal GC ratio 
and low likelihood of forming dimers and hairpins. For mouse (m) primers designed, 
confirmation of the correct PCIR product was established by undertaking PCR in tissues 
known to express TEMs. It was not possible to confirm that the human primers 
amplified had the correct product because of lack of a positive control tissue from 
humans. 
cDNA synthesis and quantitative real-time PCR. 
mRNA from lysates were purified by binding to poly(dT) magnetic beads (Dynal, USA) 
and reverse transcribed by using SuperScript 11 (Invitrogen, USA) as per manufacturer's 
instructions. Reactions were also undertaken in the absence of reverse transcriptase 
(RT-). Standard quantitative RT PCR was performed in duplicate using SYBR Green 
fluorescence on the 7900HT (Applied Biosystems, USA). 0.5 pL of total cDNA was 
amplified in duplicate with SYBR Green PCR Master Mix (Applied Biosystems) in a 25 
ul reaction mix with 7.5 pmol of forward and reverse primers. Amplification was 
performed over 40 cycles (initial denaturation 95 'C/10 minutes, followed by 95 
'C/15 
seconds, annealing and extension 60/ 'C 1 minute). RT-PCR data were normalised 
by 
measuring average cycle threshold (Ct) ratios between candidate genes and the control 
gene, eukaryotic translation initiation factor (EIF3S5 or TIF). In mice glyceraldehyde-3- 
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phosphate dehydrogenase (GAPDH) did not perform well as a control gene as pseudo 
genes were detected in the RT-samples. This indicated a degree of genomic 
contamination in our RNA preparation despite using poly (dT) magnetic beads for RNA 
purification. GAPDH was therefore not used as a control gene for experiments. PCR 
products were resolved by analysis on a 1% agarose gel in TBE with a 100-bp ladder 
and visualised with a Kodak Image station 440. In some experiments regular PCR was 
undertaken and products analysed after gel electrophoresis and ethidium bromide 
staining. 
Table 3 Primer sequences designed in house for mouse (m) and human TEM 
genes 
HUMAN MOUSE 
Name Sequence 5'-3' Name Sequence 5'-3' 
TEMl-Fl ACCCATCAGCCCTACACATCC TEM8-Fl TATGGTGGGAGAGGCGTTGG 
TEMl-Rl GTTCTGTTGGGCTCTTGCTCC TEM8-Rl AGGTGGAGTAGAGGCAGGAAGG 
TEMl-F2 TCTCTCATTCAGCACAGCCTCC TEM8-F2 AGAAGAGGAGTGGTGATAAAGCCC 
TEM1-R2 TGGGTGAGGTCTGGTTAGTGGG TEM8-R2 CCAGCATTTCCAAAGTTGTAGGC 
TEM2-Fl CCCATTTCACAGAGGATACCACCG mTEMl-Fl ATGAGTGTGTGGAAGAGGTGGACG 
TEM2-Rl TTGCTGTGTGACCTGGAGGAAGTT mTEMl-Rl TTGTGGGCAGAAGGTAGTGTGGGT 
TEM2-F2 TCCATCGTGTCTCGCTTCCTCA mTEMl-F2 ATGAGTGTGTGGAAGAGGTGGACG 
TEM2-R2 TCGCCGTGGTCGTTCTTGTT mTEMl-R2 AAGTCAGGTGGATGTGTAGGTGCC 
TEM5-Fl CAGCAAAGCAGAGATGAGAGCG mTEM5-Fl TGTGGTGTGGGAAACTTGACGG 
TEM5-Rl TAGTCCCGTGGTGTTGTAAGGC mTEM5-Rl TGATGCCGCAGATTATGAGGG 
TEM5-F2 GGCATCACACTCACCAACTACCA mTEM5-F2 GCTCCTATCCGCTCAACACTACCA 
TEM5-R2 AGCAGAATCAAAGCCACAGGG mTEM5-R2 ATTGTCTGTCGCTACTGCTGAGGG 
TEM7-Fl CCTCCACTCCTGACATTCTTTCCC mTEM8-Fl ATGCTTCCTTCCTCAGTTTCCACA 
TEM7-Rl CAATAACCAGACTCATCCGAACGC mTEM8-Rl TTGGGCGTTCTTTCAGGTCG 
TEM7-F2 CACTACCTCCTCCTCCCTCTTCAT mTEM8-F2 GAAGAAGACGATGATGGTTTGCC 
TEM7-R2 AACCACCATCTCATCTCAGCCC mTEM8-R2 TGAAGTTGATACAGCGTCCCG 
mTIF-Fl TGCTGTCTGGGAAAGTGTCTGC mTIF-Rl TGACTCAAGACCACAAAGAAACCC 
mVE-Cad-Fl TGGAACCAGCACGCTAACCG mVE Cad-Rl AGGGACTCTGCGATGGACTCTG 
mF4/80 Fl ATCTCCCTGGTATGTCTTGCCTTG mF4/80 rl AAGCAGAGATTATGACCACCAGGA 
Femoral wire injury model 
To identify the origin of cells involved in vascular development and vascular wound 
injury repair, the origin of vascular cells were studied using lineage tracing based on 
the cre-lox system to genetically mark cells of a haematopoietic origin with expression 
of LacZ. The role of the cell cycle inhibitor p27 
Kipl on EPC mobilisation after vascular 
injury was also investigated. Uninjured arteries were used to study normal development 
and injured arteries to study the role of haernatopoietic cells after injury. Mice were 
investigated using an established model of vascular wire injury [130]. This procedure 
was performed by a single surgeon (Dr Hong San). Mice were anaesthetised with 
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inhaled Isoflurane (1-2%), placed under a dissecting microscope, and the femoral 
arteries were exposed. A 0.010 inch intravascular guide wire was inserted into the 
saphenous artery, advanced proximally toward the femoral artery, and passed within 
the artery 3 times. This had been previously confirmed in house to reliably result in 
denudation of the endothelium, which is followed by re-endothelialisation and neo- 
intimal reaction [130]. Four weeks post-injury, mice were anesthetised, and the arterial 
circulation was flushed with saline. The injured arteries were excised, fixed with 2% 
para-formaldehyde 0.5% gluteraldehyde for 10 minutes and then incubated overnight 
with freshly made X-Gal reagent. Blue X-Gal stained cells would imply that the cells 
had originated from cells that had expressed the cre reporter constructs e. g. CD45, 
LysM or F4/80. Samples were then either embedded in paraffin or OCT (Tissue Tek, 
USA). Five p sections were cut and counterstained with either H&E or nuclear fast red 
(Vector labs, USA). Freshly made X Gal reagent included X-Gal 1 mg/ml, K- 
FerrIcyanide 5mM, K- FerrOcyanide 5mM, MgC122mM, NP40 0.02%, SIDS 0.01% in 
PBS (all Sigma Aldrich, USA). In order to establish the phenotype of P-gal + cells, 
femoral artery sections were co-stained for markers of smooth muscle; a smooth 
muscle action (SMact) 1: 5000 titre (Sigma, USA) and endothelium; von Willebrand 
factor (VWF) 1: 1000 titre (Dako, USA). Briefly sections were incubated with primary 
antibody or isotype control for 45 minutes after blocking with 10% goat serum. Sections 
were then incubated with secondary antibody (Alexa Fluor 594 or 488 F(ab)2, 
Molecular Probes, USA) at a titre of 1: 1000 at room temperature for 45 minutes 
(1: 1000). After secondary incubation, cells were rinsed and mounted with DAR hard 
set mounting media (Vectashield, USA). 
Mouse breeding strategy for Cre-Lox experiments 
In order to study the fate of various haematopoietic lineages (CD45, LysM and 174/80 + 
cells) lineage ancestry mice were created to genetically label these cells and their 
progeny/ ancestors. This was in order to investigate if haematopoietic cells formed 
endothelial or smooth muscle cells in vivo, either as part of normal development or 
after vascular injury. Mice expressing cre recombinase under lineage specific 
promoters (CD45, LysM and F4/80) were crossed with the reporter strain mouse R26R 
lacZ (Figure 4, page 52). The progeny of these crosses should express cre 
recombinase only in cells which express the lineage specific promoter. The cre 
recombinase will excise the STOP codon in between the 2 excision loxP sites of the 
ROSA26 promoter (Figure 3, page 51). This will result inA galactosidase expression in 
a lineage restricted manner. As the activation of the ROSA26 promoter is at the genetic 
level all progeny/ ancestors of labelled cells will also express A-Gal. By studying A-Gal 
expression in the endothelial cells and smooth muscle cells of the femoral arteries of 
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these double transgenic mice it was possible to investigate the role of CD45, LysM and 
174/80 cells in the development of these tissues. In addition by submitting the arteries to 
vascular injury it was possible to investigate the role of these cells in tissue repair and 
regeneration. Specifically evidence of endothelial or smooth muscle cells having arisen 
from cells that expressed the haernatopoietic markers, CD45, LysM and F4/80 was 
looked for. P Gal expression was assessed in various haernatopoietic lineages and in 
femoral arteries, before and after vascular injury. 
Figure 3 Structure of the R26R transgenic vector and the production of tissue 
specific labelling by specific promoter controlled expression of cre recombinase 
R26R mice were crossed with mice expressing cre recombinase under the control of 
tissue specific promoters (e. g. Tie2, CD45, LysM and F4180). There is a stop codon 
flanked by 2 LoxP sites inserted into the ROSA promoter that drives expression of 
LacZ (same vector as in the ROSA26 mouse). Under normal conditions no 8-gal is 
expressed. When a cell also expresses cre recombinase, the stop codon is excised 
from the DNA resulting in activation of the ROSA promoter and expression ofB-Gal. As 
the activationl excision is at the genetic level all ancestors/ progeny should be marked 
by expression of the LacZ gene which can be readily detected after X-Gal staining. 
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Figure 4 Breeding strategy for producing lineage specific ancestry mice based 
on CD45 cre mice 
Homozygous R26R lacZ mice were crossed with heterozygous CD45-cre mice. The CD45cre-R26R + pups express cre recombinase only in CD45 + cells. Excision of the stop codon in the R26R transgene occurs only in CD45 + cells and their progenyl ancestors. After X-Gal staining all tissues that express or are derived from cells that expressed CD45 should be positive after X-Gal stainin. q. This will be indeDendent of t expression of CD45. 
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Isolation of mouse haernatopoietic cells from blood, spleen and bone marrow 
Blood was collected via cardiac puncture and MNCs isolated by Ficoll (Sigma Aldrich) 
density-gradient centrifugation followed by incubation in ACK RBC lysis buffer (LSM, 
ICN/ Cappel Biomedicals, USA) for 15 minutes 4 'C. Splenocytes were isolated by 
gently crushing the freshly isolated spleen in PBS with the end of a2 ml syringe after 
removing fat and connective tissue. Cells were then filtered through a 40 p filter (BID 
Biosciences, USA) washed in PBS and incubated with ACK RBC lysis buffer (ICN/ 
Cappel Biomedicals, USA) for 15 minutes 4 'C. A minimum of 30 million nucleated cells 
could be isolated per spleen. Bone marrow was obtained from 8 week-old male mice 
after euthanasia with C02- Marrow cell suspensions were flushed from femurs and 
tibias, filtered and RBC lysed with ACK lysis buffer. Cells were then submitted to 
antibody and fluorescein di-p-D-galactopyranosidase (FDG) staining. 
"Ir el 
4.11 
ICD45 Specific Promoter 
52 
Flow cytornetry analysis and FDG loading of murine haernatopoietic cells 
Blood, spleen or bone marrow cells were collected from mice as described above, 
initially stained with fluorescent antibodies (Table 4) and subsequently loaded with 1 
mM fluorescein di-p-D-galactopyranosidase (FDG, Molecular Probes, USA) by 
hypotonic shock to investigate reporter gene activation in various blood lineages. 
For HSC lineage, -ve C-kit + cells were identified. Bone marrow cells were washed and 
re-suspended in 90 ul of FACS/FDG buffer (PBS with 2 mM EDTA, 10 mM HEPES and 
0.5% FBS) and incubated with 10 pl of biotin labelled lineage depletion antibody 
cocktail (Miltenyi, USA). After washing, cells were incubated with 1 pl of Streptavadin- 
PE-Cy5 and 1 ul of anti c-Kit-APC (CD1 17 APC) or isotype APC for 15 minutes at 4 OC. 
Spleen and blood cells were submitted to single antibody phenotyping to quantify 
reporter gene activation in haematopoietic lineages (Table 4). Cells were suspended in 
100 pl of buffer and incubated with 0.5 ug of primary antibody or isotype control at 4'C 
for 15 minutes. 
After antibody staining BM, spleen or blood cells were subsequently washed and re- 
suspended in buffer + chloroquine 300 uM (to inhibit endogenous lysozymal 
galactosidase activity). Cells, along with FDG 2 mM in dH20, were warmed for 10 
minutes in a 370C water bath and 100 ul of hypotonic 2 mM FDG (or dH20 as control) 
was then rapidly added to cells and returned to 37'C for 1 minute. The final 
concentration of FDG was 1 mM. After quenching with 1.8 ml of buffer media 
containing 1.5 uM propidiurn iodide (Molecular Probes) to identify dead cells, cells were 
analysed for P-Gal expression by flow cytometry. Samples were kept on ice, 
immediately analysed on a flow cytometer (Canto, BID, USA) and data subsequently 
analysed with FCS Express software (De novo Software, Canada). Failure to analyse 
cells rapidly resulted in activated fluorescein leaking from +ve to -ve cells. 
Microscopy 
Slides of cultured cells and tissue sections were viewed using a fluorescence 
microscope (Nikon Eclipse E800) and light microscope (Nikon Eclipse, E600) and 
images captured with a digital Axio Imager (Carl Zeiss, USA) and analysed with 
QCapture Pro software (Qimaging, Ca). 
Statistical analysis 
All results are expressed as mean ± sem. Statistical significance was evaluated with an 
unpaired Student Mest for comparison between 2 groups or with 
ANOVA for 
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comparison between multiple groups (Prism 4 software, Graphpad Software, USA). A 
probability value of p <0.05 was considered significant. 
Table 4 Antibodies used for haematopoietic lineage experiments 
Antibody Source/ Clone Antigen reactivity 
Lineage cell Abstaining kit Miltenyi CD5, B220, CD1 1 b, Gr-1, Terl 19 
CID 19 APC: BID 550992 B lymphocytes 
CD1 17 (c-Kit) APC: BID 553356 HSCs 
CD3 PE-Cy5: BID 555276 T Lymphocytes 
Gr-1 APC: BID 553129 Neutrophils 
CD1 1b APC: BID 553312 Myeloid cells 
CD45 PE-Cy5: BID 553082 All leukocytes 
F4/80 APC MF 48005 Monocyte/ macrophages 
IgG 2b K PE-CY5: BID 553990 
IgG 2bK APC: BID 553991 
Streptavadin APC BID 554062 
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Results 
Phenotype of human EPCs from peripheral blood. 
It was possible to reliably culture colonies of proliferating cells, and also isolated 
attached cells, from the buffy coat of human peripheral blood under conditions shown 
to allow the isolation of EPCs as shown in Figure 5. The number of EPCs were 
estimated by counting the proliferating colonies per well of 24 well plate [67] or 
counting the number of cells per high powered field [136]. However, despite repeated 
blood draws from the same individual, there was considerable variability in the assay 
system using both methods, making reliable quantitative analysis of EPCs difficult 
(range of 0-10 colonies per well or 5-80 cells per hpf for the same individual). However, 
I did confirm that these cultured cells took up Di labelled ac-LIDL and the endothelial 
specific lectin UAE. In addition to cells being positive for the endothelial markers 
CD105 and P11-112, cells were positive for the monocyte/ macrophage markers CD14 
and CD68 (Figure 6). As 'EPC colonies' became displaced during the IHC protocol, 
when blood MNC were cultured on chamber slides, the expression of antigens in EPC 
colonies was not confirmed. 
Figure 5 Light photomicrograph of human EPC colony after 7 days culture 
A light microscope image xIO0 of an EPC colony from human blood MNC cultured in 
M199 media for 7 days on human fibronectin coated plates. The central tightly packed 
cluster of proliferating cells is surrounded by spindle shaped cells migrating out from 
the colony centre. Colonies of proliferating cells could be counted per well of 24 well 
plate to give a measure of EPC numbers/ million MNC. 
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Figure 6 Light photomicrographs of human cultured EPCs confirmed expression 
of CD14 and CD68 in addition to CD105 and P11-112 
A light microscopy image of human blood MNC cultured in M199 media for 7 days before being fixed and stained with specific antibodies to monocyte and endothelial markers. Cells were incubated with primary antibodies or isotype control followed by an alkaline phosphatase conjugated secondary antibody. After incubation with alkaline phosphatase substrate, positive cells labelled with a blue colour. 'EPCs' expressed both endothelial (B) PIH12, (C) CD105 and monocytel macrophage markers (D) CD14, (E) CD69, (A) isotype control. 
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EPCs could not be cultured from pure CD133+ cells 
The CD1 33/ VEGFR2+ phenotype has been suggested to be that of EPCs in humans 
[35]. If these colonies (and attached cells) that can be cultured from whole blood 
mononuclear cells are EPCs it should be possible to culture EPCs from CD133 cells. 
CD133 cells were supplied from the NIH blood bank after collection by aphaeresis from 
G-CSF treated healthy normal volunteers. The purity of CD133 cells was over 95% by 
flow cytometry confirmed by the NIH blood bank. Cells were provided as frozen 
aliquots of 1 million cells/ml/vial. Attempts to culture CD133 cells under the same 
conditions used for blood IVINC culture (M199 media with 20% FIBS on FN coated 24 
well flasks). Despite 3 attempts each to culture EPCs from CD133+ cells from 5 
different donors, EPC colonies were never detected. In addition, almost no CD133+ 
cells attached to the wells and the rare cells that did attach failed to take up Ac LDL. 
Next attempts were made to culture cells in EGM-2, used by other groups to culture 
EIPCs, and again it was not possible to establish cells with an EPC phenotype. It has 
been shown that endothelial cells with a more 'differentiated' phenotype can be 
cultured from CD133+ cells [34]. Again despite multiple attempts growing colonies of 
cobblestone cells were never established. To prove that the CD133+ cells were 
capable of proliferation, I cultured cells under conditions known to allow HSC to 
proliferate in vitro [137]. Under these conditions (Stem Span media with TPO, G-CSF 
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and SCIF (all from Stem Cell Technologies, Ca) CD133 cells proliferated rapidly (cell 
doubling 18 hours) although the majority of cells remained in suspension. In addition, 
the proliferating cells rapidly lost their expression of CD133 measured by flow 
cytornetry (data not shown). 
Flow cytometry analysis of the frequency of CD133/ VEGF R2 + cells in human 
peripheral blood 
After optimising methods to quantify EPCs previously defined as being CD133/ 
VEGFR2 + [35]. 1 measured the frequency of cells in healthy individuals. Because of 
the low frequency of events I ensured non specific antibody binding was blocked as far 
as possible and dead cells excluded. In addition I established a dump channel to 
eliminate unwanted cells. Using this approach I could identify CD133/VEGF R2 + cells, 
however the frequency of these cells was extremely low (0.001 % of blood mononuclear 
cells) Figure 7. 
Figure 7 Identification of human CD133/KDR + EPCs with flow cytometry 
Freshly isolated blood MNCs were isolated from a healthy volunteer. LEFT A dump 
channel was used to exclude dead cells, CD3 T lymphocytes, CD19 B lymphocytes 
and CD33 myeloid cells from further analysis. RIGHT Mononuclear cells not in the 
dump channel are then examined for co-expression of CD133 and VEGFR2 (KDR). 
The frequency of dual positive cells is approx I in 100,000 blood MNC. Gates and 
acquisition voltages were set using isotype controls. 
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Phenotype of mouse EPCs from cultured splenocytes 
It was not posible to establish cultures of EPCs from the blood of mice despite multiple 
attempts using either EGM-2 or M199 with 20% serum, reproducing conditions that 
others have used [138]. However, it was possible to consistently isolate proliferating 
colonies and isolated attached cells by culturing mouse splenocytes under 'endothelial 
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growth conditions' in EGM-2 media as has been shown by others [139]. The colony 
count number after 14 days of culture was reasonably reproducible between wild type 
C57BL/6 mice (mean 14 ± 6.4, range 6-22). In addition both colonies and isolated cells 
took up LIDL and bound the mouse endothelial lectin BS1 (Figure 8). Although specific 
antibody staining for more endothelial or monocyte markers was not undertaken (as 
performed on human EPCs) a PCR analysis of cells after 2 weeks in culture using 
primers specific for the mouse monocyte marker F4-80 and the endothelial marker ve- 
cadherin was performed. The expression levels in RNA from blood mononuclear cells, 
cultured EPCs and cardiac tissue was compared. Analysis of PCR products after gel 
electrophoresis and ethidium bromide staining revealed that although the EPCs are 
positive for VE-cadherin they are also strongly positive for the monocyte marker F4-80 
(Figure 9). On the basis of these observations it could be concluded that mouse 
cultured 'EPCs' express both endothelial and monocyte markers. 
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Figure 8 Immuno fluorescent photomicrograph of cultured mouse EPCs which 
take up Di AcLDL and bind BS1 lectin 
Mouse splenocytes were cultured in EGM-2 on FN coated plates. To demonstrate the 
different culture morphologies two groips of cultured cells are shown, column I (A, C, E) 
and column 2 (B, D, F). After 14 days cells were incubated with Di Ac LDL (A &B top) 
and BS I lectin (C &D middle). Overlay of Di Ac LDL uptake and BS I lectin binding (E 
&F bottom). Clusters of cells can be seen to take up LDL and bind endothelial specific 
lectins consistent with an EPC phenotype. 
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Figure 9 Photomicrograph of electrophoresis gel of PCR products from mouse 
cultured EPCs confirming expression of markers of endothelial cells and 
monocytes. 
EPCs cultured from mouse splenocytes were collected after 14 days, RNA extracted and submitted to RT-PCR analysis for the monocyte marker F4180 and endothelial 
marker ve-cadherin. Mouse MNCs and cardiac tissue were used for comparison. F4180 is expressed in MNCs and EPCs and weakly in cardiac tissue (presumably due to 
contaminating blood within the cardiac tissue). Ve-cadherin is expressed in the cardiac tissue and also strongly in EPCs. There is no non-specific signal with the RT- or no template controls (end). There is even expression of the control gene TIF across all 
samples. 
The role of p27 
kipl 
on EPC numbers after femoral artery wire injury 
The cell cycle inhibitor protein p27 kipl may control the pool of EPCs. p27 kip' has been 
demonstrated to regulate the cell cycle of smooth muscle cells and haematopoietic 
cells, both under normal conditions and after vascular wire injury [122]. The frequency 
of EPC colony forming units both at baseline and after vascular wire injury in p27-1- 
mice and litter mate wild type controls was investigated. Three or 7 days after wire 
injury, splenocytes were isolated from WT and p27-1- mice. Cells were cultured on FN 
coated flasks in EGM-2 media and colonies counted per well after 14 days. The 
frequency of EPC colonies at baseline is significantly elevated in p27-1- mice (p<0.01) 
(Figure 10). However, 3 or 7 days after wire injury there was no difference between the 
2 groups although the WT EPC count increased initially at 3 days and then both WT 
and p27-1- EPC counts decreased to below normal 7 days after wire injury (Figure 10). 
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Figure 10 Mean EPC colonies are elevated in p27 kipl-/- mice compared with WT 
controls under normal conditions but there is no difference in mean EPC colony 
numbers after femoral artery wire injury 
Three and 7 days after wire injury mice were euthanised and splenopytes were isolated from WT and p27kP'-'- mice. N=6 spleens in each group, average of 4 wells used to 
calculate each individual animals EPC count. Cells were cultured on FN coated 24 well 
plates in EGM-2 media and number of colonies counted per well after 14 days. The frequency of EPC colonies at baseline is significantly elevated in p27kP'-I- mice 
compared to WT(* p<O. 01). There is no difference in EPC colonies between p27'ý' and WT after wire injury although there is a significant difference between p27'ý' at baseline 
and after 7 days (** p<0.05). There is no significant difference between WT EPC 
colinies at baseline and day 3 or 7. 
50.0 
40.0 
30.0 
2D. 0 
10.0 
0.0 
Tumour endothelial markers (TEMs) are not expressed in mouse or human 
cultured EPCs 
At present there is no specific marker for EPCs in humans or mice. TEMs are a 
recently described group of proteins expressed exclusively in tumour endothelium and 
other areas of active angiogenesis such as the developing embryo, in healing wounds 
or corpus luteum, but not in normal endothelium [72]. As EPCs have been suggested to 
participate in tumour vasculogenesis [50,64] it is possible that TEMs may actually be a 
specific marker for EPCs. In control experiments the TEMs primers designed were 
investigated to confirm that they can be used to detect specific TEM products in a 
sample known to express them. Initial attempts to amplify TEMs in RNA from a mouse 
renal cell tumour were unsuccessful. Despite the high yield of RNA isolated (confirmed 
by gel electrophoresis) it was not possible to detect a TEM signal, despite a clear 
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signal with the house keeping gene TIF (eukaryotic translation initiation factor). 
Subsequent PCR for ve-cadherin was also negative in the tumour RNA. This would 
indicate that the tumours were not adequately vascularised and therefore not ideal for 
detection of TEMs. Next RNA isolated from the livers of D17.5 mice foetuses was 
studied. Clear size specific products of mTEMs were easily detected after PCR along 
with a strong signal for ve-cadherin. After selecting the correct annealing temperatures 
to minimize non specific bands mTEM1 (primers 2-2), mTEM5 (primers 2-2) and 
mTEM8 (primers 1-1) were selected for further study. Attempted to detect TEMs in the 
RNA from cultured EPCs from mouse spleens was undertaken. No specific signal was 
detected by real time qPCR which was confirmed by analysis on an agarose gel (data 
not shown). It was not possible to obtain human tissues that are known to express 
TEMs. qPCR of human cultured EPCs for hTEM1, hTEM5, hTEM7 and hTEM8 all 
failed to detect a specific product. With some primers, a weak signal was detected by 
qPCR. However, analysis of the melting curve and examining the electrophoresis gel 
indicated that it did not correspond to the expected product (data not shown). 
TEMs are not expressed in human CD133 cells 
EPCs are reported to exist within CD1 33+ cells [35]. It could be speculated that hTEMs 
RNA may be detectable in human CD133 cells if TEMs are also markers for EPCs. 
Freshly isolated CID133+ cells collected by aphaeresis of G-CSF mobilised patients 
had RNA extracted and were submitted to qPCR with hTEM primer pairs. It was not 
possible to detect any specific product in CD133 cells from 4 different normal 
volunteers submitted to real time qPCR (data not shown). Gel electrophoresis of the 
PCR product confirmed the absence of any TEM products in CID133+ cells from 4 
different donors indicating TEMs are not expressed in CID1 33 + cells. 
TEMs are not expressed in atherosclerotic mouse aortas 
Finally it could be speculated that TEMs may be expressed within the neo- 
vascularisation of atherosclerotic plaques if TEMs are a marker of developing 
endotheliurn or EPCs. Aortas were harvested from 6 month old ApoE-1- or wild type 
mice, which had been fed a western diet, conditions known to induce atherosclerosis in 
these mice [140]. RNA was extracted and submitted to real time qPCR analysis with 
TEM primers 1,5 and 8. No specific TEM signal could be detected in RNA extracted 
from aortas from ApoE-1- or wild type mice submitted to real time qPCR followed by gel 
electrophoresis of the PCR product. The endothelial marker ve-cadherin was detected 
with a cycle threshold of 22-24 in all samples, indicating RNA from endothelial cells 
was present in the processed tissues (n=4 each group, data not shown). 
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Establishing mouse models that allow the tracking of CD45, LysM and F4/80 + 
cells ancestry throughout development 
To determine whether haematopoietic cells contribute to the non-haematopoietic cell 
types of endothelium and smooth muscle cells, I developed double transgenic mice 
utilising the Cre/Lox system. This is based on the hypothesis that EPCs may be 
derived from a) leucocytes (CD45) b) myeloid cells (LysM) and c) monocyte/ 
macrophages (F4/80). Strains that express Cre recombinase from the promoter 
elements of either the CD45, LysM or F4/80 genes were crossed with the LoxP 
reporter strain R26R. Expression of Cre recombinase under control of the specific 
promoter leads to irreversible activation, at the genetic level of the ROSA26 locus and 
permanent expression of, 8-gal (Figure 3, page 51). Homozygous R26R lacZ mice were 
crossed with heterozygous Cre reporter strains. Cre + mice were used for experiments 
and the Cre - litter mates served as R26R negative controls. The ROSA26 mouse was 
used to provide tissues as a positive control after X Gal staining or FDG labelling and 
the Tie2cre-R26R mouse was used to confirm that endothelium could be successfully 
labelled with LacZ after activation of the ROSA26 locus. To confirm the activation of the 
reporter gene in cells of haernatopoietic origin, nucleated cells from spleen, blood and 
bone marrow were analysed for expression of A-Gal. 
CD45 ancestry mice show unexpectedly low labelling of CD45 + cells 
To confirm that CD45 cells had been labelled with LacZ expression, leucocytes were 
isolated from blood, spleen and bone marrow and incubated with FDG. Despite all 
leucocytes from blood and spleen expressing CD45 only 23% of cells were actually 
labelled with LacZ (Figure 15). This partial labelling of CD45 cells was similar across all 
nucleated haematopoietic lineages, including lin- ckit + HSCs, T and B lymphocytes, 
myelo-monocytic cells and granulocytes (Figure 11). 
LysM ancestry mice have sub-sets of lymphocytes and HSCs labelled with LacZ 
in addition to monocytes and granulocytes 
Expression of P-Gal was analysed in haematopoietic cells from LysM ancestry mice. 
Although most granulocytes cells (Gr-l+) and myelo-monocytic cells (CDllb+) were 
positive after FDG labelling, a significant proportion of B lymphocytes (CD19+) were 
also labelled in addition to small numbers of HSCs (lin- ckit+) (Figure 15). This would 
imply that LysM cre is not an exclusive myelo-monocytic marker (Figure 12), as has 
been recently reported [141]. 
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Myelo-monocytic cells are labelled in F4/80 ancestry mice 
Expression of P-Gal was analysed in haernatopoietic cells from F4/80 ancestry mice. 
78% of F4/80+ splenocytes were labelled with P-Gal indicating a high level of excision 
of the R26R stop codon in 174/80 cells Figure 15. A similar percentage (85%) of F4/80 + 
cells were labelled in blood. The absence of significant P-Gal expression in 
lymphocytes (CD3 and CD19) and HSCs (lin-, c-kit+) confirmed the selective 
expression of the F4/80 cre. A small percentage of Gr-1 + cells also expressed P-Gal 
implying 174/80 expression in some granulocytes (Figure 13). 
Figure 11 Example of FACS analysis of LacZ expression of CD45 ancestry mice 
(CD45 cre-112611 lacZ) in different haernatopoietic lineages 
Blood (A) (top left) and spleen (B-F) MNCs were isolated from CD45 cre-R26R IaCZ 
mice. Cells were stained with various antibodies to common haematopoietic markers (x 
axis) and then incubated with FDG to detect LacZ + cells (y axis). Despite CD45 being 
expressed in all haematopoietic cells (A blood &B splenocytes) only 24 Vol 28% of cells 
had CD45 cre mediated excision of the R26R lacZ stop codon and were LacZ FDG +- 
However, despite this limited labelling of CD45 +cells all lineages have been marked to 
a similar degree. (C) CD 19 B cell splenocytes, (D) CD3 T cell splenocytes, (E) CD IIb 
myeloid splenocytes and (F) Gr-I granulocytes all had between 20-30% of cells 
labelled with LacZ after FDG loading. (see Figure 15 for quantification) 
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Figure 12 Example of FACS analysis of lysozyme ancestry mice (LysM cre-R26R 
lacZ) in different haernatopoietic lineages 
Splenopytes were isolated from LysM cre-R26R lacZ mice (right column) or R26R (left 
column) as a negative control. Cells were stained with various antibodies to common 
haematopoietic markers (x axis) and then incubated with FDG to detect LacZ + cells (y 
axis). The predominant cell types labelled are CD11b macrophages and Gr-I 
granulocytes. However, B (CD19) lymphocytes are also labelled but to a lesser degree. 
(See Figure 15 for quantification). 
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Figure 13 Example of FACS analysis of F4/80 ancestry mice (F4/80 cre-R26R 
lacZ) of different haernatopoietic lineages 
Splenocytes were isolated from F4180 cre-R26R lacZ mice (right column) or R26R (left 
column) as a negative control. Cells were stained with various antibodies to common 
haematopoietic markers (x axis) and then incubated with FDG to detect LacZ + cells (y 
axis). The predominant cell type labelled are F4180 monocytes/ macrophages. As 
monocytes also exist in the CD 11 b and CD45 fraction a smaller percentage of these 
lineages were also labelled. A small percentage of Gr-I granulocytes were also 
positive. (see Figure 15 for quantification). 
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Figure 14 Example of FACS analysis of HSC from BM of F4/80 ancestry mice 
(F4/80 cre-R26R lacZ) 
Bone marrow was harvested from F4180 ancestry mice and RBC lysed. A) MNCs were 
gated on and then viable cells were excluded after staining with propidium iodide (B). 
The hypotonic shock of FDG loading causes significant cell death. Lineage -ve cells (C) were then stained for the HSC marker c kit, (D) and LacZ expression assessed 
after FDG loading. Gates were set using BM from the R26R mice. E) HSC expression 
of LacZ1 B Gal was from F4180 ancestry mice compared to ROSA26 and negative 
control. There are no LacZ1,6 Gal + HSCs. 
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Figure 15 Fractions of different haematopoietic cell labelled with Lacz from CD45 
cre, LysM cre and F4/80 cre ancestry mice 
Bone marrow and splenocytes were isolated from Cd45 cre-R26R, LysM cre-R26R and F4180 cre-R26R lacZ mice. The percentage of cells + for LacZ (after FDG loading and flow cytometry analysis) were enumerated for various cell fractions (n=4, mean ± sem) including HSC (fin- ckit+), CD45 leucocytes, CD I Ib myeloid cells, Gr- I granulocytes, CD 19 B lymphocytes, CD3 T lymphocytes and F4180 monocvtel macronh-anp-q 
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X Gal labelling reliably identified cells expressing j8-galactosidase that could be 
phenotyped by anatomical position and VWF and SMact immuno-fluorescent 
staining 
To confirm that cells labelled 'blue' after X-Gal staining represent B-Gal expressing 
cells, sections of femoral arteries from R26R (-ve control) and ROSA26 (+ve control) 
were studied (Figure 16). To confirm that lox R26R locus could be specifically activated 
in the endothelium (which might be expected to occur if blood leucocytes differentiate 
into endothelium) I also studied femoral arteries from Tie2cre-R26R ancestry mice. I 
confirmed that no blue cells were identified in the arteries of R26R mice indicating no 
'leakage' of the R26R reporter construct and no non-specific deposition of the X-Gal 
substrate. ROSA26 arteries were uniformly positive in the media and endothelial layer, 
although the relatively acellular adventitia had very little P-Gal expression. Blood 
vessels from Tie2-cre/R26R mice had exclusive labelling of the endothelium. So that X- 
Gal labelled cells could be further phenotyped into an endothelial or smooth muscle 
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phenotype, VWF and SMact IF of endothelium and smooth muscle cells respectively 
was confirmed (Figure 17). 
Figure 16 Photomicrograph of mouse femoral arteries after X-Gal staining allows 
identification of cells expressing P-gal 
Femoral arteries were harvested from wild type and R26R (negative controls), ROSA26 
and Tie2-cre-R26R mice (positive controls) fixed and incubated with X-Gal reagent. 
Tissues were then OCT embedded and slides counterstained with nuclear fast red. No 
blue cells are seen in the R26R mouse. However, the endothelial layer is marked blue 
after endothelial specific cre mediated excision of the stop codon in the Tie2cre-R26R 
mice. The endothelium and smooth muscle cells are blue in the ROSA26 mouse which 
ubiquitously expresses B-galactosidase. The adventitia is relatively acellular and hence 
no A-gal is detected. 
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R26R ROSA26 
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Figure 17 Immuno-fluorescent photomicrograph of sections of mouse femoral 
arteries stained with antibodies to VWF and SMact allowed identification of 
endothelial cells and smooth muscle cells 
In order to track the fate of P-Gal expressing cells, sections of femoral arteries were 
stained with antibodies for endothelial and smooth muscle markers. Femoral arteries 
were stained with vWF-red (/eft) or SMact-red (right) and then counter stained with 
DAPI-blue. There is selectively expression of VWF in the endothelium (left) and of 
SMact in the media (right) of the artery sections. (XIOO) 
CD45 ancestry cells do not contribute to the normal development of endothelial 
cells and smooth muscle cells in femoral arteries 
It is possible that EPCs are a circulating haematopoietic cell that can differentiate into 
endothelium as part of normal development. To determine whether CD45+ 
haernatopoietic cells contribute to endothelial cells during mouse development, 20 
sections were analysed from femoral arteries of 12 CD45 ancestry mice. It was not 
posible to detect a single (blue), 8-Gal expressing cell in the endothelial layer or media 
in any of the sections analysed (Figure 18). This was despite easily identification of all 
blue endothelial cells in the Tie2 cre ancestry mice used as a positive control. Some 
positive cells were detected, either within the lumen of vessels, (due to inadequate 
flushing of nucleated blood cells), or alternatively in the adventitia/ perivascular space. 
It was presumed that these were either circulating CD45+ leucocytes or tissue 
macrophages. Taken together this would indicate that it is unlikely that 
CD45+ 
haernatopoietic cells differentiate into either endothelial cells or smooth muscle cells as 
part of normal development. It would also indicate that, if blood and endothelial cells 
arise from the same precursor cell, the haemangioblast, during normal 
development, 
then this cell does not express CD45. 
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Figure 18 Photomicrograph of femoral artery sections from CD45 ancestry mice 
indicating that CD45 cells do not contribute to normal vessel development 
Femoral arteries from Tie2cre-R26R (positive control), R26R (negative control) and 
CD45cre-R26R ancestry mice after X Gal staining. All endothelial cells are labelled 
blue in the Tie2cre mice due the 8-gal expression. No cells are labelled in the R26R - 
ve control. Analysis of sections from the CD45 ancestry mice failed to reveal 
endothelial or smooth muscle cells that originated from CD45+ cells. The occasional 
leukocyte was detected in the vessel lumen (arrow) or tissue macrophage in the 
adventitia (arrow). 
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LysM ancestry cells do not contribute to the normal development of endothelial 
cells and smooth muscle cells in femoral arteries 
Femoral arteries were also analysed from LysM ancestry mice. Despite studying 20 
sections from 12 femoral arteries of each mouse strain it was not possible to identify 
any blue B-Gal + endothelial or smooth muscle cells (Figure 19). This would indicate 
that LysM cells do not participate in the normal development of the femoral artery. 
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Figure 19 Photomicrograph of femoral artery sections from LysM ancestry cells 
indicating that LysM cells do not contribute to normal vessel development 
Femoral arteries from LysM cre-R26R ancestry mice were stained with X Gal. Analysis 
of sections from the LysM cre ancestry mice failed to reveal any blue endothelial or 
smooth muscle cells that would have originated from LysM+ cells. The presumed 
occasional tissue macrophage was detected in the adventitia (arrow) and circulating 
myelo-monocytic cell in the vessel lumen. 
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F4/80 ancestry cells contribute to the normal development of endothelial cells in 
femoral arteries 
Femoral arteries were also analysed from 174/80 ancestry mice. In the F4/80cre-R26R 
mice only cells of a monocyte/ macrophage lineage, and their progeny, will be marked 
with 8-Gal expression. In contrast to the CD45 and LysM ancestry mice, blue B-Gal + 
cells were identified in uninjured artery sections from 10 femoral arteries (Figure 20). 
Although blue cells were also identified within the adventitia (presumed tissue 
macrophages or dendritic cells) clearly positive cells were identified that appeared to 
be of an endothelial phenotype. 2.8% ± 1.1 of all cells lining the lumen of the femoral 
artery and vein were labelled blue. Higher magnification images confirmed that the 
labelled cells had several features of an endothelial phenotype. This would indicate that 
a proportion of endothelial cells in adult mice may have originated from F4/80 
monocytes/ macrophages. 
CD45 ancestry cells contribute to the repair of all 3 layers of the vessel wall after 
injury 
To ensure that there was no P galactosidase reporter leakage, or non specific staining 
after X Gal, femoral artery sections from R26R control mice were submitted to wire 
injury and harvested after 4 weeks. No blue cells were seen within the vessel walls or 
surrounding tissue (Figure 21). In contrast to the R26R controls and uninjured arteries 
from CD45 ancestry mice (Figure 18), significant infiltration of CD45+ cells into arteries 
was documented after wire injury (Figure 22). Wire injury results in a selective 
denudation of the femoral artery followed by re-enclothelialisation and a marked neo- 
intimal proliferative reaction composed predominantly of vascular smooth muscle cells 
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[130]. Infiltration of CD45+ inflammatory cells after injury would be expected [122]. 
However, arteries were harvested 4 weeks after wire injury following resolution of the 
acute inflammatory process. Despite this blue P-Gal + cells persisted within all three 
layers of the vessel after 4 weeks. Some of the blue cells are likely to be macrophages 
and persisting inflammatory cells. However, cells lining the lumen of the vessels have 
an endothelial morphology. In addition blue cells within the media of vessels have a 
smooth muscle phenotype. This would indicate that CD45 ancestry cells may have 
adopted a smooth muscle and endothelial phenotype after experimental vascular inury. 
Figure 20 Photomicrograph of uninjured femoral artery sections from F4/80 
ancestry cells indicating that F4/80 cells may contribute to normal vessel 
development 
Femoral arteries and veins from F4180cre ancestry mice after X Gal staining. Analysis 
of sections of 10 femoral arteries from F4180cre ancestry mice revealed that 2.8% of 
endothelial cells of the femoral artery and vein had originated from F4180+ cells 
(stained blue). Occasional blue cells were seen in the adventitia, presumed tissue 
macrophages (arrow) and in blood, presumed monocytes (arrow). 
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LysM ancestry cells also contribute to the repair of all 3 layers of the vessel wall 
after injury 
The role of LysM ancestry cells were also investigated after vascular wire injury in 
LysM ancestry mice. LysM is predominantly expressed in myelo-monocytic cells 
although it is also expressed in a fraction of HSCs [141] which also results in a fraction 
of lymphocytes being labelled in LysM ancestry mice (Figure 12). Similar to the Cd45 
ancestry mice, blue P-Gal + cells were obsereved within in all three layers of the vessel 
4 weeks after injury. Again it is likely that some of the blue cells are probably 
macrophages and persisting inflammatory cells. However, cells lining the lumen of the 
vessels clearly have an endothelial morphology as did blue cells within the media 
implying a smooth muscle phenotype. This would indicate that LysM ancestry cells may 
also adopt a smooth muscle and endothelial phenotype after vessel injury. 
Figure 21 Photomicrograph of femoral artery section of R26R control mouse 
after wire injury indicating absence of blue/ X Gal positive cells 
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Figure 22 Photomicrograph of femoral artery sections of CD45 ancestry mice 
after wire injury indicating CD45 + cells are involved in vascular repair after 
femoral artery wire injury 
Four weeks after femoral artery wire injury of 10 arteries of CD45cre ancestry mice, 
vessels were removed and stained with X-Gal. Cells of CD45 ancestry are marked 
blue, regardless of their present expression of CD45. As a result of the wire injury there 
is a pronounced neo-intimal reaction and adventitial infiltrate in all arteries. Blue CD45 
+ ancestry cells are identified in the adventitia, media and lining the lumen of the artery 
and vein. In some arteries (F and H) there is a secondary femoral vein thrombosis with 
pronounced CD45+ cell infiltrate. In 2 arteries (out of 10) (1 and J) the pronounced 
injury reaction resulted in vessel lumen thrombosis and large numbers of CD45 + 
ancestty cells are identified. 
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Figure 23 Photomicrograph of femoral artery sections from LysM ancestry mice 
after femoral artery wire injury indicating LysM + cells are involved in vascular 
repair after femoral artery wire injury 
Four weeks after femoral artery wire injury of LysM cre ancestry mice, arteries were 
removed and stained with X-Gal. Cells originally of LysM ancestry are marked blue, 
regardless of their present expression of LysM. As a result of the wire injury there is a 
pronounced neo-intimal reaction and adventitial infiltrate in all arteries. Blue LysM + 
ancestry cells are identified in the adventitia, media and lining the lumen of the artery 
and vein. (B, D, F) potential LysM ancestry mice with an endothelial phenotype are 
marked, arrow. 
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Discussion 
Summary of results 
1. 'EPCs' can be isolated from the blood of humans and from the spleen of 
mice cultured ex vivo. These cultured 'EPCs' express markers of 
endothelial cells and also of monocytes/ macrophages. 
2. Circulating CD133+/ VEGFR2+ cells are extremely rare in human blood. 
Cells with an EPC morphology could not be isolated from human CID 
133+ cells indicating that the CD133 fraction of blood may not be a 
marker for circulating EPCs 
3. The cell cycle inhibitor p27 MP regulates the number of EPC like colonies 
isolated from mouse spleen under non-injury conditions but not after 
vascular wire injury 
4. TEMs are not expressed in human or mouse EPCs and are therefore 
unlikely to be useful markers for aiding identification of EPCs 
Based on experiments utilising the Cre-Lox system 
5. CD45 haematopoietic cells do not appear to contribute to normal 
vascular development but may participate in blood vessel repair after 
injury 
6. LysM myeloid cells do not appear to contribute to normal vascular 
development but they may participate in blood vessel repair after injury 
7. F4/80 monocytic cells contribute to normal vascular development of the 
endothelium 
Accumulating evidence suggests that bone marrow-derived endothelial progenitor cells 
(EPCs) may circulate in blood and play an important role in the formation of new blood 
vessels as well as contribute to vascular homeostasis in the adult [8]. Circulating 
endothelial progenitor cells were initially identified through their expression of CD34 (a 
surface marker common to haematopoietic stem cells and mature endothelial cells) and 
vascular endothelial cell growth-factor receptor 2 (VEGFR2 or kinase-domain-related 
[KDR] receptor). Other markers seen on fully differentiated endothelial cells were not 
identified on EPCs. Subsequent studies of EPCs have used other markers, such as the 
haematopoietic stem-cell marker CD133 [35], and functional assays, including the 
ability to form endothelial like colonies in culture [67]. A number of groups have also 
suggested monocytes as the most likely source of potential EPCs [21]. Endothelial 
progenitor cells defined in these ways probably represent a heterogeneous population, 
which, in combination with the lack of a consensus definition, complicates the 
interpretation of work in this field. 
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Numerous studies in animals have implied that endothelial progenitor cells can 
integrate into new and existing blood vessels and improve perfusion and function of 
ischaemic organs. EPC number and function are also reported to predict 
cardiovascular risk [67,741. However, many studies now question the scale of EPC 
integration into the endothelial layer, if it occurs at all [18,19]. Although it is tempting to 
assume circulating EPCs may play a protective role in vascular homeostasis, there may 
be other explanations to account for published findings. Changes in the number of 
endothelial progenitor cells and in clinical events might reflect a common underlying 
aetiology, rather than a causal relation. For example, a defect in the production of nitric 
oxide, which plays an important role in both the mobilisation of endothelial progenitor 
cells [142] and blood-vessel function, might account for both observations. Similarly, 
the number of endothelial progenitor cells may mirror a person's regenerative capacity 
more broadly and predict clinical events on that basis. Even if endothelial progenitor 
cells are mechanistically linked to clinical cardiovascular events, such clinical studies do 
not distinguish between the possibility that the protection is mediated through the 
integration of endothelial progenitor cells into blood vessels or by other mechanisms, 
such as the paracrine effects of endothelial progenitor cell secreted cytokines. 
The phenotype of EPCs 
Work presented in this these has attempted to address some of this issue. First the 
phenotype of cultured EPCs was established. It was possible to culture cells from 
human blood and mouse splenocytes that could be defined as EPCs by their 
'endothelial' like morphology and uptake of acetylated LDL and binding of endothelial 
specific lectins. However, work presented here also established that these cultured 
cells (from both mice and humans) also expressed markers of monocytes/ 
macrophages in addition to other endothelial markers. As CID133/ VEGFR2 + cells are 
most commonly reported as being the phenotype of EPCs in blood, attempts were 
undertaken to quantify these cells by FACS with a view to isolating a pure fraction of 
these cells for detailed transcriptional profiling using SAGE [121]. After extensive 
optimising of the antibody staining and the FACS protocol it was possible to 
detect 
CID133/ VEGFR2 + cells in the blood of healthy volunteers. CID133/ VEGFR2 + cells 
are extremely rare in peripheral blood with a frequency of 0.001% of nucleated cells. 
As both EPC numbers, colony counts and the frequency of CID133/ VEGFR2+ cells 
appear to be reduced in patients with vascular disease [73] it was 
felt necessary to 
confirm that CID133/ VEGFR2+ cells can form EPCs, including colonies, as 
described 
previously. As it was not possible to collect CID1 33/ VEGFR2+ cells 
in sufficient number 
from humans, an attempt to culture EPCs from CID133+ cells isolated from the 
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aphaeresis product after G-CSF mobilisation of healthy volunteers, was undertaken. 
After numerous attempts, it was not possible to culture cells with an EPC phenotype 
from pure CD133+ cells. This is despite a previous report that endothelial cells can be 
cultured from CID133+ cells [37]. It is possible that CD133+ cells require the paracrine 
support of other haernatopoietic cells in order to differentiate into endothelial cells or 
that mobilised CID1 33+ cells do not contain EPCs. Alternatively one could suspect that 
EPCs most commonly cultured in vitro are derived from the more common myeloid 
cells in peripheral blood. The actual evidence that CID133+ cells are endothelial 
progenitors in vivo is limited [35]. Because of the uncertainty of the precise phenotype 
of EPCs in vivo and the technical difficulty of isolating sufficient numbers of 
CID1 33NEGFR2+ cells it was decided not to undertake a SAGE analysis of these cells. 
To date no other groups have established that CD133 cells and cultured EPCs 
originate from the same cell. However, there does appear to be a correlation between 
the number of ex-vivo cultured EPC colonies and the frequency of circulating CID1 33+/ 
VEGFR2 +cells. No causality is proven, and the conditions determinig EPC colony 
formation may have similar but independent effects on both the frequency of CD133+ 
cells in vivo which may actually have a myelo-monocytic origin. 
It should be emphasised that the methods for the culture of EPCs are not yet clearly 
defined. Establishing a reproducible assay of cultured EPC is confounded by the 
significant impact of potential variations in the culture process. It was not possible to 
achieve reproducible counts of EPC colonies from the same individual from blood 
samples obtained on different days. In addition to biological variation, many 
experimental factors may account for this including the operator technique, cell culture 
density, type and lot of human fibronectin, type and lot of serum and media and 
cytokine supplements used. A reproducible assay or specific marker of EPCs is 
needed so that data from different laboratories can be meaningfully compared. 
p27 
kiP 
regulates the number of EPCs 
If EPCs are involved in vascular homeostasis and are to be considered as potential 
therapeutic agents for patients with chronic ischaemia, understanding the mechanisms 
of their control is desirable. The cyclin dependent kinase inhibitors are key regulators of 
cell cycle progression and one of these p2lc'Pl, has previously been implicated in the 
control of the cell cycle in endothelial cells and EPCs [53]. Therefore the hypothesis 
that p27 kiP also directly regulates the proliferation of BM-derived cells, including EPCs, 
that migrate into damaged vessels and reconstitute vascular lesions may be valid. This 
rnight provide a potential therapeutic target for promoting endothelialisation. 
By 
studying cells isolated from p27 
kiP-1- and wild type mouse spleen it was observed that 
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p27 kip-- regulates the number of EPC colonies (LDL/ lectin dual + cells) at baseline. 
This indicates that p27 kip participates in controlling the cell cycle of cultured EPCs. In 
contrast, there was no difference in EPC colony formation after femoral wire injury. This 
may be due to mobilised EPCs migrating to the site of vascular injury and hence 
reduced numbers being isolated from the spleen. Although attempts to isolate EPCs 
from mouse blood to quantify circulating cells were undertaken, no cells with an EPC 
morphology/ phenotype could be isolated. To determine if haematopoietic cells had 
differentiated into endothelial cells, endothelial cells were identified by FISH in vascular 
lesions in female mice that had a male bone marrow transplant [122]. Although lesion 
formation was markedly increased in the arteries of p27 kip-/- mice along with 
inflammatory infiltrates, no Y chromosome + endothelial cells were seen. Although, Y 
chromosome + smooth muscle cells were detected, indicating at least some smooth 
muscle cells in vascular lesions may be bone marrow derived [122]. However, there 
was a marked increase in numbers of macrophages in lesions pf p27 kip-1- mice. If EPCs 
are of a monocyte/macrophage lineage then rapid migration of EPCs/monocytes into 
the vascular lesions of p27 kip-1- mice might account for the relative decrease in EPC 
numbers 3 days after injury and the fall in absolute numbers in WT and p27 
kip-1- 
mice 7 
days after injury. 
Turnour endothelial markers are not expressed on EPCs 
Due to the difficulties with EPC quantification discussed above, a specific marker of 
EIPCs allowing accurate identification is critical to research in this field. It had intended 
to undertake a gene expression profiling approach based in SAGE to potential identify 
novel EPC markers. However, as the phenotype of circulating EIPCs is unclear it was 
not possible to establish a sufficient cell definition to undertake a SAGE analysis of 
EPCs. 
It was speculated that tumour endothelial markers (TEMs) identified from a SAGE 
analysis of tumour specific endothelium [72], might also be markers of EPCs. It could 
be assumed that EPCs contribute to the neo-vascularisation of tumours and that the 
surface markers of this neo-endothelium might still retain markers of the originating 
EPCs. TEMs are also expressed at other sites of active angiogenesis, such as healing 
wounds and during embryogenesis. TEMs may be novel exclusive markers of EPCs. 
As no TEM antibodies are available, evidence of TEM expression was investigated 
using a RT-PCR based technique. Despite looking for TEMs in mouse and human 
cultured EPCs, human CD133+ cells and atherosclerotic aortas no TEM specific RNA 
could be detected. This may indicate that TEMs are not markers of EPCs. 
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EPCs arise from haematopoietic cells after significant vascular injury based on 
Cre/LoxP lineage tracing 
A transgenic mouse model was developed to determine if haematopoietic cells have 
the capacity to differentiate into endothelium, and to determine the phenotype of EPCs 
in this system. Experiments based on the Cre/LoxP system to create lineage specific 
ancestry mice to genetically mark a cell were developed. This is independent of 
expression of other markers [124]. Transgenic knock-in mice that expressed Cre 
recombinase under the control of the CD45, LysM, F4/80 and Tie2 promoters were 
used. These Cre expressing strains were then crossed with R26R reporter mice. Any 
cell expressing Cre recombinase will result in permanent activation of the ROSA26 
locus resulting in expression of P-galactosidase within the cell and its progeny. Initial 
experiments confirmed that it is possible to selectively label endothelial cells by 
activating the ROSA26 locus only in endothelial cells using Tie2cre mice. However, in 
uninjured femoral arteries from CD45 and LysM cre ancestry mice, there was no 
evidence of CD45 (Leucocyte Common Antigen) or LysM (myelo-monocytic) cells 
contributing to the endothelial or smooth muscle cells. This would imply that EPCs from 
these lineages do not participate in normal development or normal vessel homeostasis 
by providing endothelial cells. However, 4 weeks after femoral artery wire injury the 
occasional cells appeared to have an endothelial or smooth muscle phenotype. Further 
phenotyping of the A-Gal labelled cells is required to confirm their precise phenotype, 
however, this finding indicates that CD45+ cells and LysM+ cells may be involved in re- 
enclothelialisation after vascular injury, although to a limited degree. It would appear 
that most cells involved in repair of the endothelium and media hyperplasia have a 
different origin, presumably from, local cells. This supports the presently accepted 
concept that circulating EPCs are usually only recruited to sites of injury or ischaemia 
during post natal life but not during development. By utilising the cre-lox system, which 
does not rely on the continued expression of promoters often used in development and 
stem cell biology, it has been possible to demonstrate the absence of a CD45 or LysM 
cell in normal vessel development. 
Lineage tracing of F4/80 ancestry cells indicates EPCs may have a macrophage 
origin 
EPCs from mice and humans were found to express markers of monocytes/ 
macrophages, therefore the origin of endothelial cells were studied in F4/80 ancestry 
mice. F4/80 is predominantly expressed in macrophages [133] and it could be 
hypothesised, based on data in this thesis and work of others [21], that EPCs originate 
from macrophages. Under non-injury conditions F4/80 macrophages appear to adopt 
an endothelial phenotype in femoral arteries and veins. This implies that 
EPCs may 
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either be macrophages or that macrophages can differentiate into an endothelial 
lineage in vivo. An alternative explanation of this finding is that the F4/80 gene could be 
expressed during development of some endothelial cells and potentially be unrelated to 
monocyte differentiating into EPCs/ endothelium. Further experiments that could be 
done include undertaking bone marrow transplants from F4/80cre ancestry mice into 
WT mice. If with increased animal age an increase in endothelial cells originating from 
F4/80 cells was seen, this would suggest that 174/80 macrophages may be EPCs and 
participate in normal vessel homeostasis. 
Further additional experiments that could be done to characterize these labelled cells 
include immuno-fluorescent microscopy for macrophage and endothelial markers. Also 
it would be interesting to submit the F4/80 ancestry mice to vascular injury and to 
examine the role of 174/80 cells in embryos and older animals. Cell fusion could 
possibly explain these observations. To investigate whether the blue + cells are a result 
of myeloid cell fusion with endothelial cells, bone marrow transplant experiments could 
be undertaken. By transplanting F4/8OCre+ bone marrow into R26R reporter mice 
fused cells could be detected as they would have the stop codon removed from the 
R26R locus resulting in P-Gal expression. 
It is surprising that under non-injury conditions endothelial cells appear to originate 
from the F4/80 ancestry cells and not from the CD45 or LysM cre ancestry cells. One 
could assume this difference is a result of the limited activation of the reporter gene in 
the CD45 and LysM lineages in contrast to the F4/80 line which has a more robust 
excision of the ROSA26 stop codon. This highlights potential problems when using the 
Cre/LoxP system. As a result of the limited activation of the R26R reporter construct in 
CID45cre and LysM cre + cells (as measured by FACS after FDG loading) one could 
not exclude that some cells were missed due to all cells not being labelled with A-Gal. 
This is presumably due to failure of the CD45 or LysM promoters to drive sufficient Cre 
expression to excise the stop codon from the R26R construct. Other explanations 
include silencing of the ROSA26 reporter [143], position effect varigation [144] or the 
promoter residing in a chromatin configuration inaccessible for recombination [145]. All 
of these potential confounding factors decrease the sensitivity of the system to label 
and track cells but not its specificity, especially as I never found P-Gal + cells in tissues 
from the R26R mice. However, as over 300 sections were studied in each experiment 
with an estimated 30,000 endothelial cells, only events occurring with a very low 
frequency would potentially be missed. 
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Conclusion 
Endothelial progenitor cell research remains an extremely interesting area of vascular 
biology despite many controversies concerning their phenotype and physiological 
function. Work in this thesis has demonstrated that cultured EPCs express markers of 
monocyte/ macrophages in both humans and mice and from lineage tracking 
experiments, EPCs do appear to exist and probably arise from macrophages. TEMs do 
not appear to be expressed in EPCs and are unlikely to provide the novel specific 
marker for EPCs that is needed. Cells of a macrophage origin can adopt an endothelial 
cell phenotype under non-injury conditions and it could be speculated that these 
macrophage EPCs are distinct from the rare CID1 33/CD34/ VEGFR2 + cells commonly 
described as EPCs. These macrophage EPCs may be involved in the repair and 
maintenance of the endothelial compartment under both normal conditions and after 
injury. The cell cycle inhibitor p27 kip may be important for the control of these bone 
marrow derived haematopoietic cells. 
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Chapter 3 Isolation and characterisation of multi-potent adult 
progenitor cells 
Introduction 
Recently, a subset of bone marrow (BM) derived stem cells, named Multi-potent Adult 
Progenitor cells (MAPCs), have been isolated from mesenchymal stromal cell cultures, 
which in addition to being able to proliferate extensively in vitro can differentiate into 
cells of all 3 germ layers [45]. MAPCs have been isolated from human, rat, mouse, 
porcine and monkey bone marrow. Perhaps the most significant finding about MAPCs 
is that they were found to incorporate into nearly all tissues of a mouse when injected 
into a developing blastocyst. This would imply that 'embryonic like' cells may persist in 
adult bone marrow. If confirmed, the implications of this finding for cell biology research 
and potential cell therapy applications are significant. In addition using bone marrow to 
isolate stem cells overcomes many of the ethical hurdles associated with the 
production and use of embryonic stem cells. Although there have been no reports of 
other laboratories isolating cells with precisely the same phenotype as MAPCs, other 
groups have subsequently demonstrated that fractions of bone marrow derived cells 
have similar tri-lineage pluripotent potential [113-115] and these cells may be beneficial 
for improving left ventricular function after myocardial infarction. There is an inherent 
appeal of transplanting cell types capable of multi-lineage differentiation to regenerate 
diseased organs as they may be able to restore the multiple cell types often required to 
improve function in a diseased organ. Experiments presented in this chapter were 
aimed to isolate and characterise rodent MAPCs and investigate their behaviour and 
effects in a rodent in vivo model of ischaemia. 
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Isolation of MAPCs 
MAPCs apparently are a rare population of pluripotent stem cells isolated from the 
prolonged culture of bone marrow. Whether they exist in vivo or are the result of a 
reprogramming phenomenon caused by in vitro culture conditions has yet to be 
established. The principle of isolation is based on the propagation of adherent cells 
from cultured bone marrow in MAPC specific media, to achieve a proliferating attached 
mono layer of cells, similar to MSCs. Following removal of persisting haematopoietic 
cells the remaining cells are either cloned into 96 well plates to identify proliferating 
cells or cultured without the cloning step. Cells isolated by this method are then 
maintained at low density on human fibronectin coated culture flasks in specific media 
containing a low percentage of serum with EGF, PDGF-BB and LIF (also required for 
mES cell culture). According to the original publication [45] rodent MAPCs lose their 
ability to differentiate in the absence of these cytokines or if the serum concentration or 
cell culture density is increased. Protocols for MAPC isolation were based on those 
developed in the laboratory of Professor Catherine Verfaillie, University of Minnesota. 
Andrew Wragg spent 6 weeks working at the Stem Cell Institute, University of 
Minnesota, to learn the techniques for MAPC isolation and culture. 
Wild type, GFP, LacZ mice 
Isolation of murine MAPCs was attempted from a number of different knock out and 
transgenic mice. MAPC isolation was attempted not only from wild type mice, but also 
from mice constitutively expressing green fluorescent protein (GFP) under the control 
of the chicken B-actin promoter [146] and mice constitutively expressing the B- 
galactosidase gene (LacZ ROSA 26 mice) [135]. The expression of GFP and LacZ 
would potentially allow tracking of cells after in vivo transplantation. 
P27 kipl-1- and P21c1P1 -" knockout mice 
Attempts were made to isolate MAPCs from mice with homozygous deletions of the 
cyclin-dependent kinase (CDK) inhibitors P27 kipl-/- [56] and P21c1P1 
4- [147]. By reducing 
the the levels of these cell cycle inhibitors, expansion and isolation of MAPCs may be 
easier. In addition, if successful at isolating MAPCs, the role of the CDK inhibitors on 
MAPC function could be investigated by comparing MAPCs from P27 
kipl -1- and P21c'P1 
/- mice to wild type MAPCs- 
Markers of stem cell pluripotency 
Stage Specific Embryonic Antigen 
MAPCs are reported to be weakly positive for Stage Specific Embryonic Antigen, 
SSEA1 [45]. SSEA1 is a cell surface marker found predominantly on embryonic stem 
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cells [117]. By identifying SSEA positive cells in murine bone marrow cultures might 
help identify the putative MAPC and aid in its isolation. 
Oct 4-GFP mice 
MAPCs are reported to express the Pic-1, Oct-12, Unc-86 (POU) transcription factor 
Oct 4. The Oct 4 gene is expressed exclusively in the pluripotent cells of the embryo 
and is a central regulator of pluripotency [116]. Adult pluri-potent stem cells might be 
expected to be Oct4 positive. Isolating BM from mice expressing GFP under the control 
of the Oct4 promoter [148] may aid identification of MAPCs by isolating GFP (and 
hence Oct4 +) cells. 
Cytogenetic analysis of cultured cells 
Human [149] and mouse [119] embryonic stem cells can develop cytogenetic 
abnormalities when maintained in culture. Although the initial report of MAPCs 
indicated they have a normal karyotype [45] subsequent publications have indicated 
that they are also susceptible to cytogenetic instability [119]. Any cell type maintained 
for prolonged periods of time in culture may potentially develop cytogenetic 
abnormalities. As it was intended to transplant cells into animals it was important to 
ensure that cultured cells had not acquired any cytogenetic abnormalities. Cytogenetic 
stability has a significant bearing not only on the interpretation of the differentiation of 
cells in vitro and in vivo animal experiments, but also has a fundamental bearing on 
safety of potential clinical trials of ex-vivo cultured cells. 
Karyotyping of chromosomes in metaphase uses certain staining techniques called 
banding, which allows identification of individual chromosomes. The number of 
metaphases in cultured cells can be maximised by arresting the spindle apparatus with 
colcemid. Cells are then spread on a slide, stained with a suitable dye and visualized 
with a microscope. A conventional cytogenetic analysis depends on karyotyping of 
banded metaphase chromosomes. Typically 20 cells are analysed. A band is defined 
as that part of a chromosome which is clearly distinguishable from its adjacent 
segments by appearing darker or brighter with one or more banding techniques. The 
chromosomes are visualized as consisting of a continuous series of bright and dark 
bands. G-bands are most commonly used. They take their name from the Giemsa dye, 
but can be produced with other dyes. Each chromosome has a distinct banding pattern 
allowing unique identification [150]. More novel approaches used for cytogenetic 
analysis include spectral karyotyping, SKY. This is a sensitive and accurate way 
for 
visualising individual chromosomes and can be used for both mouse and 
human cells 
[1501. The karyotpes of each isolated clone/ cell line were initially screened by counting 
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the total chromosome number of 20 cells arrested in metaphase, after DAR staining. If 
this revealed a predominantly normal chromosome number then cells were sent for 
detailed G banding or spectral karyotyping. A cell line requires 2 or more cells to have 
the same abnormality to be considered abnormal [151]. Isolated events in single cells 
are of uncertain significance and lines can be still considered normal providing there is 
no evidence of clonal events defined as 2 or more cells with the same abnormality. 
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Aims 
To Isolate MAPCs from mice and rat bone marrow. 
To establish the phenotype of cells isolated. 
To confirm that MAPCs can be maintained in long term culture with a stable karyotype 
and phenotype. 
To differentiate MAPCs in vitro into a specific cell from all three germ lineages. 
Mesoderm: Endothelium 
Endoderm: Hepatocytes 
Neuro-ectoderm: Neurones 
To document the cytokines secreted by MAPCs 
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Methods 
Animals 
All experiments were conducted according to the guidelines of the Animal Care and Use Committee of the National Heart, Lung, and Blood Institute. 
Mice 
C57BL/6 wild type, GFP and ROSA 26 mice were purchased from Jackson 
Laboratories, Maine, USA. The P27 kipl-/- and P21c'P1 -1- mice were a gift from Dr E 
Nabel, NIH, USA and the Oct 4-GFP mice were a gift from Dr C Lo, NIH, USA. All mice 
were on a C57BL/6 background other than the Oct 4-GFP mice which were on a 129 
background. 
Rats 
Isogenic inbred Fisher 344 rats were obtained from Harlan laboratories (Indianapolis, 
USA). Male rats were used to produce cell lines and acted as cell donors. 
Isolation of murine bone marrow cells 
All tissue culture and handling of cells was undertaken in a laminar flow hood. Male 
mice 3-4 weeks old were used as a source of fresh bone marrow. Mice were 
euthanised byC02 inhalation followed by cervical dislocation. Under sterile conditions 
the femur and tibia were carefully dissected and placed into MAPC media as defined in 
Table 5. The ends of each femur and tibia were cut across and the bone marrow 
flushed out with a 25 gauge needle. The BM cells were dispersed and then filtered 
through a 40 micron mesh. Cells were washed once with MAPC media and counted 
with a haernocytometer or Coulter Counter. 6x1 06 cells were placed into each well of a 
6 well plate (Costar, USA) coated with 10 uglml of human fibronectin (Sigma Aldrich, 
USA) and cultured in MAPC media (Table 5, page 90) in an incubator at 370C with 5% 
C02. Media was changed every 3 days. After 7-14 days when the confluent cells were 
transferred to human fibronectin-coated 10 cm Petri dishes (Costar, USA) and split 
every 2-3 days. The cells were cultured at a high density throughout this period. After 
3-4 weeks of culture the cells were submitted to a depletion process with the intention 
to remove any remaining CD45 (pan leukocyte antigen) and Terl 19 positive cells 
(erythroid lineage cells) (see next). In separate experiments cells were isolated and 
maintained in incubators with a reduced partial pressureOf 02 (5%) in an attempt to 
decrease cytogenetic instability. 
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Table 5 IVIAPC specific culture media 
A) Mouse MAPC culture media 
Company Final Conc. 
DIVIEM GIBCO 60 0 
IVICDB (Modified Czapek Dox 
Broth) SIGMA 40% 
SITE SIGMK-- 1x 
BSA SIGMA 1 mg/ml 
Chemically defined liýiýd GIBCO 1x 
Pen/Strep Cellgro 10OU/ml 
L-ascorbic acid Sigma 0.1 mm 
FBS Hyclone 2% 
PDGF R&D 1Ong/mI 
EGF SIGMA 10ng/ml 
LIF Chemicon 1 x1 6' units 
Mercaptoethanol GIBCO ix 
B) Rat MAPC culture 
media 
Company Final Conc. 
DIVIEM GIBCO 60% 
MCDB SIGMA 40% 
ITS Sigma 1x 
LA-BSA Sigma 1x 
Pen/Strep GibcoBRL 100 U/mI 
L-Ascorbic Acid Sigma 0.1 mm 
Dexamethasone Sigma 0.05 pM 
FIBS Hyclone 2% 
PDGF R&D 1Ong/mI 
EGF SIGMA 1Ong/mI 
LIF Chemicon U167units 
Depletion of CD45 and Terl 19 cells 
After 3-4 weeks of culture the bone marrow was depleted of CD45 and Terl 19 cells 
using magnetically labelled antibodies (Miltenyi Biotech). The manufacturer's 
instructions were followed. Briefly cells were collected following incubation with Trypsin 
0.025%/ EDTA washed twice with Miltenyi MACS running buffer (PBS, 2 mM EDTA 
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and 0.5% BSA) and incubated with 10 ul of both anti CD45 beads and anti Ter 119 
beads per 1 OX1 06 cells for 15 minutes at 40C in 100 ul of MACS buffer. Cells were then 
washed with MACS running buffer and then run through an AutoMACS machine 
(Miltenyi Biotech, USA) using the DepleteS program according to the manufacturer's 
instructions. Positive and negative fractions were collected following separation, in a 
subset of experiments aliquots were removed for flow cytometry analysis. 
Cloning of CD45/ Terl 19 negative BM cells 
The negative fraction after AutoMACS separation was then washed and re-suspended 
in MAPC media and transferred to 8 human fibronectin coated 96 well plates at a cell 
density of 1 or 10 cells/well (all culture plates Costar, USA). Cells were then cultured 
for up to 14 days with media changed every 3-4 days. Wells were examined every 2-3 
days for evidence of proliferation. When a well contained cells that had proliferated to 
approximately 100 cells it was collected with trypsin/edta (Cellgro, USA) and 
transferred to a 48 well plate. If the selected clones continued to proliferate they were 
transferred daily to larger culture flasks until established in T150 human fibronectin 
coated flasks. Cells were cultured at a very low density of 200 cel IS/CM2 e. g. 30,000 
cells in a T1 50 flask. Cells were counted at each passage with a haemocytometer and 
the number of population doublings calculated. When the cells had been established in 
culture they were expanded for cell freezing, cytogenetic analysis, differentiation or flow 
cytometry analysis. 
Isolation of rat multi-potent progenitor cells 
Eight week old male Fisher 344 rats were sacrificed usingC02 inhalation and cervical 
dislocation. Bone marrow was harvested by flushing femurs and tibias with media and 
cultured in T1 75 polystyrene culture flasks (Corning, USA). Cells were maintained on 
10 ng/ml human fibronectin-coated (Sigma Aldrich, USA) flasks in rat MAPC media 
Table 5 [45]. After 2 days non-adherent haernatopoietic cells were discarded and 
media subsequently changed every 48-72 hours. Colonies of proliferating cells were 
harvested after 7 days with Trypsin/ EDTA (Cellgro, USA) and cultured at 200 cells/ 
cm 2. Cells were then either transferred to 96 well plates (cloning step as per murine 
cultures) or alternatively kept at low density by being split and re-plated at 200 cells/ 
cm 2 every 48-72 hours. At each passage cells were counted with a haemocytometer. In 
contrast to mouse cultures, no CD45/ Terl 19 depletion step was undertaken on rat BM 
cultures according to protocols from the Stem Cell Institute, University of Minnesota 
and based on results presented. 
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Retrovirall transduction of rMPCs with 0-gallactosidase 
To enable identification of transplanted cells rMPCs were transduced with a retrovirus 
carrying the LacZ gene coding for the prokaryotic P-galactosidase enzyme (P-Gal). 
Retroviral particles were derived from GP293 packaging cells (part of the Pantropic 
Retroviral transduction kit from BID-Clonetech, USA as per manufacturer's instructions) 
transformed with the pVSVG packaging plasmid (BID-Clonetech, USA) and P-Gal 
plasmid pCL-MFG-LacZ (Imgenex, USA). Briefly GP293 packaging cells were 
transfected simultaneously with the pVSVG plasmid (5ug) and the pCL-MFG-LacZ 
plasmid (5 ug). Two million GP293 cells were plated onto 10 cm Petri dishes (BID, 
USA) in DMEM (Gibco, USA) supplemented with 100 units/ml penicillin, 100 pg/ml 
streptomycin, 4 mM L-glutamine, 1 mM sodium pyruvate and 10% fetal bovine serum 
(all Gibco, USA) and incubated with 0.5 mis of the transfection solution containing 
calcium phosphate and both plasmids. After performing a transduction dose response 
curve of the viral supernatant on rMPCs, a final transduction titre of 1: 2 was chosen to 
give maximum transduction efficiency with minimal toxicity. rMPCs were plated at a 
density of 200 cells/ CM2 in MAPC media. Twelve hours later they were transduced with 
a 1: 2 titre of viral supernatant containing 4 ug/ ml of polybrene 
* 
(Sigma-Aldrich, USA) 
and incubated for 24 hours. After 24 hours media was changed for fresh MAPC media 
and 36 hours later cells were harvested and expanded under normal MAPC conditions 
as described in Methods. Seventy nine percent of cells had detectable LacZ expression 
measured by FACS-gal analysis and this was further increased by FACS sorting of P- 
Gal + cells to 100%. All in vitro and in vivo experiments on the rMPCs were performed 
on LacZ labelled cells. 
X-Gal staining of cells expressing LacZ 
To confirm that the rMPCs cells expressed sufficient LacZ for histological identification, 
cells were analysed for P-Gal activity. rMPCs were mounted onto glass slides using a 
Shandon Cytospin 4 (Shandon, USA) fixed with para-formaldehyde and gluteraldehyde 
and incubated with X-Gal reagent at 370C for 30 minutes. As negative controls un- 
labelled cells and rat aortic endothelial cells were stained with X-Gal reagent. X 
Gal 
reagent was made freshly for each experiment and composed of 
X-Gal 1 mg/ml, K- 
Ferrlcyanide 5mM, K- FerrOcyanide 5mM, MgC122 mM, NP40 0.02%, SIDS 0.01% in 
PBS (all Sigma, USA). 
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Cell freezing 
Cells were collected with trypsin/edta from culture flasks. The trypsin was inhibited with 
either foetal calf serum or media and the cells were centrifuged at 400 g for 10 minutes 
at 4'C. The cell pellet was re-suspended in freezing media (70% media, 20% FBS' 
10% DMSO) at a concentration of between 100,000 to 1 million cells per ml. Cells were 
transferred to 1.8 ml Nunc freezing vials and placed in a Nunc Freezing Container in a- 
80'C freezer for 24 hours before transferring to a liquid nitrogen freezer. 
Analysis of chromosome number and karyotyping 
Cultured bone marrow cells including cells from Athersys Inc and the University of 
Minnesota were incubated with colcemid 0.1 ug/ml to arrest dividing cells in 
metaphase. Cells were collected with Trypsin/edta and re-suspended in hypotonic KCI 
(0.075M) for 15 minutes at 370C. Cells were then fixed with methanol/ glacial acetic 
acid. The cell suspension was then dropped from 60 cm onto glass slides and 
counterstained with DAPI. Chromosome number was counted for a minimum of 20 
metaphase spreads. Mice have 40 chromosomes and rats have 42 chromosomes. In 
other instances cultured cells were sent for G-banding (Concentric Labs, Maryland, 
USA) or spectral karyotyping (Laboratory of Germline Modification, Van Andel Institute, 
MI, USA). 
Cytokine Analysis 
Cells were cultured at a density of 2x1 04 celIS/CM2 for 48 hours in 6 well plates. The 
culture media supernatant was harvested, centrifuged at 400 g for 10 minutes to 
remove cellular debris and then frozen at -80 OC. The supernatant was then sent for 
multiplex cytokine analysis (Pierce Biotech, USA). Pierce Biotech undertakes specificity 
testing on each antibody array to verify proper spotting and check for potential cross- 
reactivity or non-specific binding. As a control, media incubated without cells was also 
sent for analysis. The cytokine concentration of the media was subtracted from the 
rMPCs supernatant and protein levels corrected per 100,000 cells per 24 hours. 
Tri-Lineage differentiation 
Mouse or rat cultured bone marrow cells (including cells from the University of 
Minnesota) were propagated under specific conditions thought to promote tissue 
specific differentiation (Figure 24) [45]. These culture conditions were based on 
previous published work and what is known from the biology of other stem and 
progenitor cell differentiation pathways. Cultured bone marrow cells were collected with 
Trypsin/EDTA (Sigma-Aldrich, USA) from flasks with cultured cells growing under low 
density and re-suspended in MAPC media at the appropriate concentration. Cells were 
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then added to either 4 well or 8 well culture slides coated with ether human fibronectin 
(Sigma Aldrich, USA) or Matrigel (BD Biosciences, USA). Cells were cultured for 16 
hours and then the media was changed to 'lineage' specific differentiation media. The 
cells were then cultured for a further 2 weeks changing the media every 2-3 days. 
Differentiation assays were attempted at either 33'C or 37'C. After 14 days cells were 
then analysed for evidence of differentiation by uptake of Dil Labelled Acetylated LDL 
for endothelium and by tissue specific immuno-fluorescence for other lineages. 
Coating slides with matrigel and fibronectin 
Aliquots of frozen Matrigel (MG) were thawed on ice to prevent it precipitating and then 
diluted in ice cold PBS to a concentration of 2%. The solution was then sheared by 
passing through a 21 gauge needle, and then filtered through a 0.45 pm filter. Slides 
were then covered with 2% MG and incubated for 1 hour at 370C. Prior to use the MG 
was aspirated and the well rinsed with PBS. Aliquots of frozen human fibronectin (FN) 
were diluted in PBS to the desired concentration (10 ug/ml -10 ng/ml). Slides were then 
coated with FN and incubated for 1 hour at 37 'C or alternatively overnight at 4 T. 
Prior to use the FN was aspirated and the slide rinsed with PBS. 
Endothelium differentiation 
For endothelial differentiation cells were cultured on either plastic or glass slides, 
coated with either human fibronectin or Matrigel. The cell density was varied between 
20,000 cel IS/CM2 and 100,000 cells/ CM2. Cells were always initially cultured with MAPC 
media and differentiation was subsequently attempted with the following conditions: 
o MAPC basal media and VEGF 10 ng/ml. 
9 MAPC basal media and VEGF 10 ng/ml and 2% serum throughout 
9 MAPC basal media and VEGF 10 ng/ml and 2% serum reintroduced after 7 
days 
9 MAPC basal media and combinations of VEGF/ bFGF and serum 
* Enclothelial Growth Media 2 media (EGM-2) plus supplements (Cambrex, MID, 
USA) 
Liver 
For liver differentiation cells were cultured on plastic slides, coated with Matrigel in 
MAPC basal media with FGF4 and HGF. The cell density was varied between 20,000 
cel, S/CM2 and 100,000 cells/ CM2. 
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Neuronal 
For neuronal differentiation cells were cultured on either plastic or glass slides, coated 
with human fibronectin 10 ng to 10 ug/ml. The cell density was varied between 1,000 
celIS/CM2 and 5,000 cells/ CM2. Cells were initially cultured in either MAPC basal media 
or Neurobasal media (Gibco, USA) with 100 ng ml-1 bFGF for 7 days followed by sonic 
hedgehog (SHH) and FGF8b for 7 days to encourage a more differentiated phenotype 
[45]. 
Variations in differentiation protocol 
Due to the difficulty in achieving evidence of differentiation a number of different 
conditions were attempted. This included changing serum Lot and concentration of 
human fibronectin or Matrigel, changing all or half of the differentiation media at each 
media change, varying the concentration of cells cultured in each well and adding 2% 
FIBS (Hyclone, USA) to differentiation media either from day one or after 7 days. 
Figure 24 Schematic of differentiation assay for MAPCs 
MAPC differentiation 
Serum free media 
No LIF, EGF, PDGF 
14 day culture in chamber slides Hepatocytes 
I <t:: D FGF-4 and HGF 
VEGF 
MAPC 
Endothelium Neurones 
bFGF and SHH 
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Table 6 MAPC basal media and supplements for lineage specific differentiation 
(NB Serum free and no LIF, PDGF or EGF) 
(All cytokines for differentiation assays were form R&D, USA) 
MAPC BASAL diff MEDI 
Company 
DMEM low GIBCO 
glucose 
MCDB (Modified SIGMA 
Czapek Dox 
Broth) 
ITS Sigma 
Chemically GIBCO 
defined lipid 
Pen/Strep Cellgro 
L-ascorbic acid Sigma 
Cytokine Supplements for 
differentiation 
ENDOTHELIUM 
VEGF R&D 
NEURONAL Ist 
week 
bFGF 
NEURONAL 2nd 
week 
Sonic Hedgehog 
FGF8b 
LIVER 
FGF4 
HGF 
R&D 
R&D 
R&D 
R&D 
R&D 
Final 
Conc 
60% 
40% 
lx 
ix 
ix 
oAmm 
1 Ong/ml 
100ng/ml 
1 OOng/m I 
10 ng/ml 
lOng/ml 
20 ng/ml 
Tri-lineage differentiation of rMPCs used for transplantation 
After attempting differentiation assays with multiple conditions for rat cells, the following 
conditions were utilised for the rMPCs used for cell transplantation (Chapter 5). For 
endotheliai differentiation rMPCs cells were cultured on plastic slides (Nunc) coated 
with Matrigel (BID, USA) at a density of 50,000 cel IS/CM2 in basal media with VEGF 
long/mi. For liver differentiation cells were cultured on plastic slides coated with 
Matrigel in MAPC basal media with FGF4 and HGF at a density of 50,000 celIS/CM2 . 
For neuronal differentiation cells were cultured on glass slides coated with human 
fibronectin lOng/ml at a cell density 5,000 cells/ CM2. Cells were initially cultured in 
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Neurobasal media (Gibco, USA) with 100 ng ml-1 bFGF for 7 days followed by SHH 
and FGF8b for 7 days. All cytokines for differentiation assays were R&D, USA. 
Rat positive control cell lines 
Primary culture of aortic endothelial cells 
Male inbred Fisher 344 rats from Harlan were used for isolation of aortic endothelial 
cells. The rats were euthanised with C02 inhalation and cervical dislocation. The 
thoracic aorta was dissected free taking care not to stretch or over handle the aorta. 
The vessel was rinsed twice with endothelial specific EGM-2 media (Cambrex, MID, 
USA). The peri-adventitial fat around the vessels was carefully removed under a 
dissecting microscope using forceps and iris scissors. The vessel was opened 
longitudinally and cut into pieces 2-m M2 and placed with the lumen face down onto 
human fibronectin-coated 6 well plates covered with enough EGM-2 to keep the tissue 
moist without submerging them. The tissues were placed into an incubator at 370 C in 
5% C02 . After 1-2 days the explants should attach to the surface in this minimal 
volume of medium. After 2 days 0.5 ml of medium was added and cells began to 
migrate from the edges of explants between days 2 and 7. Cells were then expanded in 
EGM-2 media. The phenotype was confirmed by uptake of Dil labelled Acetylated LDL 
(Molecular Probes, USA) and staining with endothelial specific antibodies. 
Neuronal cell culture 
Rat foetal neurons cultured and fixed on chamber slides were acquired from the Stem 
Cell Institute, University of Minnesota. 
Hepatoma cell culture 
The rat hepatoma cell line CRL-1600 was acquired from American Type Culture 
Collection (ATCC), Manassas, USA. Cells were cultured according to the ATCC 
instructions in Dulbecco's modified Eagle's medium with 4 mM L-glutamine, 1.5 g/L 
sodium bicarbonate, 4.5 g/L glucose, 20% horse serum and 5% foetal bovine serum at 
370C. 
Mouse positive control cell lines 
Murine endothelial cell line (EOMA) 
The mouse endothelial tumour cell line EOMA CRL-2586 was acquired from ATCC and 
cultured according to instruction in Dulbecco's modified Eagle's medium with 4 mM L- 
glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10% foetal bovine serum at 
37'C. Experiments were performed with cells at 70% confluency. 
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Murine hepatocyte cell line (CRL-1830) 
The mouse hepatoma cell line CRL-1830 was acquired form ATCC and cultured 
according to instruction in Dulbecco's modified Eagle's medium with 4 mM L-glutamine, 
1 .5 g/L sodium bicarbonate, 4.5 g/L glucose, 10% foetal bovine serum at 370C. 
Rat mesenchyrnal strornal cell isolation and differentiation 
As MAPCs are reported to be a fraction of mesenchymal stem cells, MSCs were 
isolated from Fisher 344 rats according to standard protocols [152]. MSCs served as 
positive controls and were used to compare to MAPCs. For rat MSC isolation, the 
excised femur and tibia were cleaned, the marrow is flushed, and the isolated cells 
plated directly into flasks (4 T-150 flasks per animal). The cells were cultured in 
alphaMEM with 20% FIBS (Sigma Aldrich, USA), penicillin 100 u/ml, streptomycin 100 
u/ml and amphotericin 25 ng/ml and L-glutamine 2 mM (all Sigma Aldrich, USA). Every 
3 days the media was changed until the adherent cells were 90% confluent. The cells 
were then passaged at low density (50 cells/cm2) until the population was relatively 
homogenous [152]. 
Mesenchymal stromal cell colony forming assay 
One hundred cells were plated onto a 10 cm tissue culture plate and grown in standard 
media for 21 days. The colonies were then visualized after crystal violet staining and 
counted. Total colonies and large colonies counted because rMSCs form small 
satellite colonies from cells that have migrated from the main colonies. Higher CFU % 
(out of 100) was directly proportional to higher cell viability. Crystal Violet Solution 
prepared with 3g crystal violet powder added to 100 mL methanol. 
Mesenchyrnal strornal cell differentiation 
For osteogenesis and adipogenesis, differentiation media prepared using standard 
rMSC tissue culture media with 20% FBS. Highly confluent cells changed to the 
differentiation media. Media changed every 4 to 5 days for 21 days, before fixation and 
staining. 
Rat MSC adipogenesis differentiation 
Adipogenesis differentiation media consists of MSC media plus 0.5 pM 
dexamethasone, 50 pM indomethacin and 0.5 mM isobutylmethylxanthine (IBMX) (all 
Sigma Aldrich, USA) [153]. Twenty one days after differentiation cells were stained with 
oil red 0 Solution which stains fat and lipid red (300 mg of oil red 
0 powder are 
dissolved in 100 mL of 99% isopropanol). Prior to use it was diluted 3 to 2 with distilled 
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H20. Cells are fixed with 10% neutral buffered formalin for 10 minutes prior to adding 
staining solution for 15 minutes. Cells were rinsed with PBS and viewed. 
Rat MSC osteogenesis differentiation 
Osteogenesis differentiation media consists of MSC media plus U10-8 M 
dexamethasone, 10 pM beta glycerol phosphate and 50 pM ascorbic acid 2- 
phosphate[153] (all Sigma Aldrich, USA). Twenty one days after differentiation cells 
were stained with Alizarin red solution to identify potential bone. Alizarin red and 
calcium form a chelation complex which is bi-refringent and appears red. Forty mM 
Alizarin red solution is titrated to pH of 4.2 with 10% ammonium hydroxide solution. 
Cells were fixed with 10% neutral buffered formalin for 10 minutes prior to adding 
staining solution. For Alizarin red staining, cells with were washed with distilled H20 
and stained for 15 minutes. Washing with PBS caused the pH sensitive Alizarin Red to 
precipitate out of solution. Cells were rinsed with H20 and viewed. 
Immuno-fluorescent staining of cultured cells 
After the differentiation period on culture slides, cells were gently rinsed with PBS and 
fixed with either 4% para-formaldehyde for 10 minutes or methanol at -20 'C for 2 
minutes. For intra-cellular antigens cells were permeabilised with 0.1% Triton-100 for 
15 minutes. Cells were blocked with 10% goat serum (Vectashield Labs, USA) and 
incubated with primary antibody or isotype control (5 ug/ml) for 60 minutes at room 
temperature followed by goat secondary (Alexa Fluor 594 or 488 F(ab)2, Molecular 
Probes, USA) at a titre of 1: 1000 and incubated at room temperature for 45 minutes. 
Other wells were left unstained to check for auto-fluorescence or incubated with 
secondary antibody alone to document any non-specific binding of the secondary 
antibody. Staining of differentiated cells was performed alongside a positive and 
negative control cell line. After secondary incubation cells were rinsed and mounted 
with DAR hard set mounting media (Vectashield, USA) and a cover slip. Antibodies 
used for rat are shown in (Table 7, page 100) and for mouse in (Table 8, page 100). 
After endothelial differentiation cells were incubated for 4 hours with Dil Ac LDL 1 pg/ml 
(Molecular Probes, USA). 
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Table 7 Antibodies used for immuno-fluorescence staining of rat differentiated 
cells 
Anti Rat antibodies 
Liver Specific Antibodies Company/ Clone Titre Isotype 
Albumin Dako 0001 5 ug/ml Rabbit polyclonal 
HNF-1 Santa Cruz 5 ug/ml Rabbit polyclonal 
sc8986 H205 
Cytokeratin 18 Chemicon 5 ug/ml Mouse IgG1 
CB1 77 Ksl 8.04 
Neuronal Specific Antibodies 
Nerve Specific Enolase Chernicon 5 ug/ml Mouse IgG, 
MAB314 
Nestin BID 556309 5 ug/ml Mouse IgG, 
Rat401 
Neurofilament 200 Sigma N 5389 5 ug/ml Mouse IgG, 
Endothelial Specific Antibodies 
VWF Dako 0082 5 ug/ml Rabbit polyclonal 
CD31 BID 550300 0.8 Mouse IgGl 
Clone Al 2 ug/ml 
RECA1 Abcam ab9774 1 ug/ml Mouse IgGl 
Recal 
Table 8 Antibodies used for immuno-fluorescence staining of mouse cells 
Anti Mouse antibodies 
Liver Specific Antibodies Company/ Titre Isotype 
Clone 
Albumin Dako 0001 5 ug/ml Rabbit polyclonal 
HNF-1 Santa Cruz 5 ug/ml Rabbit polyclonal 
sc8986 
Cytokeratin 18 Chemicon 5 ug/ml Mouse IgG1 
CBL1 77 
Endothelial Specific Antibodies 
CD31 BID 50274 1 ug/ml Rat IgG2a 
CD1 05 BID 50546 5 ug/ml Rat IgG2a 
CD144 VE-Cadherin BID 550548 5 ug/ml IgG2a 
VWF Chemicon 5 ug/ml Rabbit polyclonal 
AB7356 
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Microscopy 
Slides of cultured cells were viewed using a fluorescence microscope (Nikon Eclipse 
E800) and light microscope (Nikon Eclipse, E600) and images captured with QCapture 
Pro software (Qimaging, Ca). 
Quantitative real time PCR 
After differentiation of rMPCs cells were lysed within chamber slides with lysis buffer 
(Stratagene, USA) and RNA extracted using Absolutely RNA MiniPrep Kit (Stratagene, 
USA) and treated with DNase I according to manufacturer's instructions. Eluted RNA 
was reverse transcribed with and without MMLV reverse transcriptase with random 
primers and dTNP mix in MMLV RT buffer (Promega, USA). 0.5 pL of total cDNA was 
amplified in duplicate with SYBR Green PCR Master Mix (Applied Biosystems, USA) in 
a 25 pl reaction mix with 7.5 pmol of forward and reverse primers. Amplification was 
performed in a 7500 ABI qPCR thermocycler for 40 cycles (initial denaturation 95 OC/ 
10 minutes, followed by 95 OC/15 seconds, annealing and extension 60OC/1 minute). 
RT-PCR data was normalised by measuring average cycle threshold (Ct) between 
candidate genes and GAPDH control gene. The formula 2c' 
(candidate)/2 Ct(GAPDH) 
was used 
to calculate normalised ratios (NR) for each candidate gene. Normalised ratios were 
then expressed as relative expression using the formula NR 
(after differentiation)/ NR (before 
differentiation) 
. As a control, relative expression 
for each candidate gene was calculated for 
rMPCs cultured in normal MAPC media during the differentiation period. 
The following rat specific PCR primers were used (prefix Y indicates rat specific and 
'mr' both rat and mouse): 
From Stem Cell Institute, University of Minnesota 
rGAPDH, F-catcttcftgtgcagtgccag, R-ggtaaccaggcgtccgata; 
rNF200, F-tcaagatggccctggatattg, 
rMAP2, F-gaagcagftgtgtccgaacca, 
Nestin, F-agagtttgaggacctagggactga, 
rVWF, F-cccaacggatggctaggtatt, 
rPECAM, F-ggactggccctgtcacgtt, 
Me-2, F-cccaagaaattaggacacttcca, 
Albumin, F-gagaaggtcaccaagtgctgtagt, 
rCK1 9; F-accacgaggaggaaattagtgc, 
rHNFla, F-agctgctcctccatcatcaga, 
Designed in house 
rl 8s, F-tttcggaactgaggccatga, 
mrOct4, F-gaacatgtgtaagctgcggc, 
R-gagaagggactgggtccaaag; 
R-tctgagcggaagagcagtftg; 
R-acgtgatctgctacctcctt; 
R-gaggcggatctgfttgaggtt; 
R-ttgttcatggtgccaaaacact; 
R-cacggtgatgcaagtcaftcc; 
R-ctgggagtgtgcagatatcagagt; 
R-caatgcctggtgtggaatcc; 
R-tgttccaagcattaagftftctattctaa; 
R-gcaaatgctttcgctctggtc; 
R-ccftctggcggftacag 
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To compare rMPCs with an Oct4 expressing +ve control (mouse ES cells) the Oct4 
primers were designed to amplify a section of DNA which in addition to crossing an 
intron was also homologous to both the rat and mouse gene sequence. The Oct4 RT 
PCR product was analysed on a 1% agarose gel in TBE with a 100-bp ladder and 
visualised with a Kodak Image station 440. 
Flow cytornetry analysis 
Cells were collected with Trypsin/EDTA and washed with FACS wash (PBS, 2 mM 
EDTA and 0.5% BSA or FBS). Two hundred thousand cells were re-suspended in 100 
ul of FACS wash with primary antibody or isotype control, at a concentration of 0.5 ug 
protein/100 ul and incubated for 20 minutes at 40C in the dark. Permeabilised cells 
were incubated with unlabelled anti-CXCR4 (ab7199) and VEGFR1 (ab2350) (Abcam, 
MA, USA), or isotype control, followed by incubation with AlexaFluor 488 secondary 
1: 1000 (Molecular Probes, USA). For unlabelled primary antibodies, cells were 
subsequently incubated with secondary fluorescent labelled antibodies from Molecular 
Probes at a titre of 1: 1000. Antibodies used are shown in (Table 9). Events were 
acquired with a FACS Canto flow cytometer (Beckman Coulter, Fullerton, CA, USA) 
and data analysed with FCS Express V3 software (De Novo software, Ontario, Ca). 
Freshly isolated blood mononuclear cells served as positive control. Circulating blood 
mononuclear cells were obtained by Ficoll gradient purification using lymphocyte 
separation medium (ICN Biomedicals Inc., Ohio, USA) as described in Chapter 2. 
FDG staining for P-Galactosidase expression (full method in Chapter 2) 
rMPCs were collected with trypsin/EDTA and loaded with 1 mM fluorescein di-R-D- 
galactopyranosidase (FDG) by hypotonic shock for 1 minute. Endogenous lysozymal 
galactosidase activity was inhibited with chloroquine (Molecular Probes, USA). After 
quenching with media containing propidiurn iodide to exclude dead cells, rMPCs were 
analysed for P-Gal expression by flow cytometry. P-Gal +ve cells were sorted and 
expanded for use in subsequent experiments. 
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Table 9 Antibodies used for flow cytometry of rat cells 
Antibodies for Flow Cytometry Company/ Isotype 
Clone 
CD90 BID 551401 Mouse 
Clone PX-7 IgG1 
CD44 BID 550974 Mouse 
Clone PX-49 IgG2a 
Mhc Class I BID 559993 Mouse 
Clone OX-18 IgG, 
MHC Class 11 BID 554929 Mouse 
Clone OX-6 IgG, 
CD45 BID 554878 Mouse 
Clone OX-1 IgG, 
SSEA1 Chemicon Mouse 
MAB4301 Igm 
CXCR4 Abcarn Rabbit 
Ab 7199 IgG 
VEGFR1 Abcarn Rabbit 
Ab 2350 IgG 
Telomere length assay 
The TeloTAGGG telomere length assay kit (Roche Diagnostics Corp. USA) was used 
for determination of mean telomere length of rMPCs cultured for 120 pd as per 
manufacturers instruction. Briefly, after isolation and digestion 1 ug of genomic DNA, 
DNA fragments were separated by gel electrophoresis and transferred to nylon 
membrane by Southern blotting. The blotted DNA fragments were hybridised to a 
digoxigenin-labelled probe specific for Telomere Restriction Fragments (TRF) and 
incubated with a digoxigenin-specific Ab covalently coupled to alkaline phosphatase. 
Finally the immobilised telomere probe was visualised by alkaline phosphatase 
metabolising CDP-Star, a highly sensitive chemi-luminescent substrate. The average 
telomere length was determined by comparison with a molecular weight standard 
marker and a control immortalized cell line with high telomere length. 
Statistical analysis 
All results are expressed as means ± sem. Statistical significance was evaluated with 
an unpaired Student Mest for comparison between 2 groups or with ANOVA for 
comparison between multiple groups (Prism 4 software, Graphpad Software, USA). A 
probability value of p<0.05 was considered significant. 
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Results 
Isolation of murine multi-potent adult progenitor cells 
Establishing bone marrow cultures 
Bone marrow was collected from 21 mice on different occasions and cultured 
according to methods. From all bone marrow cultures it was possible to establish 
growing colonies of attached cells that could be expanded significantly over a4 week 
period. However, there was considerable heterogeneity in the appearance of these 
cultures. Some cultures had small cells with a spindle morphology others had larger flat 
cells. Some cultures were uniform in their morphology whilst others where very 
heterogeneous. It was not apparent what caused this variation but the timing of splitting 
cells was important. Different flasks of cells from the same bone marrow often 
developed entirely different morphologies when split at different time points. The 
significance of this is unclear although MAPCs are reported to be small spindle shaped 
cells [45] 
Depletion of CD45 + and Teri 19 + cells using Miltenyi AutoMACS 
All 21 cultures were maintained for 3-4 weeks until they were depleted of the remaining 
CD45 and Terl 19 + cells. Although effectively 100% of nucleated cells were CD45 
positive when the bone marrow was isolated, only 5-15% of cells were positive for 
CD45 after the initial culture period (Figure 25). No cells were positive for Terl 19 after 
the initial culture period (data not shown). Also the expression intensity of CD45 
decreased in cultured cells when compared to freshly isolated cells. Although the 
depletion process enriched for CD45 negative cells there was still 2-5% of 
CD45 + cells 
in the negative fraction (n=3). 
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Figure 25 Flow cytometry histograms of CD 45 expression of bone marrow cells 
3 weeks after culture in MAPC media 
After BM was cultured for 3 weeks 12% of cells are CD45+ measured by flow 
cytometry prior to CD45 depletion (top right). Prior to culture 100% of the BM MNC 
cultured are strongly positive for CD45 (bottom panel). After MACS depletion of CD45 
and Terl 19 + cells the % of CD45 cells decreases but 5% of cells are still CD45 
positive (example from n=3) middle panel 
Isotype control: 1% Pre depletion: 12% 
Post depletion: CD45 -ve fraction: 5% Post depletion: 
; 
ve fraction: 59% 
Akk 
Control mouse MNC CD45 PE staining 
Isotype Control PE CD45 PE 100% 
Cloning of depleted cells in to 96 well plates 
In order to isolate the proliferating clones from the culture and distinguish between 
clones with different differentiation potential a cloning step was undertaken. 1 or 10 
cells were cultured in each well of a 96 well human fibronectin coated plate for up to 14 
days. Proliferating cells were selected and expanded. Again the morphology of different 
clones was heterogeneous from spindle shaped cells to flat cells growing in a 
'cobblestone' like morphology. The mean % of clones that proliferated from plates with 
1 cell per well was 4% (range 0-12) and from 10 cells per well the mean was 25% 
(range 0-47). It was assumed that proliferation from wells with 10 cells had originated 
from a single cell. Of the clones that were expanded from the 96 well plates only 20% 
could be established in low density culture of 200 cells/ CM2 in a T150. Once 
established in a T1 50 the cells morphology and growth characteristics usually 
remained stable and the cells proliferated at a constant rate (Figure 26). 
Cells that were 
successfully established were expanded for freezing, differentiation or cytogenetic 
analysis. 167 clones were isolated from the bone marrow harvested 
from 21 mice. This 
included clones from all mice strains used (wild type, GFP, ROSA26, p27 KO, p2l 
KO 
and Oct4-GFP transgenic mouse). Other than the p27 
KO cells being consistently 
larger than the other mice cultured cells (measured on a digital coulter counter) I found 
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no consistent feature to distinguish between cells isolated from different mice strains 
(such as growth kinetics, morphology, differentiation ability and cytogenetic stability). 
Figure 26 Proliferation growth curves of 2 cell lines isolated after single cell 
cloning of cultured mouse BM in MAPC conditions 
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Differentiation assay of the 'potential' of multi-potent progenitor cells 
Confirmation of positive control IF staining 
As a result of the uncertainty of the outcome of the differentiation process into cells of 
all 3 germ cell lineages (mesoderm -endothel ium, endoderm-hepatocyte and ectoderm- 
neuronal) positive, control cells lines were established and cultured in chamber slides 
and submitted to the same immuno-fluorescence protocol as for the cultured bone 
marrow cells. Cell lines from both rat and mouse were established due to the significant 
difference in antibody cross reactivity between the 2 species. 
Establishing specific conditions for immuno-fluorescent staining using positive 
control cell lines 
The initial practical working definition of a pluripotent cell was one that could 
differentiate into cells of all 3 germ cells lineages as assessed by up-regulation of 
specific antigenic makers. Positive control immuno-fluorescent (IF) staining was 
established using positive control lines in order to be confident that failure of cells to 
up-regulate antigens was due to failure to differentiate rather than failed IF staining. 
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Primary rat aortic enclothelial cells 
Rat aortic enclothelial cells were isolated as described in the methods and then cultured 
on chamber slides. All cells stained positive for CD31 which was distributed on the cell 
surface. RECA1 also had a membranous distribution whereas VWF staining was within 
intracellular cytoplasmic granules corresponding to the Weibel Palade bodies (Figure 
27). Cells also took up Dil Ac LDL into cytoplasmic vesicles (Figure 28). 
Figure 27 Photomicrograph of rat aortic endothelial cells after immuno- 
fluorescent staining for CD31, RECA1 and VWF (x200) 
All cells are positive for CD3 1, RECA I and VWF (red). Secondary antibody Alex Fluoro 
594, nuclei counter stained with DAPI (blue) 
Figure 28 Immuno-fluorescent photomicrograph of rat aortic endothelial cells 
demonstrating uptake up Dil Acetylated LDL 
(x200) nuclei counter stained with DAPI 
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Rat hepatorna cell line CRL-1600 
The rat hepatoma cell line was used as a positive control. Cytokeratin 18 which is a gut 
and liver specific cytoskeletal protein was clearly seen running in fibres through the cell 
cytoplasm. HNF1 which is a liver transcription factor was localised to the nucleus. 
Albumin was localised in the cytoplasm (Figure 29). 
Figure 29 Immuno-fluorescent photornicrographs of rat hepatorna cells CRL-1600 
stained for CK18, HNF1 and Albumin 
All cells are positive for CKI 8, HNFI and albumin. Secondary antibody Alex Fluoro 488 
(x200) Albumin counter stained with DAR 
CK1 8 HNF1 
Rat foetall neurones 
Rat foetal neurones were used for positive control staining. Cells were positive for 
nerve specific enolase, neurofilament 200 and nestin (a marker of developing 
neurones) Figure 30. 
Figure 30 Immuno-fluorescent photornicrographs of rat foetal neurones stain for 
nerve specific enolase (NSE), nestin and NF200 
All cells are positive for NSE, Nestin and NF200 (green). Secondary antibody Alex 
Fluoro 488, nuclei counter stained with DAPI (blue) (x200) 
NSE Nestin NF200 
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Albumin 
Mouse endothelial cell line EOMA and hepatorna cell line CRL-1830 
The mouse endothelial cell line EOMA was used for positive staining (Figure 31). The 
membranes of cells were positive for CD31 (PECAM), ve-cadherin and 5% of cells had 
intra-cytoplasmic granules positive for VWF consistent with Weibel Palade bodies. 
Cells were also positive for CD105 and took up Dil labelled Acetylated LDL (Data not 
shown). The mouse hepatoma cell line was used to establish positive control staining 
(Figure 32). Most cells expressed the cytoskeleton protein CK18 in their cytoplasm, 
and HNF1 in the nucleus. 
Figure 31 Immuno-fluorescent photomicrographs of mouse endothelial (EOMA) 
cells for CD31, Ve-cadherin and VWF 
Cell with good ce//-cel/ contact are positive for CD31 and Ve-cadherin. However, only 
the occasional cells are positive for VWF. Secondary antibody Alex Fluoro 488, nuclei 
counter stained with DAPI (x200) 
CD31 Ve Cadherin VWF 
Figure 32 Immuno-fluorescent photomicrographs of mouse hepatoma cells CRL- 
1830 stained for CK18 and HNFI 
All cells are positive for CK18 and HNFI. Secondary antibody Alex Fluoro 488, nuclei 
counter stained with DAPI (x200) 
CK18 HNF1 
Differentiation of rnouse cultured BM cells in MAPC conditions 
It was not possible to differentiate any of the mouse clones 
derived according to the 
MAPC isolation protocol. All cells failed to demonstrate any lineage specific markers 
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upon immuno-fluorescent staining despite confirmation of the IF staining protocol using 
positive control cell lines. Conceivably the sensitivity of our IF assay may have failed to 
detect a low expression of up-regulated antigens. However, many clones simply were 
unable to tolerate the change to differentiation media (which is serum free and without 
LIF, PDGF-BB and EGF) and the cells died over the first 3-4 days of the attempted 
differentiation. 
Numerous variations in differentiation conditions were tried which were all 
unsuccessful. This included culturing cells at different passage number, changing the 
lot of serum the cells were isolated and cultured in, varying the seeding concentration 
of cells in the culture slides, seeding cells onto human fibronectin or Matrigel. Culturing 
cells in an incubator at 330C rather than 37'C as it was postulated that the lower 
temperature may facilitate differentiation. 
Despite numerous attempts to differentiate cells derived in our laboratory and with 
assistance from the Stem Cell Institute, University of Minnesota, it was not possible to 
identify cultured bone marrow cells that revealed evidence of pluripotency. Despite 
optimising our differentiation assay and IF staining with positive controls I could not 
document the up-regulation of lineage specific antigens in any mouse line derived in 
house. In addition when each cell clone was submitted to cytogenetic analysis they 
were all abnormal. 
Cytogenetic analysis of mouse bone marrow clones derived by the MAPC culture 
process 
All of the in house clones derived from murine bone marrow isolated according to the 
MAPC protocol were found to have significant cytogenetic abnormalities. A normal 
mouse karyotype is demonstrated (Figure 33) A normal mouse karyotype is 40 XY 
(Figure 33). Aneuploidy was common e. g. tetraploidy, as were whole chromosome 
deletions, additions and translocations (Figure 34). Sometimes these cytogenetic 
abnormalities were only found in single cells but often they were clonal and the vast 
majority of metaphases analysed had the abnormality. As mouse chromosomes are 
acrocentric (the centromere is at one end of the chromosome) G-banding can still not 
detect all translocations [150]. 
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Figure 33 Photomicrograph of G- banding of a metaphase spread of cultured 
murine BM cell demonstrating a normal karyotype 40XY 
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Figure 34 Photornicrograph of G- banding of wild type clone 
There is a deletion of the Y chromosome, trisomy I and translocation of 16 onto 
chromosome I 
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Spectral Karyotyping (SKY vision) was performed on a limited number of lines as it 
provides easy visualisation of abnormalities [150]. SKY vision revealed the number of 
abnormalities in a rat MAPC line from the University of Minnesota (Figure 35). 
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Figure 35 Fluorescent micrograph of SKY analysis of Rat MAPC clone R7 (from 
the University of Minnesota) demonstrating severely abnormal karyotype 
Each chromosome is labelled with chromosome specific fluorescent probes by in-situ hybridisation and 2 images taken of each chromosome with different excitation 
wavelengths of light (hence 8 images of each chromosome due to tetraploidy). 
Fluorescent microscopy analysis of metaphase spreads indicated the karyotype was 4n1 tetraploid cells with translocations of the whole of chromosome 3 to 20 and part of 
chromosome 6 to 15 (marked with arrows) 
3 
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Due to the resources required to screen clones by full G-banding or SKY analysis I 
developed a screening system to check for major karyotype abnormalities. Essentially 
metaphase spreads were made as described, counter stained with DAPI, and total 
chromosome number counted with a florescent microscope. If the cell line was clearly 
abnormal e. g. predominantly tetraploidy or with imbalanced chromosome number no 
further analysis was undertaken. Most lines were abnormal using this method and were 
therefore not submitted to detailed G-banding. 
To investigate the karyotype of other cultured cells metaphase spreads were prepared 
from NIH 3T3 cells, an immortalized mouse fibroblast line commonly used for cell 
biology research. All cells analysed were found to be significantly abnormal (Figure 36). 
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Figure 36 Fluorescent photomicrograph of DAPI staining of metaphase spread of 
NIH 3T3 mouse fibroblast cell line 
90% of cells were 4n/tetraploid and of these 60% had chromosome deletions 
Differentiation of mouse MAPC'YH-LacZ'from the University of Minnesota 
Mouse MAPC cells, YH-LacZ, were supplied by Professor Verfaillie from the University 
of Minnesota. These cells were isolated according to their published protocol [45] which 
has been described in methods. Cells were cultured at low density in mouse MAPC 
media and submitted to cytogenetic analysis and differentiation into liver and 
endothelium. The initial karyotype by G-banding was normal and a proportion of the 
cells became positive for tissue specific antigens after differentiation (CK-18 after 
hepatocyte and VWF after endothelial differentiation) indicating potentially a degree of 
pluripotency for endothelial and hepatocyte differentiation (Figure 37). However, when 
this was repeated it was no longer possible to demonstrate up regulation of the lineage 
specific antigens. Repeat chromosomal analysis after 4 weeks in culture unfortunately 
revealed that the line was no longer cytogenetically normal but had developed a clonal 
event (Figure 38) which is suspected for causing the failure to subsequently 
differentiate. G-banding analysis of NIH 3T3 cells also revelead extensive 
chromosomal abnormalities indicating that prolonged culture of other cell types may 
result in cultures succumbing to cytogenetic derangements (Figure 36). 
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Figure 37 Immuno-fluorescent photornicrograph of mouse MAPC YJ LacZ cells 
from the University of Minnesota after attempted differentiation into liver and 
endothelium 
a) Cells after liver differentiation stained for cytokeratin 18 b) Cells after endothelial differentiation stained for VWF. Nuclei counter stained with DAPI (x 200). A few cells stained positive for CK 18 which appeared cytoskeletal in nature and a small proportion of cells had cytoplasmic granules positive for VWF after endothelial differentiation 
a) CK18 b) VWF 
Figure 38 Photomicrograph of G-banding of mouse MAPC cone: YJ LacZ (from 
University of Minnesota) 
Initial analysis revealed 19120 metaphases analysed had a normal karyotype. After 4 
weeks in culture a clonal abnormality dominated the culture consisting of a deletion of 
chromosome 4 and 15, with trisomy of chromosome 1,3 and 15. 
a) Baseline b) After 4 weeks of culture 
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The effect of reduced02partial pressure on cytogenetic stability 
Cxidative stress may initiate the cytogenetic abnormalities observed in the murine BM 
cultures. Murine bone marrow was therefore isolated and cultured under a reduced 
p02 of 5% which more closely resembles the partial pressure of 02 in vivo. Bone 
marrow was isolated from 5 separate mice and multiple clones selected according to 
methods. All clones analysed by DAR staining of metaphase spreads revealed clonal 
cytogenetic abnormalities indicating that low02 does not significantly affect the rate 
karyotype stability. 
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Attempts to identify markers of pluripotency within 'MAPC' bone marrow 
cultures 
SSEA1 expression on cells 
MAPCs are weakly positive for stage specific embryonic antigen, SSEA1 [45]. SSEA1 
is a cell surface marker found predominantly on embryonic stem cells [117]. To attempt 
to identify the putative MAPCS, SSEA positive cells were searched for in the murine 
bone marrow cultures. SSEA1 staining of mouse embryonic stem cells (gift from Cecilia 
Lo, NHLBI, NIH) confirmed their high expression level of SSEA1. Cultured BM cells 
were negative for SSEA1 (Figure 39). 
Figure 39 SSEA1 expression of mouse embryonic stem cells and murine bone 
marrow cells by flow cytometry 
mES cells are strongly positive for SSEA 1 in contrast to bone marrow cells cultured 
according to the MAPC protocol for 4 weeks which are negative for SSEA 1 (RED) 
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Analysis of cultured bone marrow from transgenic mice expressing GFP under 
control of the Oct4 promoter 
Bone marrow was isolated from transgenic mice expressing GFP under control of 
the 
Oct4 promoter. Oct4 is a transcription factor required for the pluripotency of embryonic 
stem cells. It usually expressed in the early embryo and 
in germ line cells and is a 
robust marker of embryonic stem cells. Oct4 GFP mice express 
GFP in the early 
embryo and in ES cells derived from them. MAPCs are reported 
to have a low level of 
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Oct 4 expression [45] and I attempted to use detection of GFP to identify the putative 
MAPC. Examination of eight 10 cm Petri dish with sub-confluent bone marrow cells 
cultured in MAPC media for 4 weeks failed to identify any GFP positive cells (n=2) 
(data not shown). Flow cytometric analysis of the BM from these experiments when 
compared to wild type bone marrow also failed to detect any GFP positive cells (data 
not shown). According to the original description the expression level of Oct 4 in 
MAPCs is 1000 times less than ES cells. Therefore it is possible that this was 
insufficient to drive enough GFP expression to be detected. 
Isolation and characterization of rat multi-potent progenitor cells 
As it was not possible to isolate MAPCs from murine BM their isolation was attempted 
from rats. Cultures of cells were established from the bone marrow of Fisher 344 rats 
cultured under conditions previously shown to allow isolation of MAPCs but without 
undertaking a single cell cloning step. These cells were isolated under by this process 
were named as rat multi-potent progenitor cells (rMPCs) to distinguish them from 
MAPCs. Under these conditions rMPCs could be maintained for over 220 population 
doublings (pd) (Figure 40) without a change in morphology or phenotype. 
Figure 40 rMPCs can be maintained in culture for over 200pd 
rMPCs were isolated from rat bone marrow by culture in media containing EGF, PDGF- 
BB and LIF on human fibronectin coated flasks. Cells were cultured at the low density 
of 200 ce111CM2 . 
No cloning step was undertaken. Cells were counted at each passage 
and could be maintained for over 220 population doublings. 
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After confirming the surface flow cytometry phenotype of bone marrow mono-nuclear 
cells (Figure 41) and MSCs (Figure 42) the surface phenotype of the rMPCs was 
investigated. The surface marker phenotype of rMPCs (Figure 43), assessed by flow 
cytometry after 120 and 200 pd, is MHC Class 1, CD44 and CD90 positive and MHC 
Class 11 and CD45 negative a phenotype similar to MSCs [153] but different to the 
reported phenotype of MAPCs [45]. 
Figure 41 Rat bone marrow mononuclear cell surface expression of CD45, CD44, 
CD90, IVIHC Class I and 11 by flow cytometry 
Most MN cells are MHC Class /, CD44 and CD45 positive. There are also smaller 
populations of cells positive for MHC Class // and CD90. 
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Figure 42 Flow cytometry of rat MSCs (MK-1) cell surface expression of CD45, 
CD44, CD90, MHC Class I and 11 
MSC are CD45 and MHC Class // negative and positive for CD44, MHC Class / and CD90 
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Figure 43 Flow cytometry of rat rMPCs cell surface expression of CD45, CD44, 
CD90, MHC Class I and 11 surface markers 
rMPCs cultured for 120 pd were labelled with PE- or FITC coupled antibodies against 
CD45, CD44, CD90, MHC class / and MHC class or isotype control. rMPCs are MHC 
Class /, CD44 and CD90 positive and MHC Class CD45 negative. 
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Unlike MAPCs, rMPCs did not express Oct4 by real time PCR although they did have a 
maintained telomere length of over 20kb despite prolonged culture (Figure 45). Even 
after over 220 pd the cells continued to proliferate with a stable morphology and 
showed no signs of senescence. Despite prolonged culture the karyotype of rMPCs 
also remained stable, although non-clonal abnormalities were identified (Figure 46). 
Figure 44 rMPCs do not express the pluripotency transcription factor Oct4 by RT 
PCR 
Real time PCR of rMPCs (120pd) and mES cells (+/- reverse transcriptase) using Oct 4 
primers specific for both the rat and mouse Oct 4 gene sequence. mES cells have 
cycle threshold of 16 cycles whereas rMPC have no detectable Oct 4 signal. After 
running the PCR product on a 1% agarose gel no Oct 4 specific band is seen in the 
rMPCs. 1: DNA ladder, 2: mES RT+, 3: mES cells RT-, 4: rMPCs RT+, 5: rMPCs RT- 
10 20 30 40 
i mES cells RT+ 
rMPCs cells 
mES cells RT- 
119 
1 
Figure 45 rMPCs have a maintained telomere length despite prolonged culture 
DNA was extracted from rMPCs cultured for 120 population doublings (pd) and telomere length measured using the Te/o TAGGG Telomere Length Assay kit. rMPCs have a mean telomere length of over 20 Kb indicating a high telomerase activity. 
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Figure 46 Results of chromosome analysis of rMPCs by G-banding and SKY 
Karyotype of rMPCs at 100 and 170 pd using G-banding and SKY Cells were arrested 
in metaphase with colcemid fixed with methanoll acetic acid and stained with Giemsa 
dye and submitted to G- banding analysis and spectral karyotyping. The majority of 
cells have a normal karyotype of 40XY However, isolated non clonal tetraploidy, 
translocations or deletions were seen. Normal spectral karyotype of a rMPC 
Date 42 XY Tetraploicly Other abnormalities 
rMPCs 4/11/2004 18/20 0 42, XY, del (22) 
42, XY, del 20 
rMPCs 7/7/2005 45/50 2 42, XY, del(13) 
42, XY, t(l 3) 
42, XY, t(6; 13) 
120 
1 
rMPCs were also found to secrete numerous cytokines involved in inflammation and 
angiogenesis (Figure 47) including cytokines of the chemokine family Gro/KC (1900 ± 
183 pg/ 10,5 cells/ 24 hrs), MCP1 (13982 ± 1721 pg/ 1 05cells/ 24 hrs) , 
SDF-1 (160 ± 80 
pg/ 105 cells/ 24 hrs), MIP2 (56 ± 6.5 pg/ 105 cells/ 24 hrs. MIP3a (30 ± 14.8 no/ jn5 
cells/ 24 hrs) and angiogenic factors such as HGF (6.2 ± 0.7 pg/ 105 cells/ 24 hrs , 
FGFb (25.6 ± 1.4 pg/ 105 cells/ 24 hrs , VEGF (14.3 ± 4.7 pg/ 105 cells/ 24 hrs) and 
Osteopontin (16529 ± 1053 pg/ 105 cells/ 24 hrs), TGFb (754 ± 42 pg/ 105 cells/ 24 hrs) 
and TPO (13.4 ± 1.3 pg/ 105 cells/ 24 hrs). 
As rMPCs secrete SDF1 and VEGF, which are both important signals for cell 
recruitment and homing of inflammatory cells and EPCs in ischaemia, I speculated that 
the receptors for these cytokines might be expressed on rMPCs. Flow cytometry 
analysis revealed that although only a small percentage of rMPCs expressed both 
receptors on their surface, after permeabilisation all cells were found to express 
CXCR4 and 86% expressed VEGFR1 (Figure 48). 
Table 10 Results of secreted cytokine analysis of rMPCs indicates that rMPCs 
secrete multiple cytokines in vitro 
Cells were cultured for 48 hrs and the culture media supernatant collected and sent for 
analysis of secreted cytokines (Pierce Biotech, USA). Protein concentration pg1I 00,000 
cel/s/ 24 hrs. 
mcpl 13982 +/-1721 
Osteopontin 16529 +/- 1053 
SDF-1 b 160+/-80 
TGFb 754+/-42 
Gro/KC 1900+/-183 
MIP2 56+/-6.5 
MIP3a 30+/-14.8 
HGF 6.23+/-0.7 
FGFb 25.6+/-1.4 
VEGF 14.3+/-4.7 
TPO 13.4+/-1.3 
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Figure 47 rMPCs secrete multiple cytokines in vitro 
Cells were cultured for 48 hrs and the culture media supernatant collected and analysed for secreted cytokines. Protein concentration pg1I 00,000 cel/s/ 24 hrs. 
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Figure 48 rMPCs express VEGFR1 and CXCR4 assessed by flow cytometry 
rMPCs cultured for 120 pd were labelled with antibodies against CXCR4 and VEGFR I, 
or isotype control after permeabilisation incubated with a fluorescent secondary 
antibody and submitted to flow cytometric analysis. All rMPCs expressed CXCR4 and 
86% of rMPCs expressed VEGFR I- 
VEGFR1 CXCR4 
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Multi-lineage differentiation potential of rMPCs 
Within cultures of rMPCs there may be fractions of cells capable of differentiating into 
cells of different lineages. To investigate the differentiation potential of rMPCs, cells 
were cultured under tissue specific conditions in an attempt to induce differentiation. As 
a positive control for adipogenic and bone differentiation rat IVISCs were differentiated 
according to standard protocols (Figure 49). rMPCs could also be induced to 
differentiate into bone forming and fat forming cells (Figure 50). 
Figure 49 Light photornicrographs of adipogenic and bone differentiation of rat 
MSCs after Alizarin red and Oil-red 0 staining 
The presence of lipid (red granules after Oil-red 0 staining) and extra-cellular calcium 
deposition (after Alizarin red staining) is consistent with fat and bone forming cells. 67% 
of cells are able to form colony forming units indicating a good proliferative potential of 
the MSC culture. 
Oil-red 0: lipid Alizarin red: calcium Colony Forming Units 
77. 2 Wit 
r 
fA 
41A, 7c 
I 
b 1ý I 
j 
, 
/pelt " ilp *0.. Ia, 
:0 
to "0 ý. 
fro 
Figure 50 In vitro differentiation of rMPCs into bone and fat forming cells 
rMPCs were cultured for 21 days in osteogenic (top) and 
differentiation media and stained with either Alizarin Red (top) or 
Clusters of cells were stained red after Alizarin red indicating 
isolated cell stained red after Oil Red 0 staining indicating 
occasional fat forming cell. 
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In addition a fraction of rMPCs, after both 100 and 150 pd, could be differentiated into 
cells with properties of all 3 germ cell lineages. Cells were differentiated under 
conditions similar to that described for differentiation of MAPCs [45]. rMPC were plated 
in culture slides at a concentration of 1-50 X1 03 cells CM2 in basal medium without 
serum, EGF, PDGF-BB and LIF, but with lineage specific cytokines. As an example of 
mesoderm, cells were induced to endothelial like cells by culture on Matrigel coated 
plastic chamber slides with 10 ng/ml of vascular endothelial growth factor (VEGF) for 
14 days. After 14 days expression of endothelial specific genes were significantly 
increased as assessed by real time PCR. CD31 (PECAM) had a 22 ± 4.1 fold increase 
over baseline (p < 0.001), Tie-2 35 ± 10 fold increase (p<0.001) and VWF had a 4.2 ± 
1.9 fold increase (p < 0.001) (Figure 51a). In addition clusters of cells were found to 
take up Di labelled acetylated LDL and colonies of cells were also found to be positive 
for the rat endothelial cell marker RECA1 by immuno fluorescent microscopy (Figure 
52e-f). I was unable to detect expression of VWF or CD31 by IF (data not shown). 
Neuro-ectodermal differentiation was undertaken by culturing cells in human fibronectin 
coated glass chamber slides at 1X103 cells/ cm with 100 ng/ml of bFGF for 7 days 
followed by 10 ng/ml FGF8b and IlOng/ml SHH. After 14 days cells adopted a neuron 
like morphology and expression by RT PCR of neuron specific genes were significantly 
increased. MAP2 had a 12 ± 1.3 fold increase over baseline (p < 0.001), NF200 had a 
7±0.21 fold increase (p < 0.001) and nestin had a 131 ± 9.2 fold increase (p < 0.001) 
(Figure 51b). In addition a proportion of cells were found to express nestin and nerve 
specific enolase by immuno-fluorescence microscopy (Figure 52c-d). 
rMPCs were also differentiated into endoderm like cells. 50 X1 03 rMPCs/mI were 
cultured in Matrigel coated plastic chamber slides with 1Ong/mI FGF-4 and 20ng/ml of 
hepatocyte growth factor. RT PCR expression of endodermal specific genes was 
significantly increased after differentiation. Cytokeratin 19 had a 81 ± 21.5 fold increase 
over baseline (p < 0.001), albumin 21 ± 2.2 fold increase (p < 0.001) and hepatocyte 
nuclear factor 1 alpha (HNF1 a) had a 35 ± 14.9 fold increase (Figure 52a). In addition a 
fraction of cells expressed cytokeratin 18 and albumin by immuno-fluorescence 
microscopy (Figure 52a-b). I was unable to detect the expression of 
HNF1 a by IF (data 
not shown). 
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Figure 51 In vitro differentiation of rMPCs into endodermal, neuroectodermal and 
endothelial like cells assessed by RT PCR 
rMPCs cultured for 14 days in chamber slides were treated with a) FGF-4 + HGF, b) 
bHGF followed by FGF8b + SHH and c) VEGF respectively. Relative gene expression 
by quantitative real time PCR. 10-14 days after differentiation cell lysates were 
analysed by real time PCR of tissue specific genes. Values are shown as mean ± sem. 
ACTs were normalised for GAPDH expression and data presented as relative gene 
specific expression before and after exposure to tissue specific cytokines. There is 
significant induction of a) hepatocyte b) neuronal and c) endothelial specific antigens 
after lineage specific differentiation. p<O. 01 for all antigens. Open bars; cells cultured in 
normal media. Closed bars; tissue specific differentiation media. 
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Figure 52 In vitro differentiation of rMPCs into endodermal, neuroectodermal and 
endothelial like cells assessed by immuno-fluorescence 
rMPCs cultured for 14 days in chamber slides were treated with FGF-4 + HGF, bHGF 
followed by FGF8b + SHH and VEGF respectively. Immuno-fluorescent assessment of 
rMPCs differentiated in vitro into (a-b) endodermal, (c-d) neuroectodermal and (e-0 
endothelial like cells. Fourteen days after treatment with FGF-4 + HGF cells were 
stained with anti-albumin (a) and anti-cytokeratin 18 (b). 14 days after treatment with 
bFGF followed by FGF8b + SHH cells were stained with (q) anti- Nestin and (d) anti- 
NSE. 14 days after treatment with VEGF cells were stained with (e) anti-RECA I and (0 
assessed for Di labelled acetylated LDL uptake. Alexa Fluor 488 or 594 secondary 
antibodies were used. Nuclei were counterstained with DAPI. Either isolated cells or 
clusters of cells became positive for tissue specific antigens after the differentiation 
period. 
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Discussion 
Summary of results 
1. Cells with the phenotype of MAPCs could not be isolated from murine bone 
marrow by following the protocol described by Professor Verfaillie, University of 
Minnesota [45]. 
2. Cultured murine bone marrow cells were extremely susceptible to major 
cytogenetic abnormalities. 
3. Attempts to identify potential MAPCs within BM cultures by using established 
markers of stem cells (Oct 4 and SSEA1) failed to identify any positive cells. 
4. A novel cell line was isolated from rat bone marrow named 'Multi-potent 
Progenitor Cells' (rMPCs). This line could be maintained in culture long term 
with a stable phenotype and karyotype. Specific antigens could be up-regulated 
after tissue specific differentiation into cells of all 3 germ cell lineages, indicating 
the cells may have some pluri-potent potential 
5. rMPCs do not express the stem cell pluripotency gene Oct 4 and have different 
surface markers to MAPCs. 
6. rMPCs secrete multiple cytokines related to angiogenesis and inflammation. 
Attempts to isolate MAPCs 
Despite multiple attempts to isolate MAPCs from rodents it was not possible to isolate a 
cell type with a similar phenotype to MAPCs described by the University of Minnesota 
[45]. This included a6 week attachment to the Stem Cell Institute, University of 
Minnesota, and regular conference calls with the laboratory investigators. However, 
employing similar methods used to isolate MAPCs [45] a mixed culture of cells that 
may contain pluri-potent progenitors was siolated. These rMPCs were isolated by 
propagating the adherent cells from bone marrow cultured on human fibronectin coated 
flasks in media previously used for the isolation of MAPCs. However, no single cell 
cloning step was undertaken, as previously described for MAPCs [45] and more 
recently hBMSC [113] as in rodents, single cell cloning tended to select for 
cytogenetically abnormal cells. Using this non-clonal approach cells were isolated that 
could be grown indefinitely in vitro without signs of senescence or change in 
phenotype. rMIPC also had a maintained telomere length indicating high telomerase 
activity often associated with stem and progenitor cells [154]. Importantly, rMPCs 
maintained a stable karyotype when analysed by G-banding or spectral karyotyping. 
However, there was always a few cells with isolated chromosomal abnormalities 
indicating the tendency of cultured cells to acquire cytogenetic abnormalities; this is in 
keeping with embryonic stem cells [155] and MAPCs [119]. As no clonal abnormalities 
in rMPCs cultures were documented (defined as being present in more than 2 cells) the 
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lines were considered normal according to the International System for Human 
Cytogenetic Nomenclature (ISCN 2005) [151]. 
The rMPCs isolated are CD45 negative indicating they are not of a haematopoietic 
lineage. However, rMPCs do express MHC Class 1, CD44 and CD90 which are also 
expressed on IVISCs [7] (but not MAPCs [45] or hBMSC [113]). In addition rMPCs can 
be differentiated into bone and fat forming cells indicating they have some similarities 
with IVISCs. In contrast to IVISCs, which have a differentiation ability restricted to the 
mesoderm lineage, the rMPCs used for this study did appear to have the potential to 
differentiate into cells with features of all three germ cell lineages indicating a far wider 
potential for differentiation than IVISCs [7]. 1 was able to up regulate tissue specific 
antigens of ectoderm, endoderm and mesoderm measured by both RT PCIR and by 
immuno-fluorescence. Although I was able to up regulate tissue specific antigens, 
analysis of the IF images indicated that only a small percentage of cells had 
differentiated. The original descriptions of MAPCs indicated that in vitro the majority of 
cells (60-90%) could be directed to change their phenotype. Our results would indicate 
that our cultures clearly did not have the impressive differentiation ability of MAPCs and 
with the absence of Oct4 in rMPCs may indicate that rMPCs are not pluri-potent stem 
cells but perhaps a mixture of different progenitors. In addition not all antigens that 
were up-regulated by PCIR could be detected by IF. For example we were unable to 
observe VWF or CD31 by IF after endothelial differentiation or HNF1 after hepatocyte 
differentiation, despite the upregulation of the antigens detected by PCR. This would 
indicate that the cells had either not fully differentiated into a mature phenotype or that 
the there was not complete 'physiological' differentiation but only upregulation of tissue 
specific antigens which may not reflect true differentiation. This might explain why 
engrafted cells did not differentiate in vivo (Chapter 5). rMPCs also secrete multiple 
cytokines associated with inflammation and angiogenesis which may be a major 
mechanism of action of cell therapy [80]. The amount of each of the proteins secreted 
in vitro by rMPCS is of a sufficient level to be biologically active [156-163] 
Although there are no reports of other groups isolating cells with exactly the same 
phenotype as MAPCs, cells with tri-lineage potential have been isolated [113-115] and 
hBMSC [113] were shown to be beneficial in a rodent myocardial infarct model by 
inducing therapeutic revascularisation and card iomyogenesis [113]. In addition multiple 
other cells types have been shown to be beneficial in restoring perfusion to ischaemic 
organs including IVISCs [164], EPCs [8] and HSCs [165]. However, despite the 
overwhelming number of different cell types with positive effects, differentiation of cells 
into vascular structures is controversial and it appears that paracrine mechanism may 
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explain some of the impressive functional benefits seen in these experiments [81,166]. 
As the significance of in vitro differentiation is questionable physiologically, the potential 
of rMPCs to engraft, differentiate and improve function of an ischaemic tissue in a hind 
limb ischaernia model was investigated (Chapter 5). 
The reasons for failure to isolate cells with the published phenotype of MAPCs are not 
immediately clear although there are many potential explanations. First of all MAPCs, if 
they exist in vivo are an incredibly rare cell. HSCs occur with a frequency of 
approximately 1% of nucleated cells in bone marrow. In contrast, IVISCs are an even 
less frequent with an incidence of between 0.001 % and 0.01 % of nucleated cells in BM 
[167]. However, unlike HSC once IVISC have been established in culture they can be 
expanded significantly. As MAPCs are reported to be isolated from only a small 
fraction of MSCs they are an even rarer cell. Trying to culture out a cell from bone 
marrow with an estimated frequency of less than 0.0001% is likely to be technically 
challenging. In addition it is still not clear what the phenotype of MAPCs are in vivo. 
MAPCs (and other cell types such as MSCs and BMSC) have to be expanded 
significantly before their phenotype can be established. It is at present unclear what 
their surface markers, expression profile and function are in vivo, especially as there 
are at present no exclusive markers for any of these cells. it is possible that MAPCs do 
not actually exist in vivo but are created, as a result of ex vivo cellular re-programming 
during the prolonged culture and isolation process. For cells to adopt a pluripotent 
gstem cell like' phenotype significant epigenetic and transcriptional regulatory changes 
would be required. Reproducing such a 're-programming process' is likely to be difficult 
if not impossible. However, even if the cells are a culture artefact if the phenomenon 
could be repeated consistently MAPCs could still be a very useful resource. 
Other explanations for the difficulty of our laboratory and others to isolate MAPCs 
include variations in the technical details of the isolation process. Although there 
is a 
very specific MAPC media containing multiple cytokines, such as 
PDGF-BB, EGF and 
LIF it has not been possible to fully validate that this is the optimal culture environment 
because of the difficulty of getting consistent results (even at the 
University of 
Minnesota [168]). The rMPCs isolated do secrete multiple cytokines and it is likely that 
these potential paracrine signals will affect the culture process. 
The benefit of using a 
CD45 and Terl 19 depletion step to remove haematopoietic cells 
is also questionable, 
especially as no erythroid cells are present after 
3 weeks of culture and only a small 
percent of cells still express CD45. Serum source and even serum 
lot are important for 
many types of cell culture and especially important 
for stem cell cultures [169] including 
MAPCs [168]. Numerous attempts were undertaken to isolate 
MAPCs using different 
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sources and lots of foetal calf serum, including the same lot and type as the Stem Cell 
Institute at the University of Minnesota. As there is huge variation in the composition of 
serum, not only between suppliers, but also between serum lots, the development of 
cell culture processes that are entirely serum free would help to address this potential 
source of variation. 
Due to the lack of specific surface markers on MAPCs it is not possible to isolate them 
directly from bone marrow. My attempts to identify cells with the pluripotency markers 
Oct4 (using Oct4-GFP mice) or SSEA1 (by FACS) proved unhelpful. The level of Oct 4 
maybe too low to drive the Oct4-GFP expression and the frequency of SSEA1 + cells in 
whole bone marrow cultures too low. However, the approach used was relatively crude 
and could be improved by using flow cytometry rare event isolation approaches. This 
would include using a viability stain to select live cells. Excluding other unwanted cells 
with markers known to be absent on MAPCs (e. g. CD44, CD45, MHC Class 1) and by 
gating out these unwanted cells (dump channel) from further analysis. Finally by 
analysing the remaining fraction of cells for specific markers, such as Oct 4 or SSEA1, 
the positive cells of interest could potentially be identified and sorted. 
By using cells from the Stem Cell Institute, University of Minnesota, tissue specific 
antigens could occasionally be up-regulated, indicating differentiation may be have 
taken place. However, because of the cytogenetic instability of the cells it was not 
possible to repeat this experiment. In the rMPC line isolated it was possible to 
donstrate up regulation of antigens by PCR and IF, but as mentioned it is unclear what 
the true significance of this in vitro data. Immunofluorescent analysis to confirm 
differentiation has significant limitations. For optimal IF experiments many controls and 
standards are required. First specificity of antibodies and staining protocol should be 
confirmed by analysing positive and negative control cells lines from other tissues. 
Absence of the antigen should be documented in the undifferentiated cell. Isotype 
controls should always be used and settings for microscope image capture (exposure 
time etc) and subsequent image manipulation should be the same for isotype control 
and specific antigen. Care should also be taken to confirm that the antigen localisation 
and distribution is correct. For example, transcription factors are found in nuclei and 
cell surface markers are indeed on the cell surface. Positive control cell 
lines are 
extremely useful for establishing 'normal' antigen localisation. 
However, many 
immortalized cell lines do not express all markers of primary cells. Whenever possible 
these methods were adhered to during experiments presented in this thesis. 
Review of 
numerous publications purporting to show trans-differentiation, 
by immuno 
fluorescence, have questionable image interpretation [113]. 
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It is also important to acknowledge the significant limitations of in vitro differentiation 
assays. To define a cell phenotype comprehensively requires more than up-regulation 
of tissue specific antigens. Proof also requires some functional assessments. Secretion 
of albumin or urea from hepatocytes or nitric oxide from endothelial cells would indicate 
a more convincing phenotype. In addition cells should be able to adopt a physical 
phenotype such as bi-nucleated cells for hepatocytes or tube formation for 
endothelium. However, tube formation may not be a specific marker for endothelial 
cells. One of the mouse BM derived clones isolated as part of this work, when cultured 
in Matrigel, forms what appear to be vascular tubes (Figure 53). However, analysis of 
the cells from these tubes revealed the cells were negative for the endothelial markers 
CD31, CD1 05, ve-cadherin and VWF indicating they were not actually endothelial cells. 
During neuronal differentiation attempts of the rMPCs it was possible to demonstrate 
that the cells that remained attached and survived the differentiation process and 
superficially looked like neurones. Other groups have indicated that MSCs can be 
differentiated into neurons [152] but others have indicated that the in vitro phenotype 
may be a result of non-specific cytoskeletal changes associated with up-regulation of 
certain antigens rather than true differentiation [170]. A more specific confirmation 
would include the confirming the presence of axonal and dendritic staining within the 
same cell and electrophysiological recordings of neural action potentials. 
Comprehensive confirmation of a cell phenotype might therefore include not only 
detection of cellular specific RNA and protein molecules but also their correct cellular 
localisation. In addition functional in vitro assessments are desirable and the gold 
standard is documenting in vivo incorporation of cells associated with some functional 
benefit. 
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Figure 53 Light photomicrograph of vascular 'like' tubes from mouse BM derived 
cells (DDD) cultured for 5 days in Matrigel with MAPC endothelial differentiation 
media 
BM derived cells (line DDD) isolated from K/T murine BM under MAPC conditions were cultured in Matrigel in MAPC basal media with VEGF 10 nglml for 5 days. The DDD 
cells formed what appeared to be 'vascular' tubes with apparent lumens. The cells were then harvested with trypsin/ edta and submitted to IF analysis with antibodies to CD105, VE-cadherin, VWF and CD31 which were all negative, implying the cells were not actually of an endothelial phenotype. 
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Cytogenetic instability of cultured cells 
During this work cytogenetic instability has been confirmed as a major problem for 
cultured cells. It has been established that embryonic stem cells can acquire significant 
abnormalities when cultured for prolonged periods of time [149]. In addition mouse ES 
are particularly unstable [119]. It was initially reported that MAPCs were cytogenetically 
stable [45] although more recent reports indicate that mouse MAPCs also have 
unstable karyotypes [119]. From data presented no pattern in the abnormalities of 
chromosomes or sites of translocations was recognised. It is liekely that there is an 
acquired abnormality of DNA replication during the prolonged culture process. Any 
cytogenetic abnormality which gives cells a proliferative advantage over normal cells 
will rapidly dominate the culture as has been seen with the MAPC line YJ LacZ from 
the University of Minnesota. The mechanism for the cytogenetic changes is not known 
but is likely to be a result of the rapid cycling of proliferating cells in culture without the 
normal controls that occur in vivo. Standard 02 concentrations of 21 % may create 
cytogenetic changes due to oxidative stress. However, isolating and culturing cells at a 
more physiologica102 concentration of 5% failed to prevent cells acquiring cytogenetic 
abnormalities. The use of trypsin to dissociate ES cells has also been associated with 
cytogenetic abnormalities in human ES cells [150]. The authors assume that 
dissociating ES cells into single cell suspensions is a significant stress which selects 
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for abnormal clones. MAPCs are cultured at very low cell density and this alone may be 
a significant selective pressure on cells, especially under low serum culture conditions 
and when a single cell cloning step is used. Mouse cells are generally more unstable 
than rat and human cells and as a result of this the in vivo experiments in this thesis 
focused on using the rat lines. One line (rMPCs) could be maintained in culture for a 
sufficient period of time to establish its phenotype in vitro and study its properties in an 
animal model (Chapter 5). There are clearly significant clinical implications of 
cytogenetic drift of cells that may be used for human cell therapy. This not only may 
have a bearing on efficacy but includes the risk of potential malignant transformation of 
cytogenetically abnormal cells. 
Conclusion 
Despite numerous attempts it was not possible to isolate MAPCs as described by, and 
in collaboration with, the Stem Cell Institute of the University of Minnesota. Although 
this could be explained by technically difficult aspects of the isolation process, the 
failure of us and numerous other centres [168] to isolate MAPCs raises the question of 
whether pluri-potent stem cells exist within adult bone marrow and are not an isolated 
culture artefact. The observation and reporting of the significant cytogenetic instability 
of cultured bone marrow derived cells has significant bearing on stem cell research and 
their potential clinical applications. However, it was possible to isolate a cell line from 
rat bone marrow termed rMPCs. rMPCs can be maintained in culture for a prolonged 
period of time with a stable phenotype and karyotype. rMPCs can express tissue 
specific antigens from all 3 germ lineages after differentiation in vitro. As rMPCs do not 
express the stem cell transcription factor Oct4 and are not isolated from a single cell 
they are not considered true stem cells, but one could tentatively suggest that they may 
represent a mixed culture of pluripotent progenitors that would be suitable for study in 
an in vivo model of cardiovascular disease. 
At present any potential clinical significance of using BM derived progenitor cells is 
unclear. The technique of cell isolation is at present not reproducible. Fundamental 
safety issues also remain to be addressed regarding cytogenetic stability, the use of 
serum in culture processes and concerns over potential aberrant/ pathological 
engraftment and differentiation. 
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Chapter 4 Establishing a hind limb ischaernia model in rats 
Introduction 
The rat hind limb ischaemia model has been widely used to study the metabolic 
consequences of ischaernia and angiogenesis [171,172] and is relatively easy to use 
and assess. Specifically the rat model has been used to investigate the angiogenic 
properties of putative endothelial precursor cells [173], blood mononuclear cells [174] 
and mesenchymal stromal cells [175]. To investigate the effects of local delivery of 
rMPC LacZ labelled cells on perfusion and function, a rat ischaemic hind limb animal 
model was established. A hind limb model was selected, rather than a myocardial 
infarct model, as it was intended to use the data to support a Phase I study of 
autologous transplantation of MAPCs in patients with peripheral vascular disease. 
Studying the properties of a potentially novel stem cell type was considered safer in a 
peripheral rather than a cardiac setting. A primary concern about the risks of stem cell 
transplantation in a cardiac setting (teratomas, aberrant differentiation, ectopic 
calcification and arrhythmias) made a peripheral vascular study potentially safer to 
conduct. In addition an MRI based system had been established for the assessment of 
perfusion in patients with peripheral vascular disease [176]. 
Cells used to derive the rMPC line were derived from the same colony of Fisher 344 
rats (Harlan) used for the hind limb model. There is no published model of hind limb 
ischaemia in the Fisher 344 rat. Because of the significant differences in response to 
ischaernic surgery between different strains of rodents [177] the surgical approach had 
to be developed for the Fisher 344 rat. The Fisher 344 rat from Harlan is a widely used 
inbred line, allowing us to conduct syngeneic transplant experiments to avoid the 
potential confounding effects of immune rejection of transplanted cells. Male rats were 
used for the preparation of cells so that the Y chromosome could be used as an 
additional marker to track the cells in vivo if required. 
Aims 
To establish a hind limb ischaemia model in Fisher 344 rats. 
To establish methods for evaluating perfusion in rat hind 
limbs 
To evaluate methods for assessing functional recovery after 
ischaernia. 
To establish histological methods for analysing ischaemic muscles and 
the fate of 
injected cells. 
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Methods 
Animals 
Isogenic inbred Fisher 344 rats were obtained from Harlan laboratories (Indianapolis, 
Indiana). Male rats were used to produce cell lines and acted as cell donors. Twelve to 
fourteen week old female rats were used for the femoral artery ischaemia and acted as 
recipients for cell transplantation to stimulate autologous transpla ntation. All 
experiments were conducted according to the guidelines of the Animal Care and Use 
Committee of the National Heart, Lung, and Blood Institute. 
Rat hind limb ischaemia surgery 
Rats were anaesthetised with inhaled Isoflurane (1-3%) and an incision made along the 
right femoral artery from the inguinal ligament to the knee. The femoral artery was 
ligated and transected immediately beneath the inguinal ligament and dissected and 
excised down to the knee (Figure 54). All branches in the leg were tied off down to the 
knee. Care was taken not to damage the femoral vein and femoral nerve. There are 3- 
4 branches arising from the external iliac artery immediately above the inguinal 
ligament, care had to be taken to avoid these as if they are occluded the leg is likely to 
become nonviable. For sham surgery the femoral artery was dissected and mobilised 
only. Animals received injections of sub-cutaneous fluids and analgesia for the early 
post operative period and were fed a normal diet and housed separately for the 
duration of the study. 
Figure 54 Arterial supply of the hand limb of the rat 
The femoral artery was excised from the inguinal ligament to the knee (marked) 
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Randomisation and blinding 
Rats were submitted to ischaemia surgery and then acted as recipients for 
intramuscular injections of cells. rMPC LacZ labelled cells from male Fisher rats were 
used as donor cells in all experiments and compared to a PBS control. Rats were 
randomised to cell treatment or PBS control. Assessment of perfusion and functional 
data were blinded until after all data had been collected and analysed. 
Injection of cells into ischaernic limbs 
Cultured rMPC cells were collected with Trypsin/EDTA, washed twice in PBS and 
counted with a haernocytometer. Prior to injection viability > 95% was confirmed by 
Trypan Blue (Gibco, USA) extrusion. Cells were re-suspended for injection in 200 ul of 
PBS per animal. Due to the operated leg having almost no perfusion in the immediate 
post-operative period, cells were injected 24 hours after surgery. Cells were allowed to 
equilibrate at room temperature for 15 minutes prior to injection. Cells or PBS control 
were injected in a total volume of 200 ul into 8 separate points along the ischaemic 
muscles. 
X-Gal staining of cells expressing LacZ 
To confirm that the rMPCs expressed LacZ, cells were analysed for B-galactosidase 
activity. One hundred thousand rMPCs cells were mounted onto glass slides using a 
Shandon Cytospin 4 (Shandon, USA). Cells were then fixed with para-formaldehyde 
2% and glutealdehyde 0.5% and incubated with X-Gal reagent at 37'C for 30 minutes. 
As negative controls an un-labelled BM culture and rat aortic endothelial cells were 
stained with X-Gal reagent. X Gal reagent contained X-Gal 1 mg/ml, K-Ferrlcyanide 5 
mM, K- FerrOcyanide 5 mM, MgC122 mM, NP40 0.02%, SIDS 0.01%, PBS. 
Microscopy 
Slides of cultured cells and tissue sections were viewed using a fluorescence 
microscope (Nikon Eclipse, E800, Nikon) and light microscope (Nikon Eclipse, E600) 
and images captured with QCapture Pro software (Qimaging, Ca). 
Assessment of muscle perfusion 
Introduction 
In order to investigate the effects of cell therapy in ischaemic tissues, measurement of 
blood perfusion is required. Not only is it necessary to document that 
'ischaemic 
models' have an actual decrease in perfusion, but also to monitor response 
to therapy. 
There are multiple methods available to measure perfusion in rodents with 
different 
advantages and limitations. To assess perfusion in this work 
3 approaches have been 
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slected based on tissue Doppler, fluorescent microspheres and MRI. The use of 
microspheres (either radioactive or fluorescent) is generally considered to be the gold 
standard of perfusion measurements in cardiovascular research [178]. However, they 
are technically difficult experiments to undertake and analysis of specimens and results 
is a protracted process. In addition serial analysis is not possible in rodents as cardiac 
injection of the microspheres is required. Laser Doppler imaging (LDI) is now widely 
used in this setting [179]. LDI is relatively easy to undertake and analyse and serial 
imaging is straightforward. However, LDI is based on measuring perfusion in skin, not 
muscle, and analysis of muscle perfusion is not possible. Magnetic resonance imaging 
(MRI) is now being established as a method for assessing perfusion both in skeletal 
[176] and cardiac muscle [180] by time-signal analysis after injection of a contrast 
agent. MRI also provides detailed morphological assessment of the structure allowing 
regional analysis of different muscle groups. MRI, being non invasive, can also be 
repeated. Delayed enhancement after Gd-DPTA injection is associated with non-viable 
muscle, allowing infarcted tissue to be identified [181]. In addition, as this was a new 
model being established, the 3 modalities of LDI, microspheres and MRI were all 
assessed and compared. 
Laser Doppler blood flow imaging 
Laser Doppler imaging measures blood flow in the blood vessels of the 
microvasculature. The tissue thickness sampled is typically 1 mm, and the velocity 
spectrum measurement of blood is typically 0.01 to 10 mm/s. In rodents this is 
sufficient to penetrate through the skin of the hind limb. The technique has been widely 
used in both mouse and rat hind limb ischaemia models and has been validated by 
comparison with other measures of perfusion [1791. The technique depends on the 
Doppler principle. Light from an infra-red laser diode incident on tissue is scattered by 
moving red blood cells and as a consequence its frequency is increased. The 
frequency of the scattered light, together with laser light scattered from static tissue, is 
measured by a photo-detector and the resulting photocurrent processed to provide a 
blood flow measurement. Flux units are used to describe blood flow measured by the 
laser Doppler. A 'flux' unit is a quantity proportional to the product of the average 
speed of the blood cells and their number concentration (often referred to as blood 
volume). This is expressed in arbitrary 'perfusion flux units'. 
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Laser Doppler imaging method 
Laser Doppler imaging of hind limbs was undertaken with a MoorLDI TM -Mark 2 laser 
Doppler blood perfusion imager (Moor Instruments Ltd, UK). Laser Doppler blood-flow 
imaging was used to assess the extent of blood-flow restoration in rats after surgery. 
Rats were anaesthetised with Isoflurane (1-3%), their fur shaved from both hind limbs 
and placed ventral side up onto a heated blanket. Prolonged anaesthesia was avoided 
as this significantly affected the rats' core temperature and LDI flux data results. The 
hind limbs were gently immobilised with transparent tape. A rectal thermometer was 
used to continuously measure temperature in all animals. Because of the significant 
variation in LDI scan results with core temperature, all rats were heated with an 
external heating lamp to 38'C and placed on a heated blanket. This insured maximum 
vasodilatation and improved the reproducibility of flux data. Measurements were 
acquired using a pixel resolution of 256 x 256 and a scan rate of 4 ms/pixel. Data are 
measured in arbitrary units of 'flux' (blood x area-' x time-'). Rats were scanned 
immediately prior to and after surgery and then on days 1,3,7,14,21 and 28 after 
surgery. For analysis, equal areas (± 5%) of the control and ischaemic limbs from the 
same anatomical region of the limbs were selected using the Moor LDI software and 
compared. Mean flux in the selected areas was computed using the Moor imaging 
software. Data are presented as raw flux data and percentage of mean blood flux in the 
operated ischaemic limb relative to flux in the un-operated control limb as laser Doppler 
perfusion index (LDPI). In colour 2D images of flux, data are presented using standard 
scaling with a fixed scale; red represents high perfusion (1000 flux units) and dark blue 
low perfusion (0 flux units). 
Perfusion analysis using fluorescent microsphere injection 
Fluorescent microspheres have now been widely used to measure regional blood and 
are more convenient than radioactive microspheres. The principle is based on the 
assumption that small particles injected into the heart will be evenly distributed to all 
tissues by the circulation. As the particles are too large (15 u) to pass through 
capillaries, they lodge within tissues. The number of particles within each tissue 
provides a measure of organ perfusion. Once the fluorescent particles have been 
recovered from the tissue they can be quantified, after being dissolved in a solvent and 
by measuring fluorescence emission intensity after excitation with a specific 
wavelength of light in a spectrophotometer. Green-Yellow microspheres (Molecular 
Probes, USA) were used for the study as they have the most intense emission and 
have little overlap with auto fluorescence from tissue samples 
washington. edu). Kidneys are also harvested and analysed as a 
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control to ensure that there had been adequate intra-cardiac mixing of the 
microspheres with blood and successful extraction and analysis of samples. 
Fluorescent microspheres 
The regional blood flow to skeletal muscle in both hind limbs of rats was measured 4 
weeks after surgery using yellow/green fluorescent microspheres (Molecular Probes, 
USA). Rats were anaesthetized with Isoflurane, intubated and ventilated. The right 
carotid artery was cannulated with size 10 PE tubing connected to a 27 gauge needle 
and flushed with 200 ul of heparinised saline. The catheter was connected to a 
withdrawal pump for collecting the reference blood sample. The thoracic cavity was 
opened and the heart exposed. An external heating lamp was used to warm the animal 
to 380C to ensure maximum vasodilatation prior to injection. Immediately prior to 
injection the microspheres were vortexed and sonicated to ensure adequate re- 
suspension. 1 million microspheres were then injected into the left ventricular cavity 
over 60 seconds (this amount was required to ensure a minimum of 300 microspheres 
were delivered to each tissue). The reference blood sample was withdrawn 
simultaneously with an automated pump. 5 minutes after injection the animal was 
euthanised and the adductors, gastrocnemius muscles and both kidneys were 
harvested. The kidneys confirmed adequate mixing of the microspheres within the 
circulation. 
Fluorescent microsphere tissue processing 
Microspheres were retrieved from samples using ethanolic alkaline digestion, which 
has been shown to be a reliable technique [178]. 
Figure 55 Schematic of processing of tissues after microsphere injection 
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Excised tissues were weighed and auto-digested at room temperature for 7 days prior 
to processing (Figure 55). Samples were incubated in ethanolic KOH for 72 hours at 50 
OC. They were then centrifuged for 20 minutes at 2000 G and re-suspended in 1% 
Triton X-100 followed by washing with the distilled water phosphate buffer. The cells 
were then centrifuged again and re-suspended in 2-ethoxyethyl acetate to dissolve the 
microspheres and liberate the fluorescent dye. Samples in triplicate were then placed 
into clear bottom 96 well plates and fluorescence read in a fluorescent plate reader 
(Spectra Max Gemini EM Plate Reader, Molecular Devices, USA). Samples were 
excited at a wavelength of 460 nm and the emission data collected at 505 nm. This 
ensured optimal resolution by allowing emitted specific light to be separated from the 
scattered excitation light. Each time samples were analysed, a standard curve was also 
constructed to calculate the relationship between fluorescence and microsphere 
particle number in each sample. The regional blood flow in the ischaemic limb was 
represented as the percentage of fluorescence intensity in the ischaernic limb 
standardised to tissue weight compared with that in the contra-lateral non-ischaemic 
limb (relative perfusion) [182]. As a result of malfunction of the blood withdrawal pump, 
I was unable to directly quantify the microsphere perfusion data because of inaccurate 
rates of reference blood collection. 
Assessment of ischaemic muscles using dynamic contrast-enhanced magnetic 
resonance imaging 
In order to further evaluate the rat hind limb ischaemia model and the effects of cell 
transplantation, a MRI based approach was established with the aim of measuring 
skeletal muscle perfusion. The results of perfusion measurements using laser Doppler 
imaging and fluorescent microspheres had provided conflicting results as to the effect 
of cell transplantation on perfusion in the ischaemic hind limbs of our study. However, 
both the LDI and microsphere methods had provided concordant results in 
documenting a sustained level of ischaemia following excision of the femoral artery. 
Both LDI and microspheres were unable to describe regional differences in muscle 
perfusion. Using an additional non-invasive quantitative method to monitor the 
longitudinal time-dependent changes in perfusion and perfusion distribution in different 
muscle groups is highly desirable. A number of magnetic resonance imaging (MRI) 
techniques have been developed that allow the non-invasive measurement of tissue 
perfusion at a high spatial resolution [1831. These techniques are based on the study of 
wash-in or wash-out tracer kinetics of either endogenous water in blood or exogenous 
paramagnetic compounds, such as Gd-DTPA [184]. Following an intravenous injection 
of a contrast agent, the initial accumulation and distribution of the agent in tissues can 
be followed with T'l-weighted fast MR[ sequences. During the first pass, the contrast 
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agent circulates through blood vessels into capillaries, after which it diffuses into the 
interstitial tissue space in a unidirectional fashion. This initial accumulation of the 
contrast agent into the tissue is largely dependent on tissue perfusion. It has been 
demonstrated in both experimental animal models and human studies that dynamic 
contrast-enhanced MRI can be used to evaluate perfusion and to detect perfusion 
abnormalities in myocardium. This technique has also been applied in studying 
perfusion in skeletal muscle in rodents [182] and in humans [176] and validated by 
comparison with microspheres. In addition to estimates of perfusion, MRI can provide 
detailed morphological images and allow specific regions to be explored, allowing for 
analysis of individual muscle groups or tissues. In addition, delayed enhancement of 
cardiac muscle is associated with non-viable infarcted regions [185]. 
The aim of the present study was to establish an MRI-based method to monitor muscle 
perfusion in the rat hind limb ischaemia model and relate this to the LDI and 
microspheres results if possible. In this study Tl-weighted contrast-enhanced MRI was 
used to measure time-dependent changes in perfusion following unilateral femoral 
artery ligation to evaluate the rat hind-limb muscles at rest. 
MRI methods 
MR experiments were performed on a 7.0 T magnetic resonance imaging system with 
Paravision software (Bruker, Billerica, MA, USA). Rats (control n=3, ischaemic + 
rMPCs n=6, ischaernia + PBS n=6,3 weeks after excision of femoral artery and 
transplantation of rMPCs) were anaesthetised with Isoflurane and positioned supine 
with both hind limbs centred in a 58 mm birdcage coil. Body temperature was 
maintained at 37'C with a heating blanket prior to scan acquisition. A tail vein catheter 
was inserted for delivery of contrast agent. Animal core temperature and respiration 
were continuously monitored. A water filled tube was placed between both limbs to act 
as a control for signal intensity. 
An axial cross section of both hind limbs above the knee was imaged using a Tj- 
weighted spoiled fast gradient echo pulse sequence (TR = 50 ms, TE = 2.2 ms, nex = 
1, FOV 3.4 x 3.4 cm, matrix 128 x 64, thickness 2.0 mm). Sequential images were 
acquired with a time resolution of 3 seconds/image. After 5 baseline acquisitions, a 
bolus of Gd-DTPA (Magnevist, Berlex Labs, Wayne, NJ, USA) 0.3 mmol/kg was 
administered through the tail vein catheter. Eighty images were collected in total over 4 
minutes. The nominal in-plane resolution was 265 x 531 MM2 . 
The data were zero filled 
to 128 x 128 before image processing. Two higher resolution gradient echo scans (TR 
= 300ms, TE = 3.8 ms, FOV 3.4 x 3.4 cm, matrix 256 x 256, thickness 1.0 mm, 132 
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mm 2 in-plane resolution) were performed pre- and post-contrast, before and after the 
time course acquisition (Figure 69). 
MRI image analysis 
Time signal intensity curves were analysed by either manually selecting regions of 
interest (ROls) or for more detailed analysis using custom software written in 
Interactive Data Language (Research Systems Inc., Colorado, USA). Based on the 
initial assumption that MR signal enhancement is linearly proportional to Gd-DTPA 
concentration [186], the maximum upslope of the signal enhancement represents the 
maximum Gd-DTPA uptake rate into the tissue. By comparing the maximum upslope of 
the normally perfused limb with the ischaemic limb, the relative perfusion index (PI) 
was calculated for each animal. Initially regions of interest (ROls) were manually 
outlined to include total muscle in each cross section, excluding bone, bone marrow, 
and skin. Attempts to measure skin perfusion (to correlate with the LDPI), by selecting 
a ROI only including skin, was unsuccessful due to low image resolution. For data 
analysis, the signal intensity S(t), of the 2 limb images was corrected for variation in the 
receiving surface coil sensitivity profile by % signal enhancement S% according to: 
solo(t) 
[S(t) - Sol x 100% 
so 
where S(t) is the signal intensity at time t and So is the baseline signal intensity 
determined as the average of the signal of the 5 pre-injection images [186]. 
Alternatively the signal intensity between the 2 limb images was corrected for variation 
in the receiving surface coil sensitivity profile by baseline subtraction of the average of 
the 5 pre-injection images according to: 
S "': S(t) - SO bM "" 
The maximum upslope of the time-course enhancement curve (image numbers 6 to 15) 
was then fitted to a linear regression curve (Excel software, Microsoft, USA). The 
gradient of the regression curve was used to calculate the perfusion index for both 
baseline correction (Sb) and percent signal enhancement (S%). The relative PI was 
calculated as the ratio of the gradient for the ligated limb to the gradient for the contra- 
lateral non-ischaemic limb to quantify relative changes in perfusion. 
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To facilitate more detailed analysis, computer automated leg segmentation was used to 
select ROls. A signal intensity histogram with adaptive stress holding was constructed 
to use a best fit model to remove image background. The 2 largest ROls selected by 
this method were the 2 limb cross sections. The smaller ROls of the tail or artefacts 
were excluded. By this method greater than 90% of the leg cross section was selected 
for analysis although the computer automated leg segmentation did not always exclude 
skin and bone. For signal intensity rectification the image size was increased to 256 x 
256 pixels and then a7x7 median smoothing filter applied before surface coil intensity 
correction (SCIC) using baseline histogram subtraction of the pre-contrast images. This 
more accurately corrected for in homogeneity in the magnet signal intensity. Data were 
presented as time-signal intensity histograms, which allowed identification of fibres/ 
pixels with varying enhancement after Gd-DTPA bolus. To compare the ischaemic right 
leg with the normal left leg a histogram correlation coefficient was calculated between 
legs for each image in the series. The correlation coefficient between the 2 legs of each 
animal was plotted against image number. 
To further delineate areas with different enhancement after Gd-DPTA parametric maps 
were constructed based on either contrast enhancement or integral of the time-signal 
intensity [180]. The contrast enhancement was calculated as follows: 
CE = 
S'peak 
- 
Sibaseline 
baseline 
where Slpeak is the peak signal intensity of a region of interest and Slbaseline is the 
baseline signal intensity of the same region. The CE is a measure of peak contrast 
enhancement after baseline signal adjustment. This measurement reflects the 
maximum enhancement in the muscle and ignores the temporal characteristics such as 
the rate of contrast enhancement. 
Upslope integral ratio maps of the Sl curve were calculated by integrating the area 
under the curve of each time-signal intensity rectified curve (after SCIC and baseline 
intensity correction) for each pixel [187]. This method allows for the adjustment of 
different timings and up-slopes of enhancement assuming that there is a constant input 
function implying a constant Gd-DPTA concentration in the blood. 
K-means clustering was used to attempt to quantify fibres/pixels into 3 groups (classes) 
arbitrarily defined as normal, hypo- or hyper-enhancement. Time-signal intensity 
histograms were then colour coded accordingly or data presented as image sequences 
of only the 3 selected clusters. 
143 
Quantitative methods of perfusion measurement using MRI rely on the accurate 
depiction of the arterial input function (i. e. the concentration of Gd-DPTA in the femoral 
artery in our model). As it was not possible to measure the arterial input function, 
because the femoral arteries were too small to accurately image, absolute perfusion 
was not quantified. 
Measuring exercise ability as a physiological parameter of functional recovery of 
ischaemia 
Previous angiogenesis studies using hind limb ischaemia models in rodents often 
demonstrated significant improvements in perfusion, but when this research was 
translated to the clinic there was a disappointing lack of functional improvement [188]. 
In the model developed it was intended that in addition to a decrease in perfusion a 
significant functional defect should also be induced. In addition, any improvement in 
perfusion as a result of experimental cell therapy may be associated with an 
improvement in function. Simultaneously 2 measures of physical performance in rats 
were developed, the exercise treadmill and countercurrent swimming tank. 
Rat exercise treadmill 
Rats can be trained to run on motorised treadmills and their maximum exerc se ime 
has been found to be a reliable and reproducible measure of function [189]. 
Rat exercise treadmill method 
Training rats to run on treadmill 
Rats were trained to run on 5 consecutive days (Treadmill 3/6, Columbus Instruments, 
Ohio, USA). Rats were always exercised in the morning between 8 am and 11 am to 
avoid circadian fluctuations in performance. The treadmill was set at an angle of 150 
and an initial speed of 10 m/min. A small electrical stimulus (31-1z, 1 mA) was used 
to 
encourage the rats to stay on the treadmill. Every minute the speed was increased 
by 1 
m/min for 10 minutes. This amount of exposure to treadmill running 
is below that 
required to produce a change in aerobic capacity [189]. If rats were unable 
to use the 
treadmill they were withdrawn from the study (this occurred in 5% of animals). 
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Figure 56 Exercise protocol for measuring peak aerobic running performance in 
rats 
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The treadmill velocity was started at 
10 m/min at 15' incline. Every 2 
minutes the velocity was increased 1 
m/min (Figure 56). Exhaustion was 
operationally defined as the third time 
that the rat was willing to slide onto the 
electric grid and sustain 2s of shock 
[190]. At the moment of exhaustion the 
power to the grid was stopped and the rat removed from the treadmill. Measurements 
were repeated daily for 3 consecutive days for both pre-op and post operative time 
points. Data are presented as the mean distance run over 3 days. 
Adjustable counter current swimming tank 
Although the treadmill has been used to evaluate performance in rats a swimming 
model was also developed. Rats are naturally excellent swimmers and predominantly 
use their hind limbs to swim [191]. A swimming model may be a more specific 
assessment of hind limb function than running. Because rats are natural swimmers, 
previous models have used tail weights to sufficiently stress the animals, however rats 
could still swim for up to 2 hours [192]. Use of an adjustable counter-current swimming 
pool has been found to be useful for the evaluation of endurance capacity of mice [193] 
and able to detect improvements in hind limb function after cytokine therapy of 
ischaernic hind limbs [194]. A counter current swimming model for rats was therefore 
designed. 
Design of adjustable counter current swimming tank 
A Plexiglass pool was designed and constructed (Figure 57) based on a similar model 
designed for mice [193]. The tank was filled to a depth of 40 cm with water. The sides 
of the tank were clear and smooth to prevent the animal from supporting itself while 
swimming. The current in the pool was generated by circulating water with a pump 
(Pondmaster 18, USA) capable of delivering 40 litres/minute. The intake of the pump 
was behind an angled Plexiglas panel which ensured a uniform current across the 
surface of the tank. Circular 3 mm holes were placed at 2 cm intervals along a plastic 
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pipe at the other end of the tank which was connected to the outlet of the pump. This 
provided multiple jets of water across the surface of the tank. The strength of current 
could be controlled by a valve and the flow within the system measured with a digital 
flow meter (Digital In Line Flow meter, Pulse Instruments, USA). The tank could be 
divided into 2 lanes. Surface flow was measured by timing a moving float to ensure that 
the velocity was evenly distributed. The temperature of the tank was maintained at 34.0 
OC by a water heater and thermostat. 
Measuring maximum swimming time 
Rats are natural swimmers and rapidly adjust to swimming against a current. They do 
not require formal training to swim. The rats were placed into the tank with water 
flowing at 20 litres/minute. After 10 seconds the flow was rapidly increased to 40 
litres/min. The rats were exercised until fatigue. The definition of fatigue was defined as 
when the rat was no longer able to swim into the current or maintain itself above water. 
When rats were repeatedly being submerged or they spent over 5 seconds under the 
water they were removed from the tank. 
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Figure 57 Diagram of adjustable counter current swimming tank 
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Histological analysis of hind limb muscles 
Histological analysis and X Gal staining 
Either 3,5 or 28 days after surgery rats were euthanised and the adductor muscles 
harvested. For histological analysis, muscles were fixed in 10% formalin embedded in 
paraffin and 5 um sections cut and counterstained with H&E. For assessment of 
engraftment of transplanted rMPCs, samples were fixed with 2% para-formaldehyde 
and incubated for 12 hours in X Gal reagent at 37'C. Samples were then re-fixed in 
10% formalin, paraffin embedded and 5 um sections cut. Sections were counterstained 
with nuclear fast red. Transplanted cells were labelled blue by the X gal reagent. To 
count the number of engrafted rMPCs 10 sections from each animal were analysed for 
LacZ +ve cells. The mean number of neurovascular bundles (NVB) with engrafted cells 
was calculated for each rat along with the mean number of cells in each positively 
engrafted NVB. 
Smooth muscle actin and VWF staining 
To investigate if rMPCs had differentiated in vivo into smooth muscle cells or 
endothelium, sections were counterstained with antibody to either smooth muscle actin 
(SMACT) (Sigma, Clone A-2457,1: 4000) or Von Willebrand Factor (VWF) (Dako, 
A0082,1: 200) or isotype controls. Sections were blocked with 10% goat serum with 
0.1% triton and then incubated for 45 minutes at room temperature with primary 
antibody. For VWF staining, antigen retrieval with tris-EDTA buffer, 900C for 30 min, 
was required prior to staining. Sections were then washed and incubated with goat anti 
rabbit or mouse Alexa Fluor 594,1: 1000 (Molecular Probes) for 30 minutes. After 
secondary incubation, cells were rinsed and mounted with DAR hard set mounting 
media (Vectashield, USA) and covered with a cover slip. 
Capillary density 
Muscle samples were snap frozen in OCT (Tissue Tek, Ca, USA) and 
5 um sections 
cut. Sections were fixed with 2% paraformaldehyde and stained with mouse 
monoclonal antibody to CD31 (BID, USA) followed by goat anti mouse 
Alex Fluoro 488 
(Molecular Probes, USA) to label endothelial cells. The number of CD31+ cells were 
counted in each field at a magnification of x200 
from 4 sections of each muscle (n=6 
each group). Results were expressed as number of 
CD31 + cells per muscle fibre. 
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Cytokine analysis 
5 and 14 days after transplantation of either 10 X1 06 rMPCs or PBS control into 
ischaernic limbs, adductor muscles were removed. The day 5 time point was selected, 
rather than an earlier time, to ensure that any increase in detected cytokines was a 
result of secretion from viable cells, rather than just released cytokines at the time of 
injection. The day 14 time point was selected to see if there was a sustained release of 
cytokines over time, but before the injury had completely recovered which may have 
occurred by day 28. This was based on histological observations of the ischaemic 
model over time. Samples were homogenised in ice cold lysis buffer (PBS + Complete 
Protease Inhibitor, Roche) for 60 seconds with a Polytron (Brinkman Polytron, 
Switzerland). Following homogenisation, the tissue preparation was clarified by 
centrifugation for 15 minutes at 1500g to remove excess connective tissue and large 
aggregate debris and frozen at -80 OC. Supernatant was then sent for multiplex 
cytokine analysis (Pierce Biotech, USA). To calculate the mean in vivo cytokine release 
rMPCs, protein amounts were calculated per gram of muscle and expressed as relative 
fold increase using the formula amount (rM'c')/ amount (PBS control). 
Statistical analysis 
All results are expressed as means ± sem. Statistical significance was evaluated with 
an unpaired Student t-test (Excel Software, Microsoft, USA) for comparison between 2 
groups or with ANOVA for comparison between multiple groups (Prism 4 software, 
Graphpad Software, USA). All groups were n=6 unless otherwise stated. A probability 
value of p<0.05 was considered significant. 
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Results 
To investigate the effects of local delivery of potential stem/progenitor cells an 
ischaemic hind limb model in female Fisher 344 rats was developed. The aim was to 
establish a model whereby rats were submitted to ischaemia surgery and then could 
act as recipients for intramuscular injections of cells. 
Developing the surgical approach for rat hind limb ischaernia model 
Rodents have a remarkable ability to recover after induction of ischaemia. In many 
models of experimental hind limb ischaemia there is rapid normalisation of perfusion, 
most likely as a result of the opening up of pre-existing collaterals [179]. It was 
intended to induce a degree of ischaemia that would be sustained over a 3-4 week 
period. This would allow for the investigatation of the effects of potentially pro- 
angiogenic cell interventions. Initial attempts to induce ischaemia by ligating the 
femoral artery were not successful. However, within 72 hours there was almost full 
recovery of perfusion as measured by LDPI (data not shown). In contrast, ligation and 
excision of the common iliac artery or external iliac or major internal iliac arteries, 
resulted in profound ischaemia which resulted in auto-amputation in 50% of animals. 
Modifications involving the distal branches of the external iliac artery at the level of the 
inguinal ligament also resulted in severe ischaemia and gangrene in significant 
numbers of animals. Gangrenous limbs were rapidly auto-amputated. When this 
occurred the animals were euthanised (Figure 59). 
Figure 59 Photograph of a Fisher 344 rat after ligation of the common iliac artery 
and excision of the femoral artery with resulting gangrene and auto-amputation 
A) The black dusky appearance of the limb is consistent with signs of gangrene B) 72 
hours later non-viable tissue has been removed by the rat which was then euthanised. 
A) B) 
The final model established involved removing the femoral artery from as close to the 
inguinal ligament as possible, down to the knee. All branches were tied off or 
cauterised and care was taken to ensure the femoral vein and nerve were not 
damaged. This surgical approach was selected as it induced a significant sustained 
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degree of ischaernia for up to 28 days (62% ± 10 of normal by microspheres, 48% + 
1.3 by LDI p<0.001) without causing gangrene or limb loss. However, some animals 
developed small areas of necrosis on the plantar surface of their feet. Numerous 
attempts at varying the surgical procedure to increase the degree of ischaernia resulted 
in a non viable limb and the animals had to be euthanised. It was noted that if the 
relative perfusion of the operated limb had not recovered to more than 10% of the un- 
operated control limb within 24 hours of surgery, as measured by laser Doppler 
imaging, then the limb would not remain viable. Sham surgery had no effect on 
perfusion measured by LDPI or on treadmill running 2 weeks after surgery (Figure 59). 
Figure 60 Graph of the effect of sham surgery on LDPI 
Sham surgery does not affect LDPI 
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Laser Doppler blood flow imaging 
Laser Doppler imaging provides a colour 2D picture of the area scanned (Figure 61). 
Red areas correspond to high perfusion and blue areas low perfusion. Using the Moor 
LDI data analysis software (MoorLDI, UK) specific pixels could be selected for 
quantitative analysis of the mean 'flux'. Ischaemic and control limb were compared with 
each other and presented as a ratio, LDPI (Figure 62). 
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Figure 61 2D digital laser Doppler image of a Fisher 344 rat submitted to right 
femoral artery excision: 2D image of flux data over time 
Red represents high perfusion (1000 flux units) and blue low perfusion (0 flux units). After femoral artery surgery (post-op image) the previously well perfused (red) right leg has almost no perfusion (now blue). There is gradual recovery of perfusion after 
surgery (images day 3&7. ) 
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Figure 62 Graph of Laser Doppler perfusion index (LDPI) with time after 
induction of ischaernia to right limb by femoral artery excision 
Laser Doppler imaging flux data presented as ratio of perfusion (LDPI) in ischaemic 
limb compared with un-operated control limb. An LDPI of 100 implies normal perfusion. 
There is progressive recovery of perfusion over a4 week follow up period. First data 
point on day 0 is pre surgery, second data point is immediately post-surgery (n = 12) 
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The effect of rat core temperature on LDPI flux data 
To minimize the effects of temperature on the LDI data, rats were placed on a heated 
blanket as is standard practice. However, despite this there was significant variation 
between rats, and within repeat scans for the same rat. When core temperature was 
measured with a rectal probe it was found that rats became hypothermic rapidly, such 
as during the induction phase of anaesthesia (Figure 64). Also the heating blanket was 
insufficient to restore the temperature once animals were hypothermic. Warming the rat 
with an external heating lamp to 380C prior to LDI scanning resulted in maximum 
vasodilatation and stable recordings of flux data over time. Heating the rat above 38'C 
did not result in any further increase in perfusion (Figure 65). 
Figure 63 Serial 2D Laser Doppler flux images of an un-operated Fisher 344 rat 
demonstrating the effect of changes in core temperature on perfusion 
A) 2D colour images. Scan I is at 36.7 OC with a serial drop in temperature of 0.3 
degrees with each successive scan down to a temperature of 34.3 OC in scan 9. The 
colour of the scan goes from red at normal body temperature but decreases noticeably 
to blue with a fall in core temperature. B) Data presented in graphical form. Maximum 
perfusion is achieved by warming the animal to 37 OC. 
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The effect of rat core temperature on LDPI of ischaemic limbs 
The effect of low core temperature created an artefact of apparent improved perfusion 
in ischaernic limbs. Ischaernic limbs were not as sensitive to fluctuations in temperature 
(Figure 64) due to the ischaernic limb not vasoconstricting. As a result the control un- 
operated limb perfusion dropped more than the ischaernic limb with drop in core 
temperature. This resulted in an apparent improvement in perfusion when data is 
presented as a LDPI (Figure 64). Repeated LDI over 4 consecutive days revealed 
consistent results when fluctuating core temperature was controlled using an external 
heat source (Figure 65). 
Figure 64 Graph demonstrating the effect of temperature fluctuations on LDI flux 
data of ischaemic limbs 
A) Perfusion of the ischaemic limb decreases only slightly compared to the un-operated 
limb with drop of core temperature to 35 OC (routinely seen after anaesthesia). Data 
from 4 rats 10 days after femoral artery excision. B) This results in an apparent 
increase in the LDPI of the ischaemic limb at low temperatures, normal perfusion = 
100%, no perfusion 0%. 
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Figure 65 Graph of reproducibility of LDI flux data when core body temperature 
is maintained at 38 "C 
Absolute flux values of (mean of right and left legs) of 4 un-operated Fisher 344 rats on 4 consecutive days scanned at 38 'C core temperature measured by digital rectal thermometer. Heating the animals to 38.5 "C does not result in a further increase in flux 
values. 
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Perfusion analysis with fluorescent microspheres 
After the surgical technique, tissue processing protocol and fluorescent analysis had 
been established and optimised, 2 un-operated Fisher 344 rats were injected with 1 
million yellow-green microspheres into the left ventricular cavity. A control curve of 
microsphere number and fluorescence indicated the linear relationship between 
emitted fluorescence and particle number (Figure 66). This proved a reliable technique 
as there was equal distribution of microspheres between the right and left leg muscles 
(Figure 67). 
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Figure 66 Fluorescent microsphere standard control curve 
Different concentrations of microspheres (FluoSpheres) were dissolved in aceto- acetate and the fluorescence read in a 96 well plate reader. There is a linear 
relationship of microsphere number to fluorescence. 
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Figure 67 Graph of relative perfusion of kidneys and hind limb muscles of 2 un- 
operated Fisher 344 rats injected with 1 million yellow-green microspheres 
Two rats were each injected with I million yellow-green microspheres (ratl and rat2). 
Tissues were harvested, microspheres extracted and fluorescence measured and 
calculated per g of tissue. Results are presented as a perfusion index (PI) of tissue 
from the right side divided by the /eft side. A PI of I implies equal perfusion between 
the right and /eft kidneylmuscle group. There was an equivalent distribution of 
microspheres as measured by fluorescence to both kidneys and the right and /eft limb 
muscle groups. However, the method is not reliable for measuring small changes in 
perfusion due to the potential errors of the extraction and analysis process indicated by 
the ratio of 1.28 for rat I kidneys. 
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Degree of ischaemia induced by hind limb surgery measured by microspheres 
Five weeks after excision of the right femoral artery, the adductors and gastrocnernius 
muscle remained ischaernic as measured by microspheres, confirming that the model 
induces significant and sustained ischaernia (Figure 68). The degree of ischaemia 
measured by microspheres was of a similar range to the LDPI measured in the same 
animals. 
Figure 68 Relative perfusion of hind limb muscles (and kidney controls) 5 weeks 
after right leg ischaemia in Fisher 344 rats measured by fluorescent 
microspheres 
I million yellow-green microspheres were injected into the LV cavity (n=4) and tissues 
harvested. Perfusion in the right (ischaemic limbs) is reduced to 60% when compared 
to the un-operated /eft leg indicating a sustained degree of ischaemia over the 5 weeks 
follow up period (p<O. 05). 
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Magnetic resonance imaging 
To further explore the effects of transplanted cells on ischaemic muscle in the model 
developed an IVIRI based assessment of dynamic contrast enhancement was 
undertaken. Analysis of T1 weighted images after Gd-DTPA 
injection, 3 weeks after 
induction of ischaemia revealed a heterogeneous response to 
injury, both between 
animals, and also between different muscle groups of the same 
limb (Figure 69). 
157 
Figure 69 2D MRI axial image of rat hind limbs and tail 
A) Pre-contrast high resolution image of an un-operated control rat. Image resolution is 
sufficient to allow demarcation of specific muscle groups. B) Image view with Paravision software of a rat 3 weeks after right leg ischaemia surgery, final image in 
series. ROls are selected from both legs excluding skin and bone. Mean signal intensity is presented against image number (right). The right leg is atrophied and has 
a heterogeneous uptake of Gd-DPTA with areas of low, normal and high signal, 
compared to the /eft leg. Note the initial upstroke of signal intensity is similar for both the ischaemic and non-ischaemic leg. 
B) 
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When compared to normally perfused limbs, the pixels/regions of the ischaemic limb 
could be classified into areas of normal, hypo- or hyper-enhancement , corresponding 
to are as of normal, low or high gadolinium concentration relative to the normal limb. 
While the initial rate of uptake of Gd-DTPA after bolus injection is an indicator of 
perfusion, Gd-DTPA also leaks from the capillary plasma space into the interstitial 
space of the muscle. This process will be affected by an increase in the vessel wall 
permeability leading to an increased signal intensity not directly related to perfusion. 
Increased vascular permeability can occur as a result of injury, inflammation, cytokines 
(such as VEGF) or abnormal vessel growth. Thus, the signal intensity in a given region 
is affected, not only by perfusion, but by changes in capillary permeability [195]. Areas 
of early-hyper-enhancement will therefore reflect abnormally high capillary permeability 
whereas regions of delayed enhancement reflect Gd-DTPA retention in necrotic/ 
infarcted fibres [181]. While I observed a more heterogeneous response in the 
ischaernic limb than in normal limb, the averaged signal intensity was similar (Figure 
70, Figure 71, Figure 72). Calculation of the perfusion index, by analysis of the 
maximum upslope of the time-course enhancement curve, revealed no difference in the 
averaged signal between ischaernic or normal limbs (Figure 72). This was regardless 
of whether the image series were corrected for surface coil in-homogeneity with % 
signal enhancement, baseline subtraction or signal intensity rectification using baseline 
histogram subtraction of the pre-contrast images. Also analysis of ROls of specific 
muscle groups such as the gastrocnernius or soleus failed to detect any difference in PI 
between the ischaernic leg and non-ischaemic leg (data not shown). 
Figure 70 Example of time-signal intensity curves after Gd-DTPA contrast 
enhanced MRI after manual ROI selection of rat hind limbs injected with PBS 
control or rMPCs 
Examples of whole muscle ROI time-course enhancement curves from right 
(ischaemic) and /eft (normal) hind limbs obtained from 2 rats 3 weeks after induction of 
right leg ischaemia. There is no significant difference of the maximum upslope between 
the ischaemic (right leg) and non-ischaemic (/eft leg) limb or between animals 
transplanted with PBS or rMPCs. 
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Figure 71 Example graph of MRI maximum upslope gradient of time-signal 
intensity curves from Rat6l injected with PBS. 
A manual ROI was selected with baseline correction and the average MR1 signal 
enhancement for the whole muscle cross section (both /eft and right) was plotted 
against image numberl time for the first 7 images representing the maximum upslope 
of the time signal intensity curve. This demonstrates that there is only a small difference in the slope gradient between the 2 limbs despite the right leg being 
ischaemic. 
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Figure 72 Graph of MRI relative perfusion index (Pis) in rat hind limbs 21 days 
after induction of ischaernia. 
MR1 images were analysed using manual ROI selection with baseline correction. MR1 
maximum upslope gradients of the time-signal intensity curves were calculated for 
each animal (Figure 71). Perfusion ratio was calculated by comparing the normal /eft 
let to the right leg. Mean PI +/- SEM are presented for control animals not submitted to 
ischaemic surgery (black) and for animals who had the right femoral artery excised 
(blue). There is no detectable difference in PI between normal controls and rats with an 
ischaemic right limb. 
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Although it was not possible to measure perfusion reliably by PI, cell transplantation 
may normalise the heterogeneous MRI signal seen in ischaemic limbs. To allow for a 
more specific analysis, a novel method was developed based on a mathematical 
correlation of the time-signal intensity histograms of the ischaemic limb compared to 
the normal limb. Image rectification was undertaken by applying a 7x7 median 
smoothing filter before surface coil intensity correction (SCIC) using baseline histogram 
subtraction of the pre-contrast image (Figure 73). To allow for multiple analyses to be 
undertaken, ROls were selected using a computer automation based on a best fit 
model. This approach successfully selected over 90% of the muscle cross sections of 
each limb (Figure 74). For each image frame of both the right and left limb, signal 
intensity was plotted against the number of pixels with that image intensity. This was 
then plotted against image number (Figure 75). After approximately 20 images a single 
cluster of fibres/ pixels could be identified in normally perfused limbs (Figure 75 left leg, 
right image). In contrast the ischaemic leg had 3 different clusters of fibres 
corresponding to 3 grades of image signal intensity (Figure 75 right leg, left image). For 
each image a correlation coefficient was calculated between the 2 limbs of each rat. A 
correlation coefficient of 1 indicates a similar distribution of signal between limbs 
whereas <1 implies a difference between the 2 limbs for that image. Correlation 
coefficients were then plotted against image frame number (Figure 76). Using this 
approach it was possible to clearly identify rats with an ischaemic leg as the correlation 
coefficient decreases substantial with each image number of the time course 
acquisition (Figure 77). 
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Figure 73 MRI image rectification with 7x7 median smoothing filter followed by 
surface coil intensity correction (SCIC) using baseline histogram subtraction of pre-contrast images from rat62 
Before rectification there is a significant difference in the starting image signal intensity between the 2 limbs displayed in 2D axial image on the /eft and time-signal intensity curves on the right (top). After surface coil intensity correction (SCIC) (bottom) the 2 pre-contrast images are now similar. Despite the right leg being ischaemic the time course signal intensity curves (bottom right), including the signal upstroke, are not significantly different. 
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Figure 74 MRI axial images after image rectification and computer automated 
selected ROI selection 
Series of 6 rats after PBS injection (top) or rMPC transplantation (bottom) 
rat-65 rat-66 
rat-79 rat-80 
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Figure 75 Example of time-signal intensity histograms of right ischaernic leg and 
left non-ischaemic leg 
Time-signal intensity histogram in top row demonstrates that the intensity range of the 
ischaemic limb and normal limb for a PBS treated rat are the same at baseline and are 
similar at a perfusion dependent time (frame 15), but the ischaemic limb has more late 
enhancement than the normal limb at frame 75. Continuous time-signal intensity 
histograms of the normal and ischaemic limbs are shown as 3D plots in the bottom 
row. In the late image enhancement (frame 75) there appear to be 3 different patterns 
of enhancement: normal (signal intensity 120) as seen in the Normal limb and hypo- 
enhancement (signal intensity 80) and hyper-enhancement (signal intensity 150) as 
seen in the ischaemic limb. Axis y: number of pixels, x: signal intensity, z: mage frame 
number. 
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Figure 76 Diagram explaining the basis of the coefficient correlation for 
comparison of right and left leg MRI time-signal intensity histograms 
A correlation coefficient was calculated for each image in the series by using the signal 
intensity v number of pixels for the left leg histogram and correlated with the right leg 
histogram. The correlation coefficient (comparing the left to the right leg) was then 
plotted against image frame number in the image series. A correlation of I implies the 
same signal intensity distribution between the 2 limbs. A correlation coefficient less 
than I implies that the signal intensity distribution is different. 
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Figure 77 Correlation coefficients of MRI time signal intensity histograms of rats 
with hind-limb ischaernia 
Correlation coefficient of right leg compared with /eft leg. There is a significant 
reduction in the correlation coefficient after ischaemia surgery (0) compared to non- 
operated control rats (V) *p<0.00 1. n=6. 
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Construction of parametric maps 
To further analyse and present the data parametric maps were constructed. Parametric 
maps of the contrast enhancement signal over baseline were analysed and time-signal 
intensity integral for image frame 10/15/30/60 and 80 to identify the image number that 
provided the greatest image contrast between ischaemic and non-ischaemic limbs 
(Figure 78, Figure 79). 
Figure 78 Example of parametric maps based on either contrast enhancement or 
time signal intensity integral of images from rat62. 
Parametric maps were constructed from various image numbers through the sequence. 
Contrast enhancement maps (top) present the data as absolute change in signal 
intensity compared to the pre-contrast basement. Time signal intensity integral maps 
(bottom) present the integral of the signal of each frame image, from baseline up to the 
selected frame. Different images/ time pint of the image sequence were analysed to 
detect the maximum contrast in signal between the ischaemic (right) and non 
ischaemic limb (/eft). Scale: black indicates low signal, white indicates high signal 
intensity. 
Low High 
Image 15 of the contrast enhancement maps was selected for subsequent analysis of 
both treatment groups (PBS and rMPCs). Because of the heterogeneity in response to 
the ischaemic surgery and within each treatment group, no difference between the 2 
treatment groups was observed (Figure 79). Similar results were found for analysis of 
the time-signal intensity integral (data not shown) 
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Figure 79 Parametric maps using contrast enhancement from image 15 of rats 
with ischaemic hind limbs. 
There is considerable heterogeneity of signal between limbs and rats making group distinction difficult. 
m6 ischemia PBS control 
rat-61 rat-62 rat-63 rat-64 rat-65 rat-66 
w6 ischemia cell therapy 
rat-67 rat-68 rat-69 rat-75 rat-79 rat-80 
Finally I hypothesised that developing a scoring system for each limb of normal, hypo- 
enhancing or hyper-enhancing fibres may allow us to quantify the number of these 
fibres in each muscle. Using K-means clustering based on 3 groups it was possible to 
identify fibres/ pixel groups with normal, low or high enhancement in animals with 3 
distinct regions. However, although this was useful in rats with well demarcated regions 
of Gd-DPTA uptake (Figure 80), in animals with a more complex mix of signal intensity 
this approach failed to classify areas with different signal properties which prevented 
more detailed further analysis (data not shown). 
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Figure 80 MRI data analysis for Rat62 right leg using K-means clustering based 
on 3 groups to classify fibres into low (blue)/ intermediate or high (red) 
signal groups 
Although in this rat the 3 groups are clearly identified as demonstrated by classification of the time-signal intensity histograms (top) or on the time-signal curves (bottom) this classification failed to distinguish fibres when applied to most of the other animals because of the lack of distinct signal between fibre groups. 
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Functional impairment in exercise endurance due to ischaernia 
Counter current swimming tank 
Considerable modifications were made to the swimming tank before it could be reliably 
used. Although the rats were very good swimmers they proved very ingenious at 
escaping from the current in the tank. Also a considerable velocity of water was 
required (surface velocity of 30 m/min) to sufficiently stress the rats. Rats could swim 
for at least 60 minutes at baseline before showing signs of fatigue (Figure 81). In 
addition some rats developed strategies to avoid swimming. This included diving to the 
bottom of the tank to avoid the surface flow or pushing off the back of the tank and then 
floating in the current to the back again. Once these manoeuvres were acquired by an 
animal they were repeatedly used. This resulted in considerable variation between 
animals and also made it difficult to ascertain when a rat was actually fatiguing. In an 
experiment with 2 rats the threshold of removing the animals from the tank was 
increased to see if a more reliable end point could be achieved. Under these more 
stressful conditions the rats initially showed signs of fatigue at approximately 70 
minutes. However, both rats subsequently acquired evasion strategies and were able 
to swim in the tank indefinitely. After 3.5 hours the study was abandoned with neither 
rat fatigued. Unfortunately this indicated that using a counter current swimming system 
for rats was unlikely to provide meaningful data. However, in separate experiments with 
mice, the model has proved much more reliable and able to clearly distinguish between 
different groups of mice with different exercise performance (data not shown)[1 96]. 
Figure 81 Swimming time in rats before and after induction of hind limb 
ischaemia 
Rats were exercised in a counter current swimming tank until fatigue. Although there is 
considerable loss of function 5 weeks after surgery there was wide variation in 
performance (n=4) and the difference was not statistically significant. 
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Rodent treadmill 
After initial training on the treadmill rats were exercised on 3 consecutive days to 
measure maximum running time. 5% of rats were unable to use the treadmill and 
hence these animals were removed from the study. Although most rats improved their 
running time on subsequent days the results indicated that it was a useful functional 
measure with acceptable reproducibility between rats and on repeated measures. 
Following hind limb ischaemia rats running time/ distance decreased significantly. This 
effect was seen at both 2 and 3 weeks after surgery. Sham surgery did not effect 
running times (Figure 82). 
Figure 82 Graphs of rat treadmill running times and distance. 
A) Mean running times of 18 un-operated rats from 3 consecutive days. Times tended 
to increase slightly on successive days but the mean run time seconds (+/- SE) for 
each rat indicating acceptable variation between animals and good reproducibility. B) 
Rat running distance (meters) 2 and 3 weeks after hind limb ischaemia n=6. C) Sham 
surgery does not affect rat running times 2 weeks after surgery. 
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Histological assessment of muscles after hind limb ischaernia 
Histological assessment of the adductor and gastrocnemius muscle 72 hours after 
surgery revealed widespread signs of ischaemia as well as acute inflammatory 
changes and muscle fibre necrosis (Figure 83). In addition to muscle fibre swelling and 
signs of necrosis, there was a pronounced inflammatory infiltrate consisting of both 
granulocytes and mono-nuclear cells. The distribution of the inflammatory infiltrate was 
heterogeneous and not all muscle groups were affected to the same degree. In 
addition the pattern was different between animals. 
It was possible to identify CID31+ endothelial cells in muscle sections with IF staining 
(Figure 84). This would allow quantification of capillary/ muscle fiber ratio after cell 
therapy (Chapter 5). As has been reported previously [197], skeletal muscles have a 
high background auto fluorescence. In addition there was a considerable 
heterogeneous signal between adjacent muscle fibers in ischaemic tissues, which 
would make localisation and interpretation of cells labelled with GFP difficult. 
Figure 83 Light photornicrographs of sections of rat adductor muscle stained 
with H&E 72 hours after surgical excision of the femoral artery 
Sections were stained with H&E and imaged under low magnification (a) and high 
magnification (b). 72 hours after induction of ischaemia there was signs of acute 
ischaemia characterised by muscle fibre swelling, centralisation of nuclei, necrosis and 
pronounced inflammatory cell infiltrate (as shown by blue stainingl infiltrate (a)). 
;. 
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Figure 84 CD31 staining of rat adductor muscles. 
A) OCT embedded frozen sections of ischaemic hind limbs were stained with anti 
CD31 followed by Alexa Fluor 594 goat anti mouse secondary antibody. DAPI counter 
stain. Endothelial cells are labelled red. B) Background auto-fluorescence of ischaemic 
muscles 1 week after surgically induced ischaemia. Note high auto fluorescence and 
the heterogeneity between different fibres making IF analysis using the 'greenchannel 
difficult to interpret without confocal microscopy analysis. C) Overlay of CD31 and 
DAPI with increased exposure time to delineate muscle fibres. 
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Discussion 
Summary of results 
1. A hind limb model of ischaemia has been established that resulted in a 
sustained degree of ischaemia over a4 week follow up period 
2. Methods of assessing perfusion using laser Doppler imaging and fluorescent 
microspheres within the hind limb muscle have been established 
3. Functional measures of exercise ability have also been assessed. and 
developed. The counter current swimming assay is unable to assess function. 
However, the rodent treadmill provided reproducible estimates of rat exercise 
ability. 
4. A novel MRI based assessment of rat ischaemic hind limbs was developed 
which provides insight into the effects of surgically induced muscle ischaemia. 
Hind limb ischaernia model 
A rat hind limb ischaemia model has been established for the purpose of studying cell 
transplantation into an ischaemic environment. Significant ischaemia has been 
documented by a decrease in perfusion measured by both laser Doppler imaging and 
fluorescent microspheres. In addition I have demonstrated a significant loss of function 
measured by exercise ability on an exercise treadmill. The persistence of ischaemia 
out to 4 weeks indicates that a more chronic level of ischaemia has been established 
which may have more similarities to chronic ischaemia in humans. There are very few 
rat hind limb ischaemia models that have persistence of ischaemia over a4 week 
follow up period (171 ] as both rats and mice have a remarkable ability to recover from 
ischaemia [179] indicating that our model may be useful for more long term follow up 
studies. In addition this is the first description of a hind limb ischaemia model in a 
Fisher 344 rat. 
It is tempting to assume that hind limb ischaemia models in rodents may represent 
chronic limb ischaemia in humans due to peripheral vascular disease (PVD). However, 
there are fundamental differences between them. The chronic nature of 
atherosclerosis, the major cause of PVD in humans, clearly has a very different patho- 
physiology to acute surgically induced ischaernia. Also, as most studies commence 
immediately or soon after hind limb surgery, these models are of a mix of acute 
ischaemia followed by chronic ischaemia if the animal does not spontaneously 
recover. It is likely that delivery of cells at different time points after surgery may well 
have different outcomes, especially if the acute phase is allowed to resolve. 
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The surgical approach used was more extensive than previous models which only 
ligated the femoral artery [81] and yet not as extensive as procedures which involve 
surgery to the iliac arteries [171] which I found resulted in limb loss. Multiple 
procedures were attempted before deciding on excision of the femoral artery from the 
inguinal ligament to the knee. Because of the rapid recovery of perfusion in rodents 
after femoral artery ligation a more aggressive procedure than ligation was required to 
maintain an ischaemic state at rest. This rapid recovery in perfusion seen in rodents is 
most likely due to the rapid dilatation of pre-existing collaterals rather than due to direct 
angiogenic or vasculogenic processes as recovery is seen within 24 hours [179]. 
Although the final surgical approach resulted in sustained ischaemia for up to a month 
of follow up, with no evidence of limb loss or animal death, the response to the 
ischaemic insult also included necrosis and pronounced inflammation. This was 
documented by the extensive histological changes within 72 hours of surgery and by 
presumed necrotic and inflamed areas on MRI. It is therefore likely that any 
intervention in this model is likely to modulate not only responses to ischaemia but also 
inflammation. As a result of the extensive inflammation seen, any potential benefit of 
cell therapy on angiogenesis and vasculogenesis may be lost as a result of the 
inflammation. Conversely inflammation may be required to encourage cell engraftment. 
Also transplanted cells may actually modulate the inflammatory response to ischaernia, 
for example by the release of cytokines such as MCP-1. This could potentially be a 
mechanism of action of certain types of cell therapy. 
Assessment of perfusion 
2 measures of perfusion were used which provided information from 2 different 
vascular beds. LDI samples the blood flow in the skin of the hind limb. As skin receives 
blood supply predominantly from perforating arteries of the underlying structures the 
LDI reading can be assumed to measure the overall limb blood flow. However, with a 
drop in temperature the 'flux' units of LDI decrease markedly. This occurs rapidly after 
induction of anaesthesia even when using a heated blanket. In addition, as ischaemic 
legs already have low perfusion at normal temperature, there is only a minor further 
drop when core temperature of the rats falls. This makes the LDPI unreliable at low 
temperatures as it underestimates the degree of impaired perfusion in an ischaernic 
leg. Control of body temperature is essential when using LDI as artefacts can be easily 
introduced. 
Although injection of fluorescent microspheres is the gold standard of perfusion 
measurement it is not a straightforward assay to run. Also in rodents serial 
measurements are not possible in the same animal. However, microspheres provide a 
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reliable measure of muscle perfusion and because the microspheres do not leave the 
circulation but lodge in capillary beds, they are not affected by changes in capillary 
permeability. 
MRI based assessment of ischaemic hind limbs 
Given the limitations of laser Doppler and fluorescent microspheres an MRI based 
approach was developed in order to further explore the hind limb ischaemia model. 
Initially it was intended to measure perfusion based on analysis of the upstroke 
gradient of time-signal intensity curves after Gd-DPTA bolus injection. Although it was 
possible to achieve high spatial resolution and reliably track the change in signal after 
Gd-DPTA bolus in skeletal muscle, there was significant heterogeneity in the response 
to ischaemia. As a result of the heterogeneous signal in ischaemic limbs it was not 
possible to calculate a reliable measure of perfusion index using analysis of the Gd- 
DTPA enhanced MRI signal. This was primarily as a result of the rapid hyper- 
enhancement seen, presumably due to increased capillary permeability in ischaemic 
limbs. Although MRI assessment of perfusion after Gd-DPTA injection has been used 
previously in a rat hind limb model [182] this model used a femoral artery ligation, 
rather than excision as their intervention. This results in a less severe insult to the hind- 
limb as well as less ischaemia at rest although hyper-enhancement was also seen but 
to a lesser degree. Analysing the animals after exercise (e. g. by sciatic nerve 
stimulation [182]) may have allowed for a larger signal difference between the 
ischaernic and non-ischaernic limbs. Alternatively utilising a step-input function after 
post ischaemic hyperaemia may have allowed us to increase limb perfusion and 
document a difference in PI [176]. 
A novel analysis method was therefore developed, based on the correlation coefficient 
of the time signal intensity histograms of the ischaemic and normal limb muscles. This 
approach assesses the variation in signal intensity and its distribution due to multiple 
factors including perfusion and capillary permeability. I was able to demonstrate that 
removal of the femoral artery results in a significant difference in the signal histograms 
of the ischaemic limb compared to the control limb. Interpretation of PI measures 
based on contrast enhancement can be flawed in models with a mixed response to 
ischaernia. Using the correlation coefficient of the ischaernic limb, compared to the 
non-ischaemic control limb, allows us to assess the complex and heterogeneous 
response to ischaemia seen in this model. As inflammation is a major response to 
acute ischaemic insults and capillary permeability a fundamental component of 
inflammation [1981, this is likely to significantly affect the MRI signal as Gd-DPTA 
delivery to tissues is also dependent on capillary permeability in addition to blood flow. 
174 
This hyper-enhancement has been documented in the border zone of tumours [1991 
and cerebral infarcts [195] when the blood brain barrier brakes down. It is quite likely 
that as the muscle recovers to a steady state and the inflammation recovers, Gd-DPTA 
hyper-enhancement signal should decrease. Analysing the animals at a later time point 
may allow measurement of the perfusion index when the hyper-enhancement of 
presumed inflammation may have resolved. 
The time-signal intensity curves after rectification were also converted to parametric 
maps based on either contrast enhancement or upslope integral ratio. This gives a 
measure of the accumulation of contrast material but not of the rate of contrast delivery 
or clearance. Again this is particularly evident in the areas of hyper-enhancement. 
These parametric approaches did help to distinguish ischaemic from non-ischaernic 
limbs but they were not as sensitive at separating the ischaernic from normal limbs as 
the correlation coefficients of the time course intensity histograms. 
As it was not possible to explore ROls over skin alone, due to lack of resolution and 
signal, it was not possible to compare the result of LIDI with MRI. In addition as a 
reliable measure of relative perfusion with MRI could not be calculated it was also not 
possible to compare the MRI results with the microsphere results. However, a novel 
approach for analysing the heterogeneous response of the ischaemic muscles was 
developed which clearly allows for the identification of muscles that have been 
submitted to ischaemic surgery. Further experiments exploring the reason for this 
variation in signal in ischaernic muscles after Gd-DPTA bolus (either with MRI guided 
histological analysis or investigations into capillary permeability) would allow us to 
explore the hypothesis that it is due to changes in capillary permeability. 
Functional assessments of ischaernia 
Previous angiogenesis studies using hind limb ischaemia models in rodents often 
demonstrated significant improvements in perfusion but when this research was 
translated to the clinic there was a disappointing lack of functional improvement [188]. 
It was intended to document that the model induced a significant functional defect and 
demonstrate that any improvement in perfusion may be associated with an 
improvement in function. Simultaneously 2 measures of physical performance in rats 
were developed to assess rats submitted to ischaemia surgery. Any improvement in 
perfusion would hopefully be reflected by an improvement in exercise function. 
As rats are such good swimmers and can rapidly learn strategies to avoid the water 
flow, the counter current swimming tank proved unhelpful. However, use of the rodent 
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treadmill provided consistent reliable data, and running distance decreased significantly 
after ischaemia. However, it is unlikely that the decrease in performance is exclusively 
due to reduced perfusion of the muscles of the right leg. The stress of ischaemia 
surgery resulting in muscle necrosis, inflammation and limb atrophy (but not sham 
surgery) are all likely to have significant effects on the metabolism and general health 
of the rat resulting in decreased exercise performance. 
Conclusion 
In conclusion a hind limb ischaemia model has been developed which demonstrates 
maintained ischaemia over a4 week follow up period without limb or animal loss. In 
addition methods have been established for the analysis of hind limb perfusion and 
function, by assessing exercise capacity. This model was developed specifically so that 
the effects of transplantation of rMPCs could be examined. The model itself provides a 
useful system for assessing the effects of therapy designed to potentially treat 
ischaernia. 
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Chapter 5 Transplantation of rat multi-potent progenitor cells 
into a rat ischaemic hind limb model 
Introduction 
The use of progenitor and stem cell therapies to improve the perfusion of ischaemic 
organs is an exciting field of research, which may prove a novel therapeutic option for 
patients with cardiovascular disease [200]. Although there are numerous sources of 
different cell types under study, bone marrow is a particularly attractive source of cells 
because of its relative ease of harvest in a patient specific manner. 
Several bone marrow derived cells, including endothelial progenitor cells (EPCs) [8] 
haematopoietic stem cells (HSCs) (201] and mesenchymal stem cells (MSCs) [164] 
may have the potential to differentiate into cellular components of the vasculature and 
increase the perfusion of ischaemic organs. Although clinical trials have commenced, 
the mechanism of action of cell therapy remains controversial [202] and it is not clear 
how much of any effects are attributable to BM cells giving rise to vascular cells. 
Although bone marrow cells accumulate in areas of ischaemia there are a number of 
potential mechanisms of action. Originally it was suggested that cells could trans- 
differentiate into endothelial cells (ECs) and integrate and form new blood vessels [8]. 
However, the level of engraftment reported is often minimal or absent despite 
significant improvements in perfusion [203]. Cell fusion has been suggested as one 
possible mechanism [16] and others have speculated that indirect angiogenic growth 
factor delivery by BM cells may be responsible [18] or that transplanted cells may 
modulate resident stem or progenitor cell pools by the release of the stem cell homing 
cytokine SDF1 [204]. 
Most of the recent reports studying the effects of bone marrow derived cells on 
perfusion have predominantly used experimental models based on acute ligation of 
either the femoral or coronary artery. These 'ischaemia' models stimulate an acute 
severe injury associated with a heterogeneous response of inflammation, necrosis and 
ischaernia [203]. The effects of any cell therapy are likely to be a result of interactions 
with numerous processes, such as inflammation, in addition to hypoxia. 
Recently, a subset of BM derived stem cells, named multi-potent ddult progenitor cells 
(MAPCs), have been isolated from mesenchymal stromal cell cultures, which in 
addition to being able to proliferate extensively in vitro can differentiate into cells of all 3 
germ layers [45]. Although there have been no reports of other laboratories isolating 
cells with precisely the same phenotype as MAPCs, other groups have subsequently 
demonstrated that fractions of bone marrow derived cells have similar tri-lineage 
177 
pluripotent potential [113-115] and these cells may be beneficial for improving LV 
function after myocardial infarction. There is an inherent appeal of transplanting cell 
types capable of multi-lineage differentiation to regenerate diseased organs as they 
may be able to restore the multiple cell types often required to improve function in a 
diseased organ. However, any mechanism of action is likely to be a complex process. 
It was possible to isolate cells that could be considered to be multi-potent progenitor 
cells (rMPCs) from rat bone marrow (described in Chapter 3, Isolation and 
Characterisation). rMPCs can be maintained in culture for a prolonged period of time 
with a stable phenotype and karyotype. rMPCs can express tissue specific antigens 
from all 3 germ lineages after differentiation in vitro. As rMPCs do not express the stem 
cell transcription factor Oct4 and are not isolated from a single cell they are not 
considered stem cells, but they may represent a mixed culture of pluripotent 
progenitors. When transplanted into an ischaernia hind limb model, it appears that the 
cells engraft selectively into the neurovascular bundle of ischaernic muscles and result 
in a modest beneficial effect on perfusion. Although injection of rMPCs could improve 
muscle perfusion to a limited degree, they did not regenerate the atrophied muscle 
groups or result in a restoration of exercise function. In addition, the engrafted cells do 
not differentiate in vivo as part of a 'de novo' vasculogenesis process, but probably 
exert their benefits due to paracrine mechanisms modulating local inflammatory and 
angiogenic responses resulting from the secretion of numerous cytokines. As rMPCs 
secrete SDF1 in vivo, it could be speculated that they may increase the homing of 
resident stem or progenitor cell populations, which may be one mechanism that results 
in the improved recovery from ischaemia. 
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Methods 
Rat hind limb ischaernia model 
To investigate the effects of local delivery of potential stem/progenitor cells an 
ischaemic hind limb model was established in female Fisher 344 rats. Detailed 
methods of the surgical approach and assessment methods used are described in 
Chapter 4 'Establishing a hind limb ischaemia model in rats'. Briefly, 12 week old 
female Fisher 344 rats were submitted to ischaemia surgery by excision of the right 
femoral artery and then acted as recipients for intramuscular injections of cells. 
Isolation and transplantation of rMPCs 
rMPCs were isolated from the bone marrow of male Fisher 344 rats from the same 
colony as the animals submitted to ischaernic surgery to avoid immune rejection due to 
haplotype mismatch. rMPCs labelled with LacZ were used for transplantation and 
compared with a PBS control. An alternative cell type (such as MSCs) was not used as 
a control as it was intended to document any positive effects over baseline, rather than 
make direct comparisons with other cell types at this stage. 
rMPCs, which had been phenotyped and cultured for 120 population doublings and 
had a normal karyotype, were used for transplantation (detailed methods and results in 
Chapter 3 Isolation and characterisation of MAPCs). Because there was almost no 
perfusion in the ischaemic limb in the initial post operative period this was felt to be 
unfavourable conditions for cell delivery. Transplantation of cells was undertaken 24 
hours after ischaemia surgery. 
rMPC were cultured under low density (200/cel IS/CM2) in T175 flasks coated with 10 
ng/ml of fibronectin (Human, Sigma Aldrich, USA). 72 hours later cells were harvested 
with Trypsin/EDTA (Gibco, USA) which was then neutralised with media. Cells were 
then washed twice with PBS (centrifuged at 400 g for 10 minutes) counted with a 
haemocytometer, before final re-suspension in PBS at a concentration of 50 million 
cells/ml. Approximately 30-40 T175 flasks were required to culture sufficient cells to 
inject into a single rat. Cells were injected using 1 ml micro syringe through a gauge 27 
needle, in 200 ul of PBS along either side of the excised femoral artery over the 
adductor group of muscles. Experiments using the injection of 200 ul of Green Tissue 
Marking Dye (TBS, USA) under the same conditions used for injecting PBS or rMPC 
cells, found that this approach resulted in cells being delivered to the calf muscles and 
quadriceps in addition to the adductor muscles. The un-operated left leg in each animal 
served as a control for the assessment of perfusion. Two doses of rMPCs 
transplantation were investigated: 1 million and 10 million cells/per rat. Due to the 
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limited response on perfusion after transplantation of 1 million cells the study was 
repeated with a higher dose. Due to the large numbers of culture flasks required to 
inject a single rat with 10 million cells, separate experiments were conducted with cells 
that had been previously frozen. The results on LDI and exercise performance of using 
10 million frozen cells were the same as freshly cultured cells (data from frozen cells 
not shown). Frozen cells were harvested with trypsin/EDTA as above, washed once in 
MAPC media and the cell pellet re-suspended in freezing media (70% media/ 10% 
DMSO/ 20% FIBS) at a concentration of 10 million/cells/ml . 
Cells were then transferred 
to a nunc cell freezing tube and placed in a nunc freezing container at -80'C for 24 
hours, prior to transfer to a liquid nitrogen freezer for long term storage. Prior to 
injection frozen cells were thawed rapidly in a 37oC water bath, washed in PBS twice 
and then re-suspended in PBS for injection as above. 
Randornisation and blinding 
Rats were randomised to cell treatment or PBS control and the operator (AW) was 
blinded to treatment groups until after perfusion and functional data had been collected 
and analysed. 
Results 
Transplantation of rMPCs into ischaemic hind limbs 
As rMPCs appeared to have pluripotent properties (as assessed by in vitro 
differentiation) and secrete numerous cytokines, I hypothesised that rMPCs may 
favourably affect outcome of an in vivo model of ischaemia. Twelve week old female 
Fisher 344 rats were submitted to hind limb ischaemia surgery by excising the femoral 
artery from the inguinal ligament to the knee. This surgical approach was selected as it 
induced a significant sustained degree of ischaemia (62% ± 10 of normal by 
microspheres, 48% ± 1.3 by LDI p<0.001) without causing gangrene or limb loss. 
Twenty four hours after surgery animals were transplanted with either LacZ labelled 
rMPCs or PBS control. The initial dose used was 1 million cells/ animal; however this 
was subsequently increased to 10 million cells/ animal. Cells were injected into the 
ischaernic limb along the incision resulting in cells being delivered to the adductor and 
calf muscles. 
Confirmation of expression of 8- Galactosidase in rMPCs 
rMPCs had been transfected with a retrovirus expressing 8 -Galactosidase. It was 
possible to confirm the robust specific expression of A-Galactosidase by 
X-Gal staining 
of cells compared with 2 negative controls, unlabelled rMPCs and rat aortic endothelial 
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cells (RAOECs) (Figure 85). The strong signal indicated that tracking of the cells 
histologically in vivo after intra muscular injection should be feasible by X-Gal staining. 
Figure 85 Light photomicrograph confirming the expression of P- Galactosidase 
in rMPCs after X-Gal staining 
100,000 rMPC LacZ, non-transduced cells or RAOEC cells were mounted onto glass 
slides with a Cytospin and stained with X-Gal reagent. Strong X Gal staining within 
rMPC cells is confirmed and no non-specific staining in controls. A) x200 B) x 1.5 
A) 
Non-transduced cells 
L 
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B) 
RAOEC rMPC LacZ Non-transduced 
rMPCs increase regional muscle perfusion in a hind limb model of chronic 
ischaemia measured using fluorescent microspheres 
Twenty four hours after induction of ischaemia, 10 X106 rMPCs cultured for 120 pd, or 
PBS control were injected into the ischaemic right hind limb. Four weeks after injection 
of rMPCs muscle perfusion had increased (PBS 62% ± 10, rMPCs 102% ± 14, p<0.05) 
(as measured per gram of muscle) (Figure 86). 
rMPCs increase capillary density of ischaernic hind limbs 
1 week after induction of ischaemia and transplantation of rMPCs, muscles were 
harvested, embedded in OCT and sections stained for CD31 to identify the endothelial 
cells of the muscle capillaries. The number of CD31+ capillaries per muscle fibre was 
quantified. rMPCs caused a significant increase in the capillary density of the 
ischaemic adductor muscle (Figure 87). 
181 
rMPC LacZ 
rMPCs do not increase perfusion of the skin of the hind limb measured by laser 
Doppler imaging 
In contrast to the fluorescent microsphere results, rMPCs did not increase the perfusion 
of the hind limb when measured by LIDPI. There was no difference between the rMPCs 
and PBS groups in the superficial perfusion of the skin of the distal hind leg measured 
over the 4 week study period (n=6, p=0.35) (Figure 88). 
Figure 86 Assessment of hind limb muscle perfusion by fluorescent 
microspheres after rMPC transplantation 
IX 106 green-yellow microspheres were injected into the left ventricle 4 weeks after cell 
transplantation. Adductor and gastrocnemius muscles were harvested and 
fluorescence measured. Results are expressed as relative fluorescence of ischaemic 
limb/ fluorescence of norm-perfused limb standardised by weight of tissue. 10 X 106 
rMPC increase perfusion per gram of muscle. n=6, mean ± sem. *p<0.05.1 X 106 
rMPC did not significantly effect perfusion (inset) n=5. 
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Figure 87 rMPCs increase capillary density of ischaernic muscles 
I week after rMPC transplantation OCT embedded frozen sections were stained for CD31. The number of CD31+ cells per muscle fibre was counted and presented as capillary/muscle fibre ratio. Mean ± sem. *p<0.05, n=6. 
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rMPCs transplantation results in normalisation of MRI time course signal- 
intensity curves after Gd-DPTA bolus 
I was unable to measure perfusion in our rat hind limb model because of the 
heterogeneous uptake of Gd-DPTA in ischaemic limbs and as a result there was no 
detectable effect of rMPC transplantation on MRI PI based on analysis of the upslope 
gradient (Figure 90). However, by analysing time-signal intensity histograms I was able 
to clearly distinguish ischaemic limbs from normally perfused limbs by calculating the 
correlation coefficient between the control limb and ischaemic limb. Transplantation of 
10 million rMPCs resulted in a significant normalisation of the MRI signal over the 
course of the image series compared with control (Figure 91). 
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Figure 88 Assessment of hind limb perfusion by laser Doppler imaging after 
transplantation of 10 X106 rMPCs 
A) LDPI is expressed as a percentage of the normal limb. Flow recovery in rMPC 
treated animals is no different to animals treated with PBS control. N=6, Mean ± sem. 
NS. B) LDI flux images of rat hind limbs. Red high flow, 1000 flux units. Blue low flow, 0 
flux units. Example images from day I and day 27 of rat treated with rMPCs or PBS 
control. 
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Figure 89 rMPCs do not result in muscle regeneration of ischaemic limbs 
4 weeks after ischaemia surgery and transplantation of rMPCs or injection of PBS, 
adductor and gastrocnemius muscles were harvested and weighed. Both muscle 
groups remain atrophied (by total weight) 4 weeks after surgery. There is no difference 
in weight between the rMPCs and PBS treated groups. N=6, mean ± sem. NS. 
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Figure 90 Graph of MRI relative perfusion index (Pis) in rat hind limbs 21 days 
after induction of ischaernia and transplantation of PBS or rMPCs 
Manual ROI selection with baseline correction. There is no detectable difference in PI 
between normal controls (m), ischaemic limbs with PBS (m) or ischaemic limbs 
transplanted with rMPCs (m). n=6 each treatment group, mean ± sem, NS 
s PBS + Ischemia 
* rMPC + Ischemia 
* Normal: non Ischemic 
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Figure 91 Graph of MRI correlation coefficients of time signal intensity 
histograms of the right leg compared with left leg of animals injected with PBS 
control or rMPCs 
There is a significant reduction in the correlation coefficient after ischaemia surgery (M) 
compared to non-operated control rats (V). There is significant normalisation of the 
correlation coefficient in animals with ischaemic hind limbs injected with IOXI06 rMPCs (A) compared to animals injected with PBS (m) indicating that cell therapy has 
appeared to restore the normal MR1 characteristics of the ischaemic uscle. * p<0.001 
n=6 each group. 
m PBS + Ischemia 
A rMPC + Ischemia 
v Normal: non Ischemic 
rMPCs do not result in regeneration of ischaemic muscles 
rMPCs may be able to regenerate the atrophied muscles of the ischaemic hind limb. 
However, weight of either the adductors (PBS 0.9g ± 0.03 rMPC 0.81g ± 0.06, p=0.26) 
or gastrocnemius (PBS 0.98g ± 0.06, rMPC 1.03g ± 0.02, p=0.44) remained 
unchanged after PBS or rMPC injection (Figure 89). In addition, the cross sectional 
area of each limb from the 2-D MRI axial image was measured. Using these 
measurements the ratio of the right, ischaemic muscle to left, non-ischaemic muscle 
was calculated. Un-operated control rats had a ratio of limb cross sectional area of 1.03 
+/- 0.05, whereas operated rats had a significantly lower ratio of 0.82 +/- 0.06 (p<0.05) 
after PBS injection or 0.80 +/- 0.06 (p<0.05) after rMPCs transplantation. There was no 
significant difference in the ratio of the cross sectional areas of R/L limbs 
between 
animals transplanted with rMPCs or PBS. 
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rMPCs do not improve exercise ability 
If rMPCs can improve perfusion of an ischaemic limb then this may result in an 
improvement of function. Functional recovery of the hind limb was measured using a 
rodent treadmill and counter current swimming tank. There was a significant decrease 
in exercise ability on the rodent treadmill after induction of ischaemia (480m ±24 pre 
op, 301m ± 21 post op, p<0.01) which was not improved by injection of 10 million 
rMPCs (PBS 300 ± 21 m, rMPC 320 ± 15m, p=0.5) (Figure 92). A lower dose of 1 
million rMPCs had also been studied in pilot experiments with also no effect on 
treadmill running distance (data not shown). In addition there was no difference in 
swimming time 5 weeks after transplantation of 1 million rMPCs cells or PBS control. At 
5 weeks after surgery animals still had significant functional impairment although there 
was considerable variability of the swimming time between animals making resolution 
of small functional improvements difficult (Figure 93). As the reproducibility of the 
counter current swimming assay could not be improved it was abandoned. Therefore 
swim time was not measured in rats transplanted with 10 million rMPCs- 
Figure 92 rMPCs do not improve maximal exercise capacity on rodent treadmill 
Rats were trained to use a rodent treadmill. Rats were exercised daily for 5 days prior 
to surgery and daily during week 3 and week 4 after surgery. Maximum running 
distance decreases significantly after ischaemia surgery but is not improved by 
injection Of 1OX106 rMPCs (black bars) compared to PBS (open) mean ± sem. 
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Figure 93 rMPCs do not improve maximal exercise capacity in counter current 
swimming tank 
Rats were submitted to hind limb surgery and transplanted with IX106 rMPCs or PBS 
control. Exercise ability was measured by counter current swimming time pre-op and 5 
weeks post surgery. Swimming time did not significantly decrease post operatively and 
there is no difference between animals injected with PBS or rMPCs (n=4 each group, 
mean ± sem). 
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rMPC engraft into the neurovascular bundle of ischaemic but not normally 
perfused muscles 
To track the long term engraftment and fate of rMPCs in vivo, rMPCs were stably 
transduced with a P-Gal expressing retrovirus. Four weeks after injection of rMPCs, 
tissues were harvested and stained with X-Gal reagent to identify LacZ expressing 
cells. No blue cells were identified in ischaemic or normal muscle injected with PBS. 
After rMPCs, were injected into normally perfused muscle only the occasional cell 
remained after 4 weeks. In contrast when 1 OX1 06 rMPCs were injected into ischaemic 
muscles there was significant engraftment. The rMPCs were easily identified under 
bright field microscopy as blue P Gal + cells. Although rMPCs were seen along needle 
tracks and occasionally scattered in between the muscle fibres, the cells were 
predominantly localised around the neurovascular bundles and specifically 
concentrated around arterioles. Within the ischaemic adductor muscles, 19% ±5 of 
NVBs were associated with LacZ +ve cells. Each section of LacZ positive 
NVBs 
contained 16 ±7 LacZ +ve cells. Less than 1% of NVB of normally perfused muscles 
had LacZ +ve cells and there was only 1-4 cells associated with them. It was not 
possible with the methods used to reliably estimate what percentage of 
the injected 
cells actually remained within the limb. 
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Figure 94 rMPCs engraft into ischaemic but not normally perfused muscles 
Four weeks after injection of 10 X106 rMPCs into adductor muscles tissues were 
harvested and stained with X Gal and counterstained with nuclear fast red. (a) Very few 
A Gal +ve, rMPCs remained when injected into normally perfused muscles. (b) rMPCs 
engrafted into the adventitial media border of arterioles in significant numbers. 
Occasional cells were also seen in between muscles fibres. 
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rMPCs do not differentiate into smooth muscle or endothelial cells in ischaemic 
muscle 
To investigate whether rMPCs had differentiated into smooth muscle or endothelial 
cells, sections from muscles harvested 4 weeks after cell injection were counterstained 
with antibodies against alpha smooth muscle actin (SMACT) and Von Willebrand factor 
(VWF) respectively. Despite the engraftment of rMPCs into the media-adventitial 
border of arterioles the cells were negative for smooth muscle actin. No LacZ +ve cells 
were seen lining the lumen of arterioles and they were negative for VWF. This 
indicated that they had not differentiated into smooth muscle or endothelial cells. In 
addition LacZ labelled skeletal myocytes, based on assessment of cell morphology 
under light microscopy, were not detected (Figure 95). 
rMPCs continue to secrete cytokines after transplantation into ischaemic 
muscles 
As rMPCs engrafted into ischaernic muscles, they may continue to secrete cytokines in 
vivo. Five and 15 days after injection of 1 OX1 06 rMPCs or PBS control into ischaernic 
limbs, muscles were harvested, homogenised and submitted to cytokine analysis. 
Cytokines for analysis were selected based on their known role in wound healing, 
inflammation and stem cell signalling. At 5 days SDF-1 (6 fold increase, p< 0.01), 
MCP1 (3.8 fold, p<0.01) and MIP2 levels (8.4 fold, p<0.05) were found to be 
significantly elevated, compared with limbs injected with PBS (Figure 96a). Fifteen 
days after injection there was no difference in cytokine levels between animals injected 
with rMPCs or PBS (Figure 96b). Although rMPCs secrete numerous other cytokines 
including HGF, VEGF and FGFb, increased levels of these cytokines were not 
detected, after either at 5 or 15 days. 
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Figure 95 In vivo fate of transplanted rMPCS 
Sections from ischaemic hind limbs injected with rMPCs were stained with smooth 
muscle actin (SMact) and VWF. No blue rMPCs were found lining the lumen of vessels 
and blue cells did not co-localise with VWF antibody staining. Despite the engraftment 
of rMPCs into the media-adventitial border of arterioles the cells were also negative for 
SMact. This indicates that they had not differentiated into smooth muscle or endothelial 
cells. a-b) rMPCs can be seen localised around arterioles, a) counter stain with nuclear 
fast red b) no counter stain c) overlay of SMact immuno-fluorescence (IF) (orange) with 
light microscopy d) SMact IF overlay with green auto-fluorescence of skeletal muscle e) 
X-gal blue stain fades after antigen retrieval required for VWF staining 0 VWF (orange) 
can be seen lining the lumen of the arteriole (same section as e). There is no co- 
localisation of blue rMPCs with IF for either SMact or VWF. 
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Figure 96 Graph of in vivo cytokine levels showing rMPCs continue to secrete 
cytokines after transplantation 
5 and 15 days after transplantation Of IOXI06 rMPCs or PBS control into ischaemic 
limbs, muscles were harvested, homogenised and submitted to cytokine analysis. 
Increased levels of the chemokines MCP1, SDF1 and MIP2 are still detectable 5 days 
after injection (a) although by 15 days there was no significant increase in cytokines 
over control (b). Results expressed as relative fold increase of rMPCs transplanted 
limbs compared to limbs injected with PBS. Statistically different cytokines are 
highlighted in yellow. 
A) 
Day 5 
PBS rMPCs Fold A p value 
mcp1 1854+/-498 7046+/-367 3.8 0.001 
Osteopontin 10657 +/- 3978 8498 +/- 3194 0.8 0.7 
SDF-1b 161 +/-58 969+/-89 6 0.002 
Gro/KC 70+/-19 123+/-58 1.8 0.44 
MIP2 10.4 +/- 0.46 88+/-20 8.4 0.02 
MIP3a 0 0 
HGF 797+/-177 616+/-232 0.77 0.66 
FGFb 3298 +/- 2041 1663+/-427 0.5 0.48 
VEGF 16+/-16 0 0.37 
TPO 2082+/-614 2586+/-443 1.24 0.54 
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B) 
Day 15 
PBS rMPCs fold p value 
mcpi 638 ± 339 739 ± 102 0.2 0.79 
Osteopontin 421 44 560 ± 145 1.3 0.42 
SDF-Ib 167 165 779 ± 499 4.6 0.3 
Gro/KC 667 ± 406 429 ± 262 0.64 0.65 
MIP2 81 ± 51 17 ± 3.5 0.21 0.29 
MIP3a 0 0 0 n/a 
HGF 0 0 0 n/a 
FGFb 1406 ± 637 862 ± 277 0.61 0.48 
VEGF 0 0 0 n/a 
TPO 1163 ± 576 2516 ± 677 2.2 0.21 
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rMPCs interact with the VEGF-SDFI system in ischaemic tissues 
Following induction of ischaemia, tissue levels of both VEGF and SDF1 rise 
significantly (Figure 97). In addition, injection of rMPCs further potentiates the levels of 
SDR. Flow cytometric analysis of rMPCs indicates that they express both the VEGF 
receptor VEGFR1 and interestingly the SDF1 receptor CXCR4. It is possible that 
rMPCs interact and potentiate this endogenous secretion of VEGF and SDR. This 
may explain the dense infiltrate of CID1 1b cells around large collections of engrafted 
rMPCs during the acute stages after limb ischaernia. CID1 1b myeloid cells are believed 
to migrate and home to ischaernic tissues via VEGF-SDF1 signalling [19]. 
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Figure 97 rMPCs interact with the VEGF-SDF1 system in ischaemic tissues 
(a) Five days after induction of ischaemia VEGF and SDFI levels are increased. 
rMPCs also further increase SDF1 levels but do not potentiate VEGF levels. SDFI is 
undetectable in normally perfused muscle. Mean ± sem. * p<0.05, n=6. (b) rMPCs 
express VEGFR1 and CXCR4. rMPCs cultured for 120 pd were labelled with 
antibodies against CXCR4, VEGFRI or isotype control. (q) CD1 Ib+ inflammatory cells 
(red) co-localising with rMPCs (blue) I week after transplantation. OCT embedded 
frozen sections from ischaemic muscles injected with rMPCs were incubated with X- 
Gal and then stained with anti CD IIb followed by peroxidase/biotin amplification and 
staining with Novared substrate. 
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Discussion 
Summary of results 
1. rMPCs increase the regional muscle perfusion when transplanted into a model 
of limb ischaemia measured by fluorescent microspheres 
2. rMPCs increase the capillary density of ischaemic hind limb muscles 
3. However, rMPCs do not increase the perfusion of the skin of the hind limb 
measured by laser Doppler imaging 
4. rMPCs transplantation normalises the MRI time course signal-intensity curves 
after Gd-DPTA bolus 
5. rMPCs do not result in overall regeneration of the ischaemic atrophied muscles 
and they do not improve maximal exercise capacity assessed by running on a 
rodent treadmill. 
6. However, rMPCs do engraft into the neurovascular bundle of ischaemic, but not 
normally perfused muscles. They do not differentiate into a smooth muscle or 
endothelial phenotype. 
7. rMPCs continue to secrete cytokines up to 5 days after transplantation, which 
may have a role modulating local angiogenic and inflammatory responses 
Recently there has been intense interest in the therapeutic use of bone-marrow derived 
cells for augmentation of angiogenic and regenerative responses during treatment of 
myocardial and peripheral ischaemic disease [200]. In the present study the effects of 
bone marrow derived cells with apparent pluripotent properties in a hind limb model of 
ischaemia were investigated. Although rMPCs can be differentiated in vitro, they do not 
differentiate in vivo, despite engraftment and improving perfusion. It is possible that the 
improvement in perfusion may result from paracrine mechanisms due to the secretion 
of inflammatory cytokines which modulate inflammation and wound repair. 
rMPC phenotype 
Employing similar methods used to isolate MAPCs, [45] a mixed culture of cells that 
appear to contain pluri-potent progenitors were isolated. These rMPCs were isolated by 
propagating the adherent cells from bone marrow cultured on human fibronectin coated 
flasks in media previously used for the isolation of MAPCs. However, a single cell 
cloning step was not undertaken as previously described for MAPCs [45] and more 
recently hBMSC [113] as in rodents, single cell cloning tended to select 
for 
cytogenetically abnormal cells. Using this non-clonal approach, the isolated cells could 
be grown indefinitely in vitro without signs of senescence or change in phenotype. 
Importantly, rMPCs maintained a stable karyotype when analysed by G-banding or 
spectral karyotyping. However, a few cells with isolated chromosomal abnormalities 
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were identified, indicating the tendency of cultured cells to acquire cytogenetic 
abnormalities; this is in keeping with embryonic stem cells [155] and MAPCs [119]. As 
no clonal abnormalities were identified in rMPC cultures (defined as being present in 
more than 2 cells) the lines were considered normal according to the International 
System for Human Cytogenetic Nomenclature (ISCN 2005) [151]. 
The rMPCs isolated are CD45 negative indicating they are not of a haematopoietic 
lineage. However, rMPCs do express MHC Class 1, CD44 and CD90 which are also 
expressed on MSCs [7](but not MAPCs [45] or hBMSC [113]). In addition rMPCs can 
be differentiated into bone and fat forming cells indicating they have some similarities 
with MSCs. In contrast to MSCs, which have a differentiation ability restricted to the 
mesoderm lineage, the rMPCs used for this study did appear to have the potential to 
differentiate into cells with features of all three germ cell lineages, indicating a far wider 
potential of differentiation than MSCs [7]. It was not possible to up regulate tissue 
specific antigens of ectoderm, endoderm and mesoderm measured by both RT PCIR 
and by immuno-fluorescence. Although it was possible to up regulate tissue specific 
antigens, analysis of the IF images indicated that only a small percentage of cells had 
differentiated. The original descriptions of MAPCs indicated that in vitro the majority of 
cells (60-90%) could be directed to change their phenotype. Our results would indicate 
that our cultures clearly did not have the impressive differentiation ability of MAPCs and 
with the absence of Oct4, may indicate that rMPCs are not pluri-potent stem cells, but 
perhaps a mixture of different progenitors. In addition not all antigens that were up- 
regulated by PCR could be detected by IF. For example, VWF or CD31 up regulation 
by IF after endothelial differentiation or HNF1 after hepatocyte differentiation, was not 
observed. This was despite the upregulation of the antigens detected by PCR. This 
would indicate that the cells had either not fully differentiated into a mature phenotype 
or that there was not complete 'physiological' differentiation, but upregulation of tissue 
specific antigens. This might explain why engrafted cells did not differentiate in vivo. 
Although there are no reports of other groups isolating cells with exactly the same 
phenotype as MAPCs, cells with tri-lineage potential have been isolated by other 
groups [113-115] and hBMSC were shown to be beneficial in a rodent myocardial 
infarct model by inducing therapeutic revascularisation and card iomyogenesis [113]. In 
order to investigate the potential of rMPCs to improve function of an ischaemic tissue a 
hind limb ischaemia model was developed to allow the syngeneic transplantation of 
cells. 
A hind limb model was developed initially as a phase I clinical study may have followed 
if the animal models were encouraging. Transplanting potentially pluripotent stem cells 
196 
was considered to have a number of theoretical but plausible risks. These included 
aberrant differentiation, teratoma formation and foci for abnormal electrical activity. 
Injecting these cells into a skeletal muscle bed was therefore considered safer for early 
clinical studies and we elected to study a hind limb model with a view to proceeding to 
a clinical study in patients with peripheral vascular disease. 
After exploring various surgical approaches for inducing hind limb ischaemia, I selected 
a procedure that resulted in significant sustained ischaemia as measured by both 
fluorescent microspheres and laser Doppler imaging. This resulted in a significant 
functional impairment measured by distance ran on a rodent treadmill. Although the 
primary insult to the muscle is ischaemic, I found that the acute nature of the surgery 
also resulted in a profound inflammatory response due to the ensuing muscle damage 
and necrosis. The host inflammatory response is a fundamental part of these animal 
models and hence cell transplantation experiments are in the context of acute 
inflammation as well as ischaemia [203]. 
Effects of rMPC on hind limb perfusion 
10 million rMPCs were injected into the ischaemic adductor muscle, a dose that is 
similar to previous studies in rats [174,205]. Despite the impressive benefits of other 
cell types on perfusion and function in similar rodent hind limb models [174,205,206], 
only a modest beneficial effect on perfusion was seen. Although rMPCs increased 
perfusion of the muscles measured by microspheres, it was not possible to 
demonstrate any improvement in perfusion by laser Doppler imaging. These 2 
techniques measure perfusion by different mechanisms. Microspheres measure 
perfusion per gram of muscle (and are generally considered the gold standard' of 
perfusion measurement) whereas the laser Doppler imaging measures the velocity of 
blood flow in the skin of the distal hind limb which is used as a marker for the overall 
limb blood flow. Although skin is predominantly supplied by perforating arteries from 
underlying muscle the 2 measures actually are from different vascular beds. Although 
the rMPCs increased the perfusion per gram of muscle, they did not result in overall 
recovery of limb perfusion or of regeneration of the ischaemic limb within the limited 
follow up period of 4 weeks. Because the blood flow to skeletal muscle can vary 
considerably under different conditions standardised measurements were made by 
controlling for variations in body temperature. Control experiments, using LDI, 
demonstrated significant variations in limb perfusion with changes in core temperature. 
All LDI and microsphere experiments were performed at 37.5 OC which resulted in 
reproducible data. However, there is considerable variation in muscle and limb blood 
flow with exercise, even in an ischaernic limb [207]. It is possible that measuring 
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perfusion after exercise may have resulted in an increase in relative perfusion by LDI of 
limbs transplanted with rMPCs compared to PBS. 
IVIRI based assessment of the ischaernic hind limb 
As a result of the heterogeneous signal in ischaernic limbs, it was not Possible to 
calculate a reliable measure of perfusion index using Gd-DTPA enhanced MRI. Mainly 
as a result of the rapid hyper-enhancement, presumably due to increased capillary 
permeability in ischaemic limbs. Although MRI assessment of perfusion after Gd-DPTA 
injection has been used previously in a rat hind limb model [182] this model used a 
femoral artery ligation, rather than excision as their intervention. This results in a less 
severe insult to the hind-limb, as well as less ischaemia, at rest although hyper- 
enhancement was also seen but to a lesser degree. Analysing the animals after 
exercise (e. g. by sciatic nerve stimulation [182]) may have allowed for a larger signal 
difference between the ischaemic and non-ischaemic limbs. Alternatively utilising a 
step-input function after post ischaernic hyperaemia may have allowed us to increase 
limb perfusion and document a difference in PI [176]. 
A novel analysis method was therefore developed, based on the correlation coefficient 
of the time signal intensity histograms of the ischaemic and normal limb muscles. This 
approach assesses the variation in signal intensity and its distribution due to multiple 
factors including perfusion and capillary permeability. I was able to demonstrate that 
rMPC transplantation results in a significant restoration of the signal histograms of 
ischaernic limbs. Interpretation of PI measures based on contrast enhancement can be 
flawed in models with a mixed response to ischaemia. Using the correlation coefficient 
of the ischaernic limb, compared the non-ischaemic control limb, allowed to 
assessment of the complex and heterogeneous response to ischaemia seen in our 
model. As inflammation is a major response to acute ischaemic insults and capillary 
permeability a fundamental component of inflammation [1981, transplantation of rMPCs 
may modulate this process via paracrine mechanisms in a favourable manner. In 
addition, as late hyper-enhancement due to Gd retention in necrotic/infarcted fibres 
occurs in ischaernic muscles, the normalisation of the signal after rMPC transplantation 
may imply that there are less necrotic fibres than in the PBS treated group. Further 
experiments linking MRI guided histological analysis and assessment of capillary 
permeability (e. g. with Gd labelled albumin) would be useful to establish the exact 
mechanism for the improvement of the MRI images seen with rMPC transplantation. 
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rMPCs do not regenerate the ischaemic atrophied muscle or increase exercise 
capacity 
Despite the normalisation of the MRI time signal intensity histograms documented, the 
atrophy and wasting of the ischaemic limb was not reversed by rMPCs as measured by 
the cross sectional area of the hind limb. This result fits with the observation that 
rMPCs do not regenerate muscles as measured by wet muscle weight 4 weeks after 
transplantation. This would indicate that the local increase in muscle perfusion seen 
after cell transplantation (as measured by microspheres) is insufficient to increase the 
overall perfusion of the limb (as measured by LDI) and does not result in regeneration 
of the atrophied muscles. It is perhaps therefore not surprising that rMPCs do not 
improve exercise performance. Although the follow up of the study was 4 weeks, it is 
possible that this was an insufficient time for the benefit of cell therapy to be 
demonstrated in this study. A longer term follow up of 3-6 months may reveal a more 
significant response. In addition, based on previous published data in rodent hind limb 
ischaernia models, power estimations were based on the assumption that at least a 
25% increase in function of the ischaernic limb would be seen after cell transplantation 
[174,205,206]. This assumption was over optimistic and hence it is quite possible that 
the sample size used was under powered to detect any positive effect. 
rMPCs fate after transplantation 
IrMPCs did engraft selectively into the neurovascular bundle, primarily into the 
adventitia of arterioles, of ischaemic muscles. Only the occasional cell was detected 
after injection into normally perfused muscles indicating rMPCs selectively engraft only 
into ischaernic limbs. Despite engraftment 4 weeks after transplantation, the majority of 
cells did not differentiate into either endothelial cells or smooth muscle cells. 
Although 
differentiation of rMPCs into smooth muscle cells was not attempted in vitro, the rMPCs 
may have adopted a smooth muscle phenotype due to their anatomical 
location in vivo, 
predominantly surrounding arterioles. However, as the engrafted cells were clearly 
SMact negative, this would suggest that they had not differentiated 
into a smooth 
muscle phenotype. This would indicate that any increase 
in perfusion was more likely 
the result of paracrine effects rather than rMPC forming 
de novo blood vessels which is 
increasingly becoming the most accepted explanation for any beneficial effects of cell 
therapy [202]. 
Although no specific staining for skeletal myocytes was undertaken, 
no blue/LacZ 
labelled myocytes were detected under light microscopy. 
This would indicate that 
rMPCs can not differentiate into muscle cells or 
fuse with the recipient's cells and that 
rMPCs can not directly regenerate skeletal muscle after 
an ischaemic insult. 
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This study was not designed to rule out cell fusion, which may explain the persistence 
of LacZ labelled cells after transplantation into ischaernic limbs. However, fusion is 
usually a rare event and most commonly documented as being due to fusion of 
monocytes with host cells [129]. It is unlikely that the majority of engrafted cells are the 
result of fusion events although this can not be discounted. Fusion could be 
investigated by undertaking FISH staining for both X and Y chromosomes. Tetraploidy 
nuclei with 3X and 1Y chromosome would imply fusion of a transplanted rMPC (XY 
male) with the host XX (female) cells. Regardless of the potential role of cell fusion this 
does not change the apparent observation that there may be profound paracrine 
effects of cells therapy. 
rMPCs secrete multiple cytokines 
In keeping with other studies of BM derived cells [80,206], rMPCs also secrete multiple 
cytokines in vitro that are known to modulate inflammatory and angiogenic processes. 
These include members of the chemokine family, such as MCP-1 and SIDF1, as well as 
known angiogenic cytokines such as VEGF, FGFb and HGF. MCP-1 is known to recruit 
monocytes to the peri-vascular compartment, which in addition to their role in 
inflammation, orchestrate processes that ultimately lead to collateral vessel growth 
[208]. Subsets of EPCs are also believed to be derived from monocytes [21]. 
Endothelial cell proliferation is a crucial component of angiogenesis and is followed by 
smooth muscle cell proliferation and migration [31]. Both VEGF and FGFb enhance 
proliferation of endothelial cells and FGFb enhances smooth muscle cells proliferation. 
In addition both of these cytokines can enhance collateral formation in response to 
ischaemia [209]. 
Also in vivo SDR, MCP1 and MIP2 can still be detected 5 days after transplantation of 
rMPCs. SDF1 is a chemokine that has been shown to be important for the homing of 
cells via the chemokine receptor CXCR4. CXCR4 is expressed on Hz-jus ana 
endothelial progenitor cells, which can both home to areas expressing 
SDF1 [210, 
211 ]. It has been speculated that EIPCs may play a role in maintaining the endothelial 
layer and participate in neo-vascularisation after injury or 
ischaemia [8]. SDF1 
expression is known to be transiently increased in ischaemic muscles, 
but this effect is 
generally short lived [156]. Local VEGF production 
in ischaemic tissues is believed to 
be the key cytokine controlling SDF-1 release [19]. Perivascular myofibroblasts 
secrete 
VEGF which subsequently induces the expression of 
SIDF-1. VEGIF recruits circulating 
bone marrow derived cells, predominantly myeloid mononuclear 
cells, which are then 
retained in close proximity to angiogenic vessels. 
Retention is mediated via the 
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chemokine receptor CXCR4 interacting with locally produced SDF-1. These retained 
myeloid cells then enhance the local proliferation of endothelial cells via secreting pro- 
angiogenic cytokines [19]. Increasing SDF-1 expression in ischaemic tissues with cell 
transplantation is likely to augment the physiological recruitment, homing and trapping 
of bone marrow derived cells, as will increasing MCP expression. In this study rMPCs 
do continue to secrete SDF-11 and MCP after transplantation into an ischaernic hind 
limb and that CD1 1 b+ cells co-localise with rMPCs. The recruitment of myeloid cells by 
rMPCs is likely to further improve perfusion via the stimulation of local endothelial cells 
[19]. Developing a semi-quantitative histological method to assess the role of 
endogenous BM derived cells in this process would help establish their significance. As 
rMPCs also express VEGFR1 and CXCR4, the recruitment and retention of rMPCs to 
the perivascular area of blood vessels may also be mediated via the VEGF-SDF1 
system (Figure 97). Further repeat experiments using either blocking antibodies to 
VEGF or using AMD3100 a selective CXCR4 inhibitor (the receptor for SDR) could 
establish the importance of this mechanism in this model. In vitro experiments could 
also be undertaken using transwell co-culture systems and cell migratory assays to 
investigate the role of VEGF and SDF1 in the homing of rMPC and also their paracrine 
effects on inflammatory BM derived cells. 
As rMPCs secrete inflammatory cytokines, it is possible that this primarily results in the 
recruitment of more inflammatory cells to the ischaemic lesion. Independent of any 
angiogenic or vasculogenic processes, the increased blood flow may simply be due to 
vasodilatation classically associated with inflammation. This may explain the increase 
in perfusion seen, especially as no muscle regeneration or functional improvement was 
seen. A later follow up, when all inflammation may be expected to resolve, would be 
helpful in establishing how much of the increase in perfusion is due to this. As the 
rMPCs transplanted were isolated from syngeneic donors the role of tissue rejection 
was minimised in this study. However, cell mediated immunity may have a profound 
bearing on the use of tissue mis matched cells in either animal or human studies. 
How rMPCs fit together in a hierarchical system with other adherent cells isolated from 
bone marrow culture is not clear. Indeed it is still not known what the phenotype of 
these various cells are (MSCs, MAPCs, BMSC or MPCs) in vivo. Because they are 
expanded from rare adherent cells by prolonged culture it has been speculated that 
they may be 'created' by a reprogramming process as a result of culture conditions 
[45]. Many details of the culture process become extremely important, such as the 
media used, cytokine supplements, serum lot and passaging frequency. 
This may 
explain why it is difficult for other groups to reliably isolate pluri-potent 
bone marrow 
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derived cells with similar phenotypes. I have found significant differences in cytokine 
profiles by analysing culture media supernatant of different BM derived cell lines. I 
speculate that the large variation in outcomes between different studies may be a result 
of fundamental differences in the secreted cytokine profiles of different MSC-like 
cultures. 
As mentioned the outcome in our study is significantly less impressive of other studies 
using similar models of hind limb ischaemia [81,174,205,212,213], injecting a variety 
of cells including MSCs, BM mononuclear cells and cultured EPCs. However, this is 
the first study exploring the effects of potential pluripotent BM derived progenitors in a 
hind limb ischaemia model. There are many potential explanations for the difference in 
outcome in our study. These include technical details of the animal model e. g. surgical 
approach, severity of ischaemia, background strain of rodent and timing and site of cell 
injections. In attempting to develop a model with persisting chronic ischaemia, the 
model may have resulted in too severe an environment for cell therapy to be fully 
effective. In addition, as mentioned above, differences of the cell phenotype including 
surface markers, degree of karyotype stability, degree of pluripotency and secreted 
cytokine profile are all likely to have a bearing on outcome. Study design is also 
important; in contrast to all of the above mentioned studies, randomised treatment 
groups and blinded data analysis were used to avoid any bias. Finally, further 
experiments comparing different cell types would be invaluable to define how much of 
these observed responses are cell type specific. 
Conclusion 
rMPCs improve perfusion in an ischaemic hind limb model presumably through the 
release of multiple cytokines that potentially modulate numerous processes, including 
the inflammatory response to injury and angiogenesis. Although this study was not 
designed to specifically explore the role of cytokines in this setting, further studies 
might return to angiogenesis experiments using delivery of either naked protein or gene 
therapy. Proteins that might be considered for study include either SDF1 or MCP, as 
has been done with angiogenic cytokines, such as VEGF and FGF. It is possible 
that 
controlled modulation of inflammatory responses may favourably affect angiogenesis 
[19]. 
I find no evidence of significant trans-differentiation or new vessel 
formation from 
transplanted rMPC cells, despite engraftment possibly mediated through 
VEGFR1 and 
CXCR4 interactions. Although the increase in perfusion following cell therapy was not 
reflected by an increase in function, it is possible that modulation of 
local responses to 
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ischaernia by secreted cytokines, such as VEGF and SDF-1, may prove a potentially 
important mechanism. Using cell therapy to treat ischaemic cardiovascular diseases 
may still be of clinical benefit, even if the majority of transplanted cells do not 
differentiate. 
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Chapter 6 General discussion 
Summary of thesis results 
In this thesis the biology of bone marrow derived EPCs and MAPCs has been 
explored. Ex-vivo cultured 'EPCs' express markers of endothelial cells and also 
monocytes/ macrophages. In addition, results from gene tracking experiments utilising 
the ere-lox system, suggest that EPCs may originate from a monocytic cell lineage and 
be important for normal vessel development and homeostasis. The cell cycle inhibitor 
p27 kiP regulates the number of these EPC colonies. It was not possible to find a novel 
marker for EPCs as TEMs were not expressed in human or mouse EPCs. A novel 
marker for EPCs is needed in view of the controversy over what defines an EPC- As 
MAPCs have been suggested to be the precursor cell of EPCs the isolation and study 
of MAPCs was attemtped. Cells with the precise phenotype of MAPCs could not be 
isolated from murine bone marrow by following the published protocol. In addition the 
cultured murine bone marrow cells were extremely susceptible to major cytogenetic 
abnormalities. Attempts to identify potential MAPCs within BM cultures by using 
established markers of stem cells (Oct 4 and SSEA1) also failed to identify any positive 
cells. However, a novel cell line was isolated from rat bone marrow named 'multi-potent 
progenitor cells' (rMPCs). This line could be maintained in culture long term with a 
stable phenotype and karyotype. Specific antigens could be up-regulated after tissue 
specific differentiation into cells of all 3 germ cell lineages, indicating the cells may 
have some pluri-potent potential. These rMPCs did not express the stem cell 
pluripotency gene Oct 4 and have different surface markers to MAPCs. rMPCs 
increase the regional muscle perfusion when transplanted into a model of limb 
ischaemia measured by fluorescent microspheres and increase the capillary density of 
ischaemic hind limb muscles. However, rMPCs do not increase the overall perfusion of 
limb measured by laser Doppler imaging and do not result in regeneration of the 
ischaernic atrophied muscles. Also they do not improve maximal exercise capacity 
assessed by running on a rodent treadmill. Transplanted rMPCs do engraft into the 
neurovascular bundle of ischaemic muscles, but they do not differentiate. rMPCs 
continue to secrete cytokines after transplantation and this may have a role 
in 
modulating local angiogenic and inflammatory responses. In addition during work on 
this thesis a new model of cardiovascular disease was developed based on rat 
hind 
limb ischaemia. As part of this model multiple methods of assessment were 
established, including laser Doppler imaging, fluorescent microspheres, 
histological 
analysis and MRI. This work contributes to the understanding of 
EPCs, MAPCs and 
hind limb ischaemia models. 
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Discussion 
The concept of creating new blood vessels through the infusion of specific growth 
factors was the basic premise that initiated the field of angiogenic research. 
Subsequent work then indicated that stem and progenitor cells may also be able to 
form new blood vessels by vasculogenesis. A process previously thought to occur 
exclusively during development. Despite the initial enthusiasm for the potential benefits 
of cell therapy, the challenges ahead for researches in the field are significant as the 
science has become more complex as the fields have evolved. However, the concept 
of using cell therapy to improve the function of diseased organs is now firmly 
established as a therapeutic goal for all chronic diseases. Cardiology research is at the 
forefront of cell therapy research and many clinical studies have been completed or are 
underway. The basic premise being that transplantation of stem cells, or cells capable 
of trans-differentiation, may be able to regenerate not only diseased cardiac muscle but 
also restore a functioning vasculature. Despite the fact that clinical studies for the 
treatment of chronic cardiac ischaernia have started, there are many fundamental 
questions to be answered before the concept of cell therapy can be reliably and safely 
translated into clinical practice. These include, the optimal cell source to use, the 
mechanism of action of cell therapy, the effects of cells on tissue regeneration and the 
in vivo mechanisms of cell homing and engraftment. In addition, what are the clinical 
indications and what are the optimal therapeutic dose, frequency, timing and 
mechanism of delivery for cell therapy? Finally there are multiple issues concerning 
potential harmful effects of cell therapy. 
At present none of these questions have been fully answered. In particular it is not 
clear which cell source will prove optimal as endothelial and cardiomyocyte progenitor 
cells. The focus of this thesis has been to further explore our understanding of adult 
bone marrow derived cells capable of differentiating into endothelium, which in turn 
may be used to improve perfusion of ischaemic organs. Although there is considerable 
overlap of cells that may be potentially capable of differentiating into cardiomyocytes 
this thesis focused primarily on the vasculature and endothelial differentiation. The 
bone marrow is a potentially attractive source of cells because it is easily accessible, 
can be harvested in an autologous, patient-specific manner and contains many cell 
types potentially capable of endothelial like differentiation. This thesis 
focuses on 
Endothelial Progenitor Cells (EPCs) and Multi-potent Adult Progenitor cells (MAPCs). 
Endothelial progenitor cells 
One of the intial aims of this thesis was to undertake a 
detailed analysis of the gene 
expression of EPCs using serial analysis of gene expression 
(SAGE). This was based 
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on the assumption that the phenotype of EPCs was CD34/CD133NEGFR2+. However, 
analysis of our cultured EPCs (from both mouse and humans) indicated that these ex- 
vivo cultured cells may originate from monocytes, rather than rare CID133/ VEGFR2+ 
cells. In addition, pure human CD133+ cells failed to differentiate into an endothelial 
phenotype questioning whether CID133+ haematopoietic progenitors can directly adopt 
an endothelial morphology. A SAGE analysis of EPCs was therefore not warranted 
because of the controversy over the phenotype of EPCs. Although differentiation of 
human CID1 4+ cells into endothelial-like cells was not attempted in this work, numerous 
other groups have confirmed that monocytes can be differentiated into an endothelial 
like phenotype and many believe that monocyte/macrophages may actually be EPCs 
[21,214]. The picture now emerging is that cultured EPCs that take up LIDL and bind 
endothelial specific lectins are probably of a monocytic lineage, but these cells also can 
express endothelial specific markers. 
What is the relationship between CD34/CD133/VEGFR2 + cells and monocytic 
EPCs? 
The evidence linking CD34/CD133/VEGFR2 + cells and monocytic cultured EPCs is 
limited. Although it has been suggested that CD14 + cells with 'EPC' potential also 
weakly express CD34 [214] it is likely that they are not directly related. CD133/ 
VEGFR2+ cells are extremely rare in blood and CD133+ cells do not readily adopt an 
endothelial like phenotype in culture. CD133/ VEGFR2+ cells are unlikely to be 
endothelial progenitors, unless they differentiate through a monocytic intermediate. 
Despite this it appears that CD34/CD133NEGFR2 + cells measured by FACS and 
EPCs quantified by ex-vivo culture are both related to vascular risk [71,108,215]. 
Although it has been assumed that these circulating EPCs may play a role in vascular 
homeostasis other explanations for this association remain possible. For example the 
number of circulating endothelial progenitor cells may mirror a person's regenerative 
capacity more broadly rather than actually reflecting a patients circulating angiogenic 
potential. This may explain why cultured monocytic/ EPC counts often mirror 
CD133NEGFR2+ cell numbers in blood measured by FACS even though these cell 
groups are potentially unrelated. 
Do EPCs actually exist? 
Whether EPCs, defined as a haematopoietic cell that circulate in blood and can 
subsequently differentiate into endothelial cells, actually exist 
has also become 
controversial [18-20,203]. Many of the differences between studies can 
be explained 
by the different approaches and systems used. However, it remains contentious 
whether new endotheliurn can arise from circulating 
blood cells. A number of authors 
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have recently suggested that although bone marrow derived inflammatory cells 
(specifically myeloid intermediates) do localise close to vessels of ischaemic tissues 
[18] or turnours [20], they may not actually differentiate into endothelium as previously 
thought. Paracrine mechanisms have been suggested as the mechanism of benefit of 
these 'EPCs' whereby bone marrow derived cells secrete multiple cytokines at sites of 
injury to modulate the repair/ recovery process rather than by endothelial differentiation 
[19,166]. This includes modifying local angiogenic responses by the secretion of 
angiogenic cytokines such as VEGF. In humans, bone marrow derived endothelial 
cells have been identified in tumours [64] and heart transplants [65] (using Y 
chromosome FISH) although with a much lower frequency than some animal studies 
have suggested. In addition these events could have occurred through cell fusion of a 
bone marrow derived cell with an endothelial cells [16] which is also likely to be myeloid 
intermediate (216]. Further studies using mice bone marrow transplants of Cre 
expressing cell lines into R26R reporter strains to investigate the role of fusion of 
myeloid cells to endothelial cells would help investigate the role of cell fusion in these 
cell transplant experiments. 
What is the role of EPCs on vasculature homeostasis? 
Previous clinical studies have shown that traditional risk factors for coronary 
atherosclerosis are associated with low levels of circulating endothelial progenitor cells 
[67], whereas protective interventions, including statin therapy [66] and exercise [100], 
appear to increase the supply of these cells. In healthy volunteers, levels of EPCs are 
inversely correlated with the Framingham risk score and actually appeared to predict 
vascular function better than the Framingham risk score [67]. In patients with 
established coronary artery disease EPC numbers are inversely related to prognosis 
[74] although at present the precise mechanism of this is not established. Together, 
these data suggest that circulating endothelial progenitor cells may participate not only 
in forming new blood vessels but also in maintaining the integrity and function of the 
vascular endothelium, thereby mitigating disease processes such as atherosclerosis 
and its complications. However, the actual role of EPCs on vessel homeostasis is still 
not clear. Many authors have shown that transplantation of cells with 'EPC' phenotypes 
may home and engraft at sites of injury and ischaemia, although the degree of this 
incorporation remains controversial. However, the contribution of a circulating blood 
cell to the endothelium during development has not been fully studied. 
In addition, the 
role of EPCs at maintaining the endothelial compartment during non 
injury states in 
adults is unclear. Novel experiments in mice were designed, using 
lineage ancestry 
tracing based on the Cre/Lox system to attempt to answer some of these questions. 
F4/80 monocytes do appear to have a role in maintaining the endothelial 
layer under 
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non-injury conditions. If the endothelial phenotype of these cells is confirmed this would 
imply that monocytes are indeed endothelial progenitor cells. Taken together with the 
PCR and IHC analysis of EPCs, and observations of others, thet monocytes are the 
most likely phenotype of EPCs. In this regard further experiments using the lineage 
ancestry models to investigate the role of haematopoietic cells in vascular homeostasis 
and other disease states would be interesting. 
Mechanisms for controlling the mobilisation of EPCs 
The evidence now seems to be converging on a monocytic like cell being the most 
likely candidate for the putative EPC, however, there are still many questions 
concerning the control of these cells and their precise mechanism of action. In this 
work a rather crude approach to investigate the role of the cell cycle inhibitor protein 
p27 kip on EPC numbers was used. The results indicated that the number of cultured 
'EPC colonies' does increase in p27 kip-/- mice but the in vivo significance of this finding 
is unclear, primarily as there is no method for identifying EPCs in vivo. However, as 
part of this study, collaborators found that the number of tissue macrophages was 
increased in the p27 kip-/- mice after vascular injury [122]. Further experiments include 
crossing the p27 kip4- mice with the F480cre-R26R mice and then quantify the number of 
cells originating from F480 EPCs. It is quite likely that cell cycle inhibitor proteins will 
have a role in controlling the EPC pool as has been found for p2l [53]. However, the 
process whereby a bone marrow derived cell is mobilised from its niche, migrates in 
the blood and engrafts into an ischaemic tissue and results in improved perfusion is a 
complex process which is only starting to be unravelled (reviewed [217]). Bone marrow 
derived cells are known to migrate to areas of damage and ischaemia as part of an 
organisms inflammatory response to injury [18]. However, recent experiments have 
shed light on the mechanisms of this process. It appears that ischaemia alone is 
sufficient to cause the migration of bone marrow derived inflammatory cells [203] and 
that this process is primarily controlled by the local release of VEGF [19]. VEGF not 
only causes the mobilisation and homing of inflammatory cells to the ischaemic tissue 
(via their expression of the VEGF receptor VEGFR1), but VEGF also induces the local 
production of the chemokine SDF-1, which results in the trapping of cells within the 
ischaernic tissue via the SDF-1 receptor CXCR4 [19]. In addition it would appear that 
the predominant cell type recruited by this mechanism are CD11b + monocytes 
[19, 
203]. These CID11b monocytes then improve perfusion cells by release of pro- 
angiogenic cytokines, which result in proliferation of local endothelial cells 
[19]. These 
myeloid cells may also differentiate into endothelial cells 
(c. f. EPCs), although as 
mentioned this remains controversial. 
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Novel markers for EPCs 
Although evidence suggests that EPC may be monocytes, there is still a paucity of 
markers that might identify monocytic cells with EPC potential. Although tumour 
endotheliurn may also be derived from EPCs I was unable to find expression of tumour 
endothelial markers (TEMs) in various cells from humans and mice. Other groups have 
tried to look for fractions of monocytes that may harbour the EPC potential [214], but 
there is clearly more work to be done on finding a precise phenotype of EPCs. Having 
a specific marker for a circulating EPC would not only allow a normal range to be 
defined but also allow interventions that purport to increase EPCs to be more 
accurately assessed. 
The basis for cell therapy 
Even though there are many outstanding questions in the EPC field, our understanding 
of vascular biology has increased dramatically and a number of clinical studies have 
commenced. These have been based on attempts to increase EPC numbers in 
patients with ischaemic disease, e. g. with exercise [109] or mobilising cytokines such 
as G-CSF [108]. Other groups have also tried the more ambitious approach of 
delivering cells which may have 'EPC' potential into ischaemic organs [83,93]. The use 
of cell therapy in humans is now established as a basis for clinical research studies. 
If cell therapy is to be considered for chronic ischaemic disease the optimal cell source 
to promote angiogenesis, vasculogenesis and card io-myogenesis needs to be 
identified. At present there are numerous potential candidates, each cell type has its 
benefits and disadvantages. Cell types presently under study include embryonic stem 
cells, haernatopoietic stem cells, bone marrow mononuclear cells, EPCs and 
mesenchymal stem cells, including potentially multi-potent fractions of MSCs as 
discussed in this thesis. Multi-potent adult progenitor cells (MAPCs) were selected for 
further study in this work. Since the first description of the endothelial progenitor cell 
[8] 
there have been numerous reports of cells originating from bone marrow that have the 
ability to differentiate into endotheliurn or at least adopt an endothelial-like phenotype. 
The multi-potent adult progenitor cell described by Professor 
Verfaillie in 2002 [45] was 
perhaps the most exciting because of its tri-lineage pluripotency and significant 
similarities with embryonic stem cells. The authors 
implied that an embryonic 'like' cell 
may reside in the bone marrow of adults and that this may 
be the precursor stem cell 
for EPCs [112]. The implications of this were significant in that, 
if independently 
confirmed, tissue specific cells could be produced 
from bone marrow in a patient 
specific manner. This would avoid many of 
the hurdles of embryonic stem cell 
research. Early MAPC publications suggested 
that they may actually be the source of 
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EPCs- To further explore these cells attempts to isolate MAPCs and study their 
potential angiogenic effects in a rodent hind limb ischaemia model were undertaken. 
Can pluri-potent stem cells be isolated from bone marrow? 
Despite multiple attempts, it was not possible to isolate MAPCs from murine or rat bone 
marrow. This may result from a lack of understanding of the properties of these cells 
and the optimal method to isolate them. Numerous experienced labs have attempted to 
isolate MAPCs, also without success. This inability of the MAPC isolation method to be 
replicated has been acknowledged in a review article in Nature, entitled the Problems 
with Replication [168], in which was published the original paper on MAPCs [45]. The 
Stem Cell Institute at the University of Minnesota, which first isolated these cells, is 
also challenged by repeating the isolation and phenotyping of these cells. As a result 
the protocol developed for MAPC isolation was not always based on controlled 
observations. In addition, it is not clear whether the cell actually exists in vivo or is 
created by the prolonged culture process. Isolation of MAPCs is also confounded by 
their absence of any specific cell surface markers. 
Regardless of the problems isolating MAPCs associated with there are other reports of 
bone marrow derived cells having more widespread pluripotency than previously 
thought possible. There are now multiple reports of MSCs capable of differentiation into 
cells of an ectodermal or endodermal origin although the biological significance of this 
is still debatable [218]. Three independent groups have published on bone marrow/ 
cord blood derived cells with tri-lineage pluripotency [113-115]. These groups isolated 
their cells by different methods to MAPCs. This indicates that bone marrow may be the 
source of cells that either are 'pluripotent' or can be re-programmed by specific culture 
processes. Although it was not possible to identify a cell with a phenotype like the 
MAPC, employing similar methods used to isolate MAPCs [45] a cell line was isolated 
with apparent pluripotent properties in vitro, but not in vivo, despite engraftment and 
improving perfusion. These cells were termed rMPCs. The improvement in perfusion 
probably results from paracrine mechanisms due to the secretion of inflammatory 
cytokines which modulate inflammation and wound repair rather than cell 
differentiation. This could include the increased recruitment and retention of bone 
marrow derived myeloid cells which may well differentiate into endotheliurn or at 
least 
secrete cytokines that result in the proliferation of local endothelial cells 
[19]. 
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Cytogenetic stability of cultured cells 
Importantly, the rMPCs isolated maintained a stable karyotype when analysed by G- 
banding or spectral karyotyping. However, there was always a few cells with isolated 
chromosomal abnormalities indicating the tendency of cultured cells to acquire 
cytogenetic abnormalities; this is in keeping with embryonic stem cells [155] and 
MAPCs [119]. With time it is possible that a cytogenetically abnormal clone would take 
over the culture of rMPCs. It is impressive how easily cultured cells can acquire 
dramatic cytogenetic abnormalities and detailed cytogenetic analysis is advisable for all 
bone marrow derived cell lines used for both in vitro and animal studies because of the 
potential confounding effects on the cells phenotype. For clinical studie, karyotyping 
should be mandatory because of the risk of malignant transformation. The malignant 
transformation of human MSCs in culture has recently been reported [219] and is likely 
to be major concern for future clinical trials of in vitro culture expanded cells. 
Much of cell biology and pre-clinical research to date has been based on experiments 
on cell lines maintained for prolonged periods of time. One could speculate that many 
of these cell lines would have major clonal cytogenetic abnormalities. Inevitably this will 
likely have a bearing on any observed results from experiments. Cytogenetic analysis 
of all routinely used cell lines could be considered mandatory as part of good laboratory 
practice. 
Do MSC cultures contain rare pluri-potent progenitor cells? 
The rMPCs isolated have numerous similarities to IVISCs including surface marker 
expression and the ability to differentiate into bone and fat forming cells. In contrast to 
IVISCs, which are generally considered to have a differentiation ability restricted to the 
mesoderm lineage, the rMPCs used for this study did appear to have the potential to 
differentiate into cells with features of all three germ cell lineages indicating a far wider 
potential of differentiation than MSCs [167]. However only a small percentage of cells 
differentiate and not all antigens become up-regulated. In addition the rMPC isolated in 
this study do not express Oct4 which might be expected in a pluri-potent stem cell. The 
absence of Oct4 in rMPCs and the fact they were not isolated from a single cell may 
indicate that rMPCs are not pluripotent stem cells but perhaps a mixture of different 
progenitors. It is unknown whether a rare fraction of Oct4 expressing stem cells exists 
within bone marrow in vivo. Although it is tempting to assume that they may contain a 
mixture of different progenitors it is likely that the differentiation assay is relatively un- 
physiological and more likely reflects the up-regulation of antigens rather than true 
differentiation. This might explain why engrafted cells did not differentiate in vivo. One 
could also speculate that transformation of cultured cells may induce 
the expression of 
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OCK either by a subtle cytogenetic change or epigenetic phenomenon, potentially 
explaining the MAPC phenotype reported by Professor Verfaillie [45]. 
How are different bone marrow derived cells related? 
How rMPCs fit together in a hierarchical system with other adherent cells isolated from 
bone marrow culture is not clear. Indeed it is still not known what the phenotype of 
these various cells are (MSCs, MAPCs, BMSC or MPCs) in vivo. Because they are 
expanded from rare adherent cells by prolonged culture it has been speculated that 
they may be 'created' by a reprogramming process as a result of culture conditions 
[220]. Many details of the culture process become extremely important, such as the 
media used, cytokine supplements, serum lot and passaging frequency. This may 
explain why it is extremely difficult for other groups to reliably isolate pluri-potent bone 
marrow derived cells. Although, there are no reports of other groups isolating cells with 
exactly the same phenotype as MAPCs, cells with tri-lineage potential have been 
isolated by other groups [113-1151 and shown to be beneficial in a rodent myocardial 
infarct model by inducing therapeutic revascularisation and endogenous and 
exogenous card iomyogenesis. 
Paracrine effects of cell therapy 
As part of this work the effects of transplantation of autologous rMPCs in a rat hind limb 
ischaernia model were also studied. Despite the impressive benefits of other cell types 
on perfusion and function in similar rodent hind limb models [174,205,221], only a 
modest beneficial effect on perfusion was demonstrated, but no improvement in 
function. Even though no effect on exercise function was observed, the rMPCs did 
engraft selectively into the adventitia of arterioles. However, the cells did not 
differentiate into either endothelial cells or smooth muscle cells. This would indicate 
that any increase in perfusion may have been the result of paracrine effects rather than 
rMPC forming de novo blood vessels. In keeping with other studies of BM derived cells 
(80,221] rMPCs also secreted multiple cytokines in vitro that are known to modulate 
inflammatory and angiogenic processes. These include members of the chemokine 
family, such as MCP-1 and SDR, as well as known angiogenic cytokines such as 
VEGF, FGFb and HGF as discussed in Chapter 5. In vivo SDF1, MCP1 and 
MIP2 can 
still be detected 5 days after transplantation of rMPCs. 
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Figure 96 Suggested model for the paracrine interaction of rMPCs in ischaernia 
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One could speculate that transplantation of cells, such as the rMPCs, delivers a 
favourable selection of cytokines to an ischaemic tissue which then modulates the 
recovery process. It is possible that these cytokines modulate local angiogenesis, 
inflammation and potentially vasculogenesis. This could be via the recruitment of local 
or bone marrow derived stem/ progenitor cells (e. g. EPCs) that subsequently form new 
blood vessels. In addition, via SDF1 secretion, cell therapy may also encourage the 
recruitment of monocyte which then deliver more cytokines to the ischaemic tissue to 
modulate local angiogenic responses [19]. 
Although the paracrine role of cell therapy is appealing as a potentially beneficial 
therapeutic intervention it is almost certainly more complicated. Not only is our 
understanding of the pathways, cytokines and cellular responses of ischaemic tissues 
growing rapidly, so is our understanding of the potential paracrine consequences of cell 
therapy. Understanding the effects of local delivery of a single cytokine, by either naked 
protein, plasmids or viruses, is complicated enough, let alone multiple cytokines 
released simultaneously. Although one could speculate that the cellular machinery may 
be able to sense the local environment and release cytokines appropriately, this is a 
major assumption. In addition the beneficial effects of cytokines in one 
location may be 
harmful in another. For example, MCP-11 is a chemokine that activates mononuclear 
phagocytosis by promoting leucocyte-endothelial binding and migration 
to sites of 
inflammation and rMPCs increase MCP-1 levels after transplantation 
into ischaemic 
213 
- Vascular Remodeling - 
muscles. MCP-1 is known to stimulate angiogenesis (222] and its increased expression 
may stimulate angiogenesis in a desirable manner in an ischaemic tissue. However, 
MCP1 also has detrimental effects after myocardial infarction [223] and can stimulate 
atherosclerotic progression [224] or intimal hyperplasia after vascular balloon injury 
[225] 
. Therefore delivery of MCP-1 in the context of cardiac ischaemia may have 
mixed and un-predictable results. As MCP1 also induces the expression of other 
cytokines, such as the induction of VEGF [222], the picture becomes more 
complicated, especially when a cell may secrete significant levels of multiple cytokines 
simultaneously. Preliminary data, not included in this thesis, also indicates that MSCs 
isolated from different individuals can have significantly different secreted cytokine 
profiles. This may have a significant bearing on standardising cell therapy. Different cell 
lots may require profiling by their secreted cytokines as much as their surface markers 
and karyotype. However, it is still feasible that the sustained release of multiple 
cytokines in ischaemic tissues will interact with the local tissue's response to result in 
an improvement in perfusion and subsequent function. 
The clinical relevance of rodent hind limb ischaernia models 
Although rodent hind limb models do not recapitulate the complex patho-physiology of 
peripheral vascular disease the hind limb model was selected as a pre-clinical study for 
the potential use of human MAPCs in PVD. PVD was selected for a phase I study 
(rather than ischaemic heart disease) because transplanting cells into skeletal muscle 
is potentially safer than intra-cardiac injections. As the risks of tumours, electrical 
instability or aberrant differentiation after transplantation of MAPC into muscle are 
unknown the risk of using them in Phase 1 cardiac study are significant. In addition 
detailed MRI based imaging with perfusion measurements of humans with PVD had 
already been established [176] at our centre. Therefore, in order to investigate the 
potential of rMPCs to improve function of an ischaemic tissue a hind limb ischaemia 
model was developed to allow the syngeneic transplantation of cells. After exploring 
various surgical approaches a procedure was selected that resulted 
in significant 
sustained ischaemia as measured by both fluorescent microspheres and 
laser Doppler 
imaging. This resulted in a significant functional impairment measured 
by distance run 
on a rodent treadmill. Although the primary insult to the muscle was 
ischaemic the 
acute nature of the surgery also resulted in a profound 
inflammatory response due to 
the ensuing muscle damage and necrosis. The 
host inflammatory response is a 
fundamental part of these animal models and hence cell transplantation experiments 
are in the context of acute inflammation as well as 
ischaemia. Hind limb models 
probably resemble acute critical leg ischaemia rather 
than chronic ischaemia. As 
rodents have a remarkable ability to develop collaterals 
after acute injury, this in 
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combination with the patho-physiological differences of atherosclerosis to acute artery 
ligation questions generalising data from animal studies to human disease. 
Future clinical implications of cell therapy 
Although it is tempting to speculate that cell therapy may eventually be a therapeutic 
option for patients with chronic diseases, the logistic and financial implications of cell 
therapy are significant. In addition, the mechanism of action of cell therapy and cell 
differentiation is likely to be a complex process that at present is poorly understood. It 
is likely to be some time before the basic science reaches a consensus on the real 
potential of cell therapy and its mechanism of action. Many small clinical studies in 
patients with cardiac disease have been presented. However, most of these studies 
have only demonstrated no obvious harm from cell treatments rather than any benefit 
and most have been under powered to detect small effects which may be clinically 
relevant. If further clinical studies are to take place they should be randomised and 
blinded with sufficient power to detect meaningful clinical end points. 
Whether any benefits from cell therapy are related to organ regeneration via stem cell 
differentiation or via other paracrine mechanisms is at present unclear. Understanding 
the exact mechanism may not be important for a new therapy to offer clinical benefit. 
The success of cell therapy will depend on its clinical efficacy rather than any putative 
mechanism of action [226]. As suggested by the European Society of Cardiology task 
force, the clinical need, feasibility, and safety of the treatment, as well as the need to 
resolve discrepant results, mandate additional clinical trials [227]. Further research 
studies should be conducted to explore any clinical benefit and ensure patient safety. 
Patients should now only be treated as part of randomised, controlled, blinded studies 
ideally designed with sufficient power to answer clinically meaningful questions. 
Alongside this basic translational research can continue to explore the mechanism of 
action and help direct the clinical studies. 
Clinical benefit from the study of stem and progenitor cells is likely to arise from an 
increased understanding of vascular biology in both health and disease. 
This may allow 
the development of novel therapeutic approaches, independent of direct cell therapies. 
In this regard, isolation of a putative pluri-potent bone marrow 
derived stem cells would 
be a great resource for further basic science research. 
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Conclusion 
0 Despite the potential for stem and progenitor cells to be used for the treatment 
of chronic cardiac ischaemia, the biology of stem and progenitor cells is still 
relatively poorly understood, as is the mechanism of action of cells after 
transplantation. 
The work in this thesis adds further to our understanding of both EPCs and BM 
derived pluri-potent stem cells. The phenotype of EPCs has been clarified and 
data presented from cre-lox animal models that a blood monocyte may be 
important for maintaining the integrity of the enclothelial layer during 
development and normal homeostasis. 
9 This thesis has demonstrated that the isolation of MAPCs is not easy and may 
be impossible. It remains unclear at present whether a pluri-potent stem cell 
actually exists within bone marrow. 
0 Cytogenetic instability has been identified as a major problem that can occur 
with prolonged culture of cells. 
* During this thesis an animal model of hind limb ischaemia has been developed 
including the use of multiple methods for assessing it. 
By studying the consequences of cell therapy in an animal model of disease the 
beneficial effects of cell transplantation may be the result of paracrine effects 
modulating the response to the ischaemic injury, rather than by cell 
differentiation and tissue regeneration. 
0 It is unclear from this work, and that of others, whether 
this paracrine 
phenomenon will be clinically useful. More basic science research in this 
field is 
needed before findings can be translated to clinical practice. 
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